# Chapter 131: Major or Mild Neurocognitive Disorder Due to Parkinson’s Disease

## The Biological and Neurological Basis of Major or Mild Neurocognitive Disorder Due to Parkinson’s Disease

## Introduction

Parkinson's disease (PD) is a chronic, progressive neurodegenerative disorder recognized as the second most common neurodegenerative disease after Alzheimer's disease (Krishna et al., 2018; Armstrong & Okun, 2020). First described by James Parkinson in 1817 as the "shaking palsy," its clinical diagnosis is anchored by a core set of motor symptoms, often referred to as parkinsonism: bradykinesia (slowness of movement), resting tremor, muscular rigidity, and postural instability (Jankovic, 2008; Krishna et al., 2018; Hoehn & Yahr, 1967). For many decades, PD was conceptualized primarily as a motor system disorder (Bonnet, 2001). However, it is now unequivocally established that PD is a complex, multisystem disorder with a vast spectrum of non-motor symptoms (NMS) that significantly impact quality of life, often more so than the motor deficits themselves (Poewe, 2008; Jankovic, 2008; McKinlay, 2013).

Among the most debilitating of these NMS are cognitive impairments, which exist on a continuum from subtle, domain-specific deficits to a fully developed dementia syndrome (Rodríguez Constenla et al., 2010; McKinlay, 2013). According to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), these conditions are classified under the umbrella of Neurocognitive Disorders (NCDs), which includes Major NCD (dementia) and Mild NCD (Presečki et al., 2014; Reichenberg & Seligman, 2016). The prevalence of mild cognitive impairment (MCI) in newly diagnosed PD patients is estimated to be between 20-50% (Aarsland et al., 2011; Ospina & Orozco Vélez, 2019), and dementia will ultimately develop in 40% to as many as 80% of individuals over the course of their illness (Press, 2004; Ransmayr, 2015; Aarsland et al., 2011; Zhang, 2012). When dementia develops at least one to two years after the onset of motor symptoms, it is termed Parkinson’s disease dementia (PDD) (Press, 2004; Seppi & Rascol, 2007). If dementia precedes or occurs within one year of parkinsonism, the diagnosis is typically dementia with Lewy bodies (DLB) (Seppi & Rascol, 2007; Ransmayr, 2015). Despite this temporal distinction, PDD and DLB are now widely considered to represent a continuum of the same underlying α-synucleinopathy (Seppi & Rascol, 2007; Aarsland et al., 2005; McKeith et al., 2005).

The biological basis of these cognitive changes is far more complex than the foundational pathology of motor symptoms. While the loss of dopaminergic neurons in the substantia nigra pars compacta (SNc) is the defining neuropathological hallmark of PD motor dysfunction (Riederer & Gerlach, 1993; Jankovic, 2008), the emergence of cognitive and neuropsychiatric disorders reflects a much more widespread neurodegenerative process. This process implicates multiple neurotransmitter systems, including cholinergic, noradrenergic, and serotonergic pathways, and extends anatomically from the brainstem to limbic structures and extensive regions of the cerebral cortex (Menza, 2010; Poewe, 2008; Chakraborty & Diwan, 2022). The accumulation of misfolded α-synuclein protein into Lewy bodies (LBs) and Lewy neurites (LNs) is central to this pathology, with the topographical progression of these inclusions correlating with the evolving clinical phenotype of the disease (Eckert et al., 2007; Armstrong & Okun, 2020; Braak et al., 2003). This chapter will provide a comprehensive overview of the biological and neurological mechanisms that underpin the development of Major and Mild Neurocognitive Disorder in Parkinson's disease, drawing exclusively upon the provided body of evidence. It will explore the intricate interplay of neurotransmitter systems, neural circuits, genetic predispositions, molecular pathways, and structural brain changes that contribute to this challenging and life-altering aspect of PD.

## Neurobiological Systems

The cognitive and neuropsychiatric manifestations of Parkinson’s disease arise from a complex and progressive disruption of multiple neurobiological systems that extend far beyond the nigrostriatal pathway. The traditional dopamine-centric view of PD, while sufficient to explain many core motor symptoms, is inadequate for understanding the basis of cognitive decline, dementia, depression, anxiety, and psychosis (Barone, 2009; Poewe, 2008). The pathophysiology involves the degeneration of several key neurotransmitter systems and the circuits they modulate, creating a cascade of functional impairments that ultimately manifest as neurocognitive and behavioral disorders.

### Neurotransmitter Systems and Neuropharmacology

A defining feature of the neurobiology of cognitive impairment in PD is the widespread degeneration of multiple ascending neuromodulatory systems (Menza, 2010; Barone, 2009). While dopamine loss is foundational, deficits in acetylcholine, norepinephrine, and serotonin are critically implicated in the non-motor, and particularly the cognitive, phenotype of the disease (Chakraborty & Diwan, 2022; Poewe, 2008).

**The Dopaminergic System:** The pathological hallmark of PD is the profound loss of dopaminergic neurons in the substantia nigra pars compacta (SNc) and the subsequent depletion of dopamine in the striatum (caudate and putamen) (Riederer & Gerlach, 1993; Armstrong & Okun, 2020; Eckert et al., 2007). This nigrostriatal pathway is a key component of basal ganglia-thalamocortical loops that regulate motor control (Bergman & Deuschl, 2002; Marsden, 1984). However, dopamine systems also play a crucial role in cognition, primarily through the mesocortical and mesolimbic pathways, which originate in the ventral tegmental area (VTA) (Menza, 2010; Yokochi, 2007). The mesocortical pathway projects to the prefrontal cortex and is vital for executive functions, such as planning, working memory, and attention (Narayanan et al., 2013; Starovasnik & Sever, 2004). Dysfunction in this pathway contributes to the "dysexecutive syndrome" frequently observed even in early, non-demented PD, characterized by cognitive slowing (bradyphrenia), impaired set-shifting, and reduced problem-solving abilities (Pillon et al., 1996; Levin & Katzen, 2005; Bédard et al., 1999). The mesolimbic pathway, projecting to structures like the nucleus accumbens, is involved in motivation, reward processing, and emotion (Fibiger, 1984; Yokochi, 2007). Its dysregulation is linked to apathy, depression, and the psychiatric side effects of dopaminergic medications, such as impulse control disorders (ICDs) and psychosis (Menza, 2010; Sobrido et al., 2009; Fibiger, 1984). The neuropharmacology of dopaminergic drugs highlights this dual role; while levodopa and dopamine agonists improve motor symptoms by replenishing striatal dopamine, they can induce or worsen psychosis, hallucinations, and ICDs by overstimulating the relatively preserved mesolimbic D2/D3 receptors (Factor et al., 1995; Mestre et al., 2013; Sobrido et al., 2009).

**The Cholinergic System:** Deficits in the cholinergic system are considered a primary driver of dementia in PD (Hornykiewicz & Kish, 1984; Pérez-Lloret & Barrantes, 2016). The neurodegeneration involves the loss of cholinergic neurons in the nucleus basalis of Meynert, which provides the main cholinergic innervation to the cerebral cortex (Mann & Yates, 1983; Hornykiewicz & Kish, 1984). This cortical cholinergic deficiency is a shared feature with Alzheimer's disease (AD) and is strongly correlated with the severity of cognitive impairment, particularly deficits in attention and memory (Hornykiewicz & Kish, 1984; Bédard et al., 2003; Pérez-Lloret & Barrantes, 2016). The resulting attentional deficits and memory retrieval problems are hallmarks of PDD and DLB (Emre, 2003; Aarsland et al., 2011). The critical role of this system is underscored by the efficacy of cholinesterase inhibitors, such as rivastigmine and donepezil, which are approved treatments for PDD (Ransmayr, 2015; Aarsland, 2006; Kashihara, 2015). These drugs work by increasing the synaptic availability of acetylcholine, thereby partially compensating for the neuronal loss and improving cognitive and neuropsychiatric symptoms (Aarsland, 2006; Bohnen et al., 2024). Conversely, anticholinergic drugs, sometimes used to treat tremor, can worsen cognitive function and should be avoided in patients with or at risk for cognitive decline (Reichmann & Sommer, 2001; Factor et al., 1995).

**The Noradrenergic System:** The noradrenergic system is also severely affected in PD, with profound neuronal loss in the locus coeruleus (LC), the brain's primary source of norepinephrine (Mizuno, 1997; Mann & Yates, 1983). This degeneration occurs early in the disease process, often preceding SNc involvement (Braak et al., 2003; Szot et al., 2011). Norepinephrine is crucial for arousal, attention, mood regulation, and autonomic function (Chakraborty & Diwan, 2022; Barone, 2009). Its depletion is strongly linked to the high prevalence of depression, anxiety, and apathy in PD (Kano et al., 2011; Menza, 2010; Grimbergen et al., 2009). Furthermore, noradrenergic deficits are implicated in executive dysfunction and postural instability, a motor symptom often refractory to dopaminergic therapy (Grimbergen et al., 2009; Tredici & Braak, 2012). The widespread projections of the LC mean its degeneration contributes to a broad array of both cognitive and non-motor symptoms (Szot et al., 2011).

**The Serotonergic System:** Degeneration of serotonergic neurons in the dorsal raphe nuclei is another consistent finding in the PD brain (Mann & Yates, 1983; Chakraborty & Diwan, 2022). Serotonin plays a key role in mood, anxiety, sleep, and impulse control (Barone, 2009; Faggiani, 2014). Disruption of this system is a major contributor to depression and anxiety in PD (Kano et al., 2011; Menza, 2010; Fukunishi et al., 1991). The complex interaction between the serotonergic and dopaminergic systems is also implicated in the pathophysiology of levodopa-induced dyskinesias and psychosis (Faggiani, 2014; Factor et al., 1995). For example, serotonergic neurons can take up levodopa and release dopamine in an unregulated, non-physiological manner, contributing to motor complications (Faggiani, 2014). Atypical antipsychotics like clozapine and quetiapine, used to treat psychosis in PD, have potent serotonin 5-HT2A receptor antagonist properties, which is thought to contribute to their antipsychotic effect without worsening motor symptoms (Poisson, 2014; Schneider et al., 2017).

In summary, the neurocognitive disorder associated with PD is not the result of a single neurotransmitter failure but a multi-system chemical imbalance. The progressive degeneration of dopaminergic, cholinergic, noradrenergic, and serotonergic neurons disrupts the intricate neural circuits governing cognition, mood, and behavior, leading to the complex and heterogeneous clinical presentation of the disorder.

## Genetic and Molecular Basis

While the majority of Parkinson's disease cases are sporadic and of unknown etiology, a confluence of genetic and environmental factors is thought to be involved (Krishna et al., 2018; Marino et al., 2019). Research over the past few decades has illuminated several key genetic contributors and molecular pathways that drive the neurodegenerative process, providing a crucial framework for understanding the biological underpinnings of not only the motor symptoms but also the associated cognitive decline.

### Genetic Factors and Heritability

Although most PD is idiopathic, approximately 5-15% of patients report a family history of the disease (Krishna et al., 2018; Bonifati, 2003). The identification of specific gene mutations has confirmed a genetic basis for rare, familial forms of parkinsonism, which often present with early onset (Bonifati, 2003; Quadri, 2013). These monogenic forms, while accounting for a small fraction of total cases, have provided invaluable insights into the molecular mechanisms of the disease.

Key genes associated with autosomal dominant PD include *SNCA* (α-synuclein) and *LRRK2* (leucine-rich repeat kinase 2) (Saunders‐Pullman et al., 2019; Chiba‐Falek & Nussbaum, 2003). Mutations and multiplications of the *SNCA* gene, which encodes α-synuclein, cause early-onset PD and underscore the central role of this protein in pathogenesis (Bonifati, 2003; Chiba‐Falek & Nussbaum, 2003). *LRRK2* mutations are one of the most common genetic causes of both familial and sporadic-appearing late-onset PD, with a clinical phenotype often indistinguishable from idiopathic PD (Saunders‐Pullman et al., 2019; Zhang, 2019).

Autosomal recessive forms of young-onset parkinsonism are caused by mutations in genes such as *PARK2* (parkin), *PINK1*, and *DJ-1* (Bonifati, 2003; Schneider & Klein, 2014; Khan et al., 2003). These genes are fundamentally linked to mitochondrial function and cellular stress responses (Kroemer & Blomgren, 2007; Schneider & Klein, 2014). An interesting pathological feature of parkinsonism due to *parkin* and *DJ-1* mutations is the frequent absence of Lewy bodies, despite severe nigral degeneration (Doherty et al., 2013; Narendra et al., 2019). This highlights that dopaminergic neurodegeneration can occur independently of α-synuclein aggregation, suggesting alternative or parallel pathogenic pathways (Bonifati, 2003).

In addition to causative mutations, several genetic risk variants have been identified that increase susceptibility to PD. Notably, heterozygous mutations in the *GBA* (glucocerebrosidase) gene, which cause the lysosomal storage disorder Gaucher's disease in a homozygous state, are the most common known genetic risk factor for PD (Beccari et al., 2011). *GBA* mutations are associated with a higher risk of developing cognitive impairment, dementia, and hallucinations in PD (Barrett, 2017; Aarsland, 2006).

### Molecular Mechanisms

At the molecular level, a few core processes have emerged as central to the pathogenesis of PD and its associated neurocognitive disorders: α-synuclein aggregation, mitochondrial dysfunction, oxidative stress, and neuroinflammation.

**α-Synuclein Aggregation and Lewy Body Pathology:** The defining neuropathological hallmark of idiopathic PD is the presence of Lewy bodies (LBs) and Lewy neurites (LNs), which are abnormal intraneuronal proteinaceous inclusions composed primarily of misfolded and aggregated α-synuclein (Eckert et al., 2007; Armstrong & Okun, 2020; Goedert et al., 2003). α-synuclein is a presynaptic protein, and its aggregation is thought to disrupt synaptic function, axonal transport, and cellular homeostasis, ultimately leading to neuronal death (Bellucci et al., 2015; Xie, 2011). The distribution and density of Lewy pathology correlate with the clinical progression of the disease. The spread of LBs from brainstem nuclei to the substantia nigra, and later to limbic and neocortical regions, is thought to underlie the evolution from motor symptoms to cognitive decline and dementia (Braak et al., 2003; Wolters & Braak, 2006; Dickson & Orr, 2011). This stereotypical progression has led to the "prion-like" hypothesis, which posits that misfolded α-synuclein can act as a seed, propagating from cell to cell and inducing the misfolding of native α-synuclein in recipient neurons (Giubilei & Orzi, 2014; Mou et al., 2019; Johnson et al., 2018). The specific conformation of α-synuclein filaments has been shown to differ between synucleinopathies; for instance, the filaments in PD and DLB share a common "Lewy fold" that is structurally distinct from the filaments found in multiple system atrophy (MSA) (Yang et al., 2022).

**Mitochondrial Dysfunction and Oxidative Stress:** There is substantial evidence implicating mitochondrial dysfunction and oxidative stress in the selective demise of dopaminergic neurons (Sarkar et al., 2016; Ogawa & Mori, 1995; Rezaee et al., 2019). Dopaminergic neurons are particularly vulnerable due to their high energy demands and the oxidative stress generated by dopamine metabolism itself (Ogawa & Mori, 1995; Ruberg et al., 1997). Pathological studies have identified defects in complex I of the mitochondrial respiratory chain in the substantia nigra of PD patients (Betarbet & Greenamyre, 2007). The link between mitochondrial health and PD is further solidified by the functions of genes like *parkin* and *PINK1*, which are involved in mitochondrial quality control, including the removal of damaged mitochondria (mitophagy) (Kroemer & Blomgren, 2007; Schneider & Klein, 2014). When this process is impaired, dysfunctional mitochondria accumulate, leading to increased production of reactive oxygen species (ROS), energy failure, and initiation of apoptotic cell death pathways (Sarkar et al., 2016; Ruberg et al., 1997).

**Neuroinflammation:** Neuroinflammation, characterized by the activation of microglia and astrocytes, is a consistent feature in the PD brain (Rogers & Kovelowski, 2003; Mollenhauer & Weintraub, 2017). Initially viewed as a secondary reaction to neuronal death, it is now considered an active contributor to the neurodegenerative cascade (Nath et al., 2020; Johnson et al., 2018). Activated microglia release pro-inflammatory cytokines (e.g., TNF-α, IL-1β) and reactive oxygen species, which are neurotoxic and can exacerbate dopaminergic cell death (Rogers & Kovelowski, 2003; Gao et al., 2008). Furthermore, inflammation can promote the misfolding and aggregation of α-synuclein, creating a vicious cycle of neurodegeneration and inflammation (Gao et al., 2008; Rocha et al., 2014). This inflammatory process is not confined to the brain; evidence of systemic inflammation has also been reported in PD patients (Mollenhauer & Weintraub, 2017).

Together, these genetic and molecular pathways paint a picture of a complex, multifactorial disease process. The interplay between protein misfolding, mitochondrial failure, oxidative stress, and neuroinflammation drives the progressive and widespread neuronal loss that underlies both the motor and the devastating cognitive consequences of Parkinson's disease.

## Brain Structure and Function

The clinical manifestations of Major or Mild Neurocognitive Disorder in Parkinson's disease are the direct result of progressive structural and functional alterations within the brain. While the initial pathological focus is subcortical, the development of cognitive impairment reflects the spread of pathology to cortical regions and the disruption of large-scale neural networks that integrate motor, cognitive, and emotional processing (Bergman & Deuschl, 2002; Bellucci et al., 2015). Neuroimaging techniques have become indispensable tools for visualizing these changes in vivo, aiding in differential diagnosis and providing insights into the underlying pathophysiology.

### Neuroanatomical and Pathological Findings

The neuropathology of PD is characterized by neuronal loss and the presence of α-synuclein-positive Lewy bodies (LBs) and Lewy neurites (LNs) (Eckert et al., 2007; Armstrong & Okun, 2020). The topography of this pathology dictates the clinical phenotype.

**Subcortical Structures:** The most profound and defining neuronal loss occurs in the dopaminergic neurons of the substantia nigra pars compacta (SNc) (Riederer & Gerlach, 1993; Eckert et al., 2007). This degeneration disrupts the nigrostriatal pathway, leading to dopamine deficiency in the basal ganglia (caudate and putamen) and causing the cardinal motor symptoms (Ogawa & Mori, 1995; Marino et al., 2019). However, the pathology is not confined to the SNc. Degeneration also affects other brainstem nuclei, including the noradrenergic locus coeruleus and the serotonergic raphe nuclei (Mizuno, 1997; Mann & Yates, 1983). These structures are part of ascending pathways that modulate cortical activity, and their degeneration is strongly linked to non-motor symptoms like depression, anxiety, and sleep disorders (Kano et al., 2011; Tredici & Braak, 2012). The cholinergic nucleus basalis of Meynert, a key source of cortical acetylcholine, is also frequently affected, and its degeneration is a primary substrate for the attentional and memory deficits seen in PDD (Hornykiewicz & Kish, 1984; Mann & Yates, 1983).

**Cortical Involvement and Co-pathologies:** The transition from motor-predominant PD to PDD is marked by the extensive spread of Lewy pathology into limbic and neocortical areas (Apaydın et al., 2002; Dickson & Orr, 2011; Gibb et al., 1989). High densities of cortical Lewy bodies are a robust pathological correlate of dementia in PD (Apaydın et al., 2002; McKeith et al., 2005; Dickson & Orr, 2011). This cortical pathology disrupts higher-order processing, leading to the characteristic cognitive profile of PDD, which includes prominent executive and visuospatial dysfunction (Emre, 2003; Levin & Katzen, 2005).

The neuropathological picture is often complicated by the presence of co-pathologies, most commonly Alzheimer's disease (AD)-type pathology (senile plaques and neurofibrillary tangles) (Dickson & Orr, 2011; Jendroska, 1997; Hakim & Mathieson, 1979). While concurrent AD pathology sufficient to meet diagnostic criteria for AD is found in a subset of PDD cases, many patients exhibit a level of AD pathology that would be considered subclinical in the absence of Lewy body disease (Jendroska, 1997; de Vos et al., 1996). There is evidence that Lewy body and AD pathologies may act synergistically to lower the threshold for cognitive impairment, suggesting that the presence of both pathologies leads to a more severe and rapid cognitive decline than either would alone (Apaydın et al., 2002; Dickson & Orr, 2011). Vascular pathology, such as small vessel disease and lacunar infarcts, can also coexist and contribute to the cognitive phenotype, particularly in older patients (Ebersbach, 2002; Korczyn, 2010).

### Neuroimaging Findings

Neuroimaging provides a window into the structural and functional brain changes associated with PD and its cognitive complications.

**Structural Imaging:** Conventional magnetic resonance imaging (MRI) is typically unremarkable in the early stages of idiopathic PD and is primarily used to exclude other causes of parkinsonism, such as vascular parkinsonism (VP), normal pressure hydrocephalus, or brain tumors (Mizuno, 1997; Camicioli, 2002; Armstrong & Okun, 2020). In VP, MRI may show extensive white matter hyperintensities or lacunar infarcts in the basal ganglia (Thanvi et al., 2005; Zijlmans et al., 2013). In atypical parkinsonian syndromes like progressive supranuclear palsy (PSP), MRI can reveal characteristic midbrain atrophy (the "hummingbird sign") (Ogata et al., 2016; Karimi & Perlmutter, 2011). In patients with PDD and DLB, more advanced MRI techniques can demonstrate generalized cortical atrophy, which may be more pronounced in frontal, temporal, and parietal regions, as well as hippocampal atrophy (Sánchez Castañeda, 2009; Oare, 2017; Ellfolk et al., 2013).

**Functional and Molecular Imaging:** Functional imaging techniques like single-photon emission computed tomography (SPECT) and positron emission tomography (PET) are powerful tools for assessing neurotransmitter system integrity and brain metabolism.
*   **Dopamine Transporter (DAT) Imaging:** SPECT imaging with ligands such as [123I]FP-CIT (DaTSCAN) visualizes the density of presynaptic dopamine transporters in the striatum. A reduction in DAT binding is a hallmark of nigrostriatal degeneration and is highly sensitive and specific for differentiating PD and other degenerative parkinsonisms from conditions without presynaptic dopaminergic loss, such as essential tremor, drug-induced parkinsonism, or psychogenic parkinsonism (Armstrong & Okun, 2020; Tolosa et al., 2003; Cummings et al., 2011).
*   **Metabolic Imaging:** PET with [18F]-fluorodeoxyglucose (FDG-PET) measures regional cerebral glucose metabolism. Patients with PDD and DLB often exhibit a characteristic pattern of hypometabolism in the parieto-occipital regions, including the precuneus, which differs from the temporoparietal pattern seen in AD (Arnaldi et al., 2012; Trošt et al., 2019). These metabolic changes correlate with the severity of cognitive and neuropsychiatric symptoms (Arnaldi et al., 2012; Nicastro, 2021).
*   **Other Molecular Imaging:** Myocardial scintigraphy using [123I]-metaiodobenzylguanidine (MIBG) can detect cardiac sympathetic denervation, a common feature of PD and DLB but not MSA or PSP, making it a useful diagnostic tool (Rascol & Schelosky, 2009; Orimo, 2007; Braune, 2002). Amyloid-PET imaging can detect the presence of cortical Aβ plaques, helping to identify the contribution of AD co-pathology to the dementia syndrome (Arnaldi et al., 2012).

**Functional Connectivity:** Resting-state functional MRI (rs-fMRI) studies have begun to map the disruption of large-scale brain networks in PD. These studies show altered functional connectivity within the basal ganglia-thalamocortical motor loops, as well as within cognitive networks such as the default mode network and frontoparietal attention networks (Disbrow et al., 2014; Feng, 2013). These connectivity changes are associated with cognitive dysfunction, particularly in executive function (Disbrow et al., 2014). Furthermore, specific neuropsychiatric symptoms like depression, anxiety, and apathy have been linked to distinct patterns of altered functional connectivity within fronto-limbic circuits (Dan et al., 2017). These findings support a network-level understanding of the disease, where focal pathology leads to widespread functional disorganization.

## Developmental Neurobiology

The emergence of Major or Mild Neurocognitive Disorder in Parkinson's disease is not an abrupt event but the culmination of a neurodegenerative process that unfolds over decades (Savica et al., 2010; Gaig & Tolosa, 2009). Understanding the developmental neurobiology of PD requires looking back long before the onset of the classic motor signs to a protracted "premotor" or "prodromal" phase (Peralta, 2013; Wolters & Braak, 2006). During this period, the underlying pathology is already accumulating and spreading through the nervous system, producing a constellation of subtle, often overlooked, non-motor symptoms that herald the future development of the full-blown disease (Poewe, 2008; Visanji & Marras, 2015).

### The Prodromal Phase and Early Non-Motor Symptoms

Pathological and neuroimaging studies have convincingly demonstrated that by the time a clinical diagnosis of PD is made based on motor symptoms, a substantial loss of dopaminergic neurons in the substantia nigra—often greater than 50%—has already occurred (Mollenhauer & Weintraub, 2017; Gitelman & Simuni, 2012). This implies a lengthy preclinical period, estimated to last from 5 to more than 20 years, during which the neurodegenerative process is active but motor symptoms are not yet manifest (Savica et al., 2010; Hawkes, 2008; Gaig & Tolosa, 2009).

This prodromal phase is characterized by the appearance of a variety of non-motor symptoms (Peralta, 2013; Poewe, 2008). Among the most well-established are:
*   **Olfactory Dysfunction (Hyposmia):** A reduced sense of smell is one of the earliest and most common prodromal symptoms, affecting up to 90% of individuals who later develop PD (Doty & Tekelı, 2012; Hawkes, 1995). The onset of hyposmia can precede motor symptoms by years or even decades (Hawkes, 2008; Gaig & Tolosa, 2009). Its presence is considered a key diagnostic criterion and a strong predictor of future PD development (Adler, 2011; Doty & Hawkes, 2022). Severe olfactory dysfunction has also been linked to a higher probability of subsequent mental decline (Saito & Murayama, 2012; Baba, 2023).
*   **Constipation:** Gastrointestinal dysfunction, particularly constipation, is another very common early symptom that can precede motor onset by as much as 20 years (Savica et al., 2010; Pfeiffer, 2012). It reflects early involvement of the enteric nervous system (ENS) (Braak et al., 2003; Cersosimo & Benarroch, 2012).
*   **REM Sleep Behavior Disorder (RBD):** RBD is a parasomnia characterized by the loss of normal muscle atonia during REM sleep, leading to dream-enacting behaviors (Schenck et al., 2003; Boeve & Saper, 2006). Idiopathic RBD is one of the strongest known predictors of future synucleinopathy, with over 80% of individuals developing PD, DLB, or MSA over time (Postuma et al., 2010; Boeve, 2008; Iranzo et al., 2013). The onset of RBD can predate motor symptoms by decades (Claassen et al., 2010; Gaig & Tolosa, 2009).
*   **Depression and Anxiety:** Mood disorders, particularly depression and anxiety, are highly prevalent in PD and can also be among the earliest manifestations of the disease (Schuster, 2014; Savica et al., 2010). Depression may antedate the onset of motor symptoms by several years and is considered by some to be an intrinsic part of the disease process rather than a purely psychological reaction (Bell, 2008; Fukunishi et al., 1991; Schrag et al., 2001).

### The Braak Hypothesis and Pathological Progression

The temporal sequence of these prodromal symptoms provides clinical support for the influential staging hypothesis proposed by Braak and colleagues (Braak et al., 2003). Based on post-mortem examinations, this hypothesis posits that Lewy pathology does not begin in the substantia nigra but rather in specific peripheral and lower brainstem locations. The process is thought to start in the olfactory bulb (explaining early hyposmia) and the dorsal motor nucleus of the vagus nerve in the medulla oblongata, which also innervates the enteric nervous system (explaining early constipation) (Braak et al., 2003; Wolters & Braak, 2006; Tredici & Braak, 2012).

From these initial sites, the pathology is hypothesized to spread in a stereotypical, ascending manner through synaptically connected and vulnerable neuronal populations (Wolters & Braak, 2006; Johnson et al., 2018). In stages 1 and 2, the pathology is confined to the medulla, pontine tegmentum (including the locus coeruleus), and olfactory bulb, correlating with the prodromal phase (Braak et al., 2003). It is only in stage 3 that the pathology reaches the midbrain and substantia nigra, leading to the onset of motor symptoms (Braak et al., 2003). In later stages (4-6), the pathology ascends further to involve limbic structures (e.g., amygdala) and ultimately widespread areas of the neocortex, correlating with the development of cognitive impairment and dementia (Braak et al., 2003; Tredici & Braak, 2012).

While the Braak hypothesis provides a compelling framework that aligns clinical and pathological observations, it is not without controversy. Some autopsy findings do not fit the proposed sequential pattern (Saito & Murayama, 2012). This has led to alternative models, such as the "brain-first versus gut-first" hypothesis, which suggests that the initial site of α-synuclein aggregation may differ between individuals, leading to different clinical subtypes and progression patterns (Borghammer & Berge, 2019). For instance, a "gut-first" subtype might present with prominent early RBD and autonomic dysfunction, whereas a "brain-first" subtype might have a later onset of these symptoms (Borghammer & Berge, 2019).

### The Role of Aging

PD is fundamentally an age-related disease, with age being the single largest risk factor (Hindle, 2010; Krishna et al., 2018). Normal aging is associated with a gradual decline in the number of dopaminergic neurons and striatal dopamine levels (Hindle, 2010; Beck, 1980; Martin, 2019). It is hypothesized that the pathological process of PD accelerates this age-related decline, pushing the dopaminergic system below the symptomatic threshold much earlier than would occur with aging alone (Hindle, 2010; Knoll, 1993). Furthermore, advanced age at the onset of PD is one of the most robust predictors for a more rapid motor progression and a higher risk of developing dementia (Ransmayr, 2015; Ebersbach, 2010; Levy & Marder, 2003). This suggests that the aging brain has reduced compensatory capacity and is more vulnerable to the widespread neurodegenerative insults of PD, leading to a more rapid and severe clinical course, including the emergence of dementia.

## Treatment Mechanisms

Currently, no treatments exist that can halt or reverse the underlying neurodegeneration in Parkinson's disease; all available therapies are symptomatic (Armstrong & Okun, 2020; Poewe, 2006). The biological mechanisms of these treatments are aimed at either compensating for the neurochemical deficits or modulating the aberrant neural circuit activity that results from the disease process. Managing the cognitive and neuropsychiatric symptoms of PD is particularly challenging, as therapies effective for motor symptoms can sometimes exacerbate behavioral issues, and treatments for cognitive decline have only modest efficacy.

### Pharmacological Interventions

Pharmacotherapy for PD primarily targets the profound dopamine deficiency, but agents acting on other neurotransmitter systems are crucial for managing cognitive and psychotic symptoms.

**Dopaminergic Therapies:** The cornerstone of motor symptom management is dopamine replacement therapy, most effectively achieved with levodopa (L-dopa), the metabolic precursor to dopamine (Armstrong & Okun, 2020; Marino et al., 2019; Factor, 2007). Levodopa crosses the blood-brain barrier and is converted to dopamine within remaining nerve terminals, temporarily restoring striatal dopamine levels and alleviating bradykinesia, rigidity, and tremor (Fahn et al., 2004; Factor, 2007). Dopamine agonists (e.g., pramipexole, ropinirole) directly stimulate postsynaptic dopamine receptors, mimicking the effect of dopamine (Elmer & Hauser, 2012; Reichmann & Schüpbach, 2008). While highly effective for motor control, these therapies have complex effects on cognition and behavior. They can sometimes improve aspects of executive function tied to the fronto-striatal dopamine system (Leiva Santana & Álvarez Saúco, 2006), but their long-term, pulsatile stimulation of dopamine receptors is thought to contribute to the development of motor complications like wearing-off and dyskinesias (Onofrj et al., 1998; Fahn et al., 2004). Critically, dopaminergic drugs are a primary trigger for psychiatric complications. By overstimulating mesolimbic and mesocortical dopamine pathways, they can induce or worsen hallucinations, delusions (psychosis), and impulse control disorders (ICDs) such as pathological gambling and hypersexuality (Factor et al., 1995; Menza et al., 2006; Mestre et al., 2013; Sobrido et al., 2009). Management of these side effects often requires a difficult balancing act of reducing dopaminergic medication, which may worsen motor function (Factor et al., 1995; Friedman & Sienkiewicz, 1991).

**Cholinesterase Inhibitors:** Given the strong evidence for a cortical cholinergic deficit in PDD, cholinesterase inhibitors are the primary pharmacological treatment for cognitive impairment (Hornykiewicz & Kish, 1984; Ransmayr, 2015). Drugs like rivastigmine and donepezil work by inhibiting the acetylcholinesterase enzyme, thereby increasing the synaptic availability of acetylcholine (Aarsland, 2006; Kashihara, 2015). This mechanism helps to partially compensate for the loss of cholinergic neurons originating from the nucleus basalis of Meynert (Pérez-Lloret & Barrantes, 2016). Randomized controlled trials have shown that these agents provide modest but clinically meaningful benefits for cognition, attention, and global function in PDD and DLB (Aarsland, 2006; Emre et al., 2004). They can also be beneficial for managing associated neuropsychiatric symptoms, particularly visual hallucinations (Fénelon, 2006; Ransmayr, 2015).

**Atypical Antipsychotics:** Treating psychosis in PD is challenging because traditional antipsychotics, which are potent dopamine D2 receptor antagonists, invariably worsen parkinsonism (Factor et al., 1995; Patel et al., 2011). Atypical antipsychotics, such as clozapine and quetiapine, are preferred because they have a lower affinity for D2 receptors and a higher affinity for serotonin 5-HT2A receptors (Poisson, 2014; Schneider et al., 2017). This pharmacological profile is believed to mediate their antipsychotic effects with a much lower risk of exacerbating motor symptoms (Fénelon, 2006; Juncos, 1999). Clozapine is considered the most effective agent for PD psychosis, though its use is limited by the need for regular blood monitoring (Poisson, 2014; Friedman & Sienkiewicz, 1991). Pimavanserin, a selective 5-HT2A inverse agonist without dopaminergic activity, was specifically developed and approved for PD psychosis, representing a targeted mechanism to treat hallucinations and delusions without impacting motor function (Schneider et al., 2017; Segal et al., 2021).

### Surgical Interventions: Deep Brain Stimulation

Deep brain stimulation (DBS) is an established surgical treatment for advanced PD with motor complications refractory to medication adjustments (Giladi & Melamed, 2000; Armstrong & Okun, 2020). The procedure involves implanting electrodes into specific basal ganglia targets, most commonly the subthalamic nucleus (STN) or the globus pallidus interna (GPi) (Richter & Lozano, 2004). These electrodes deliver high-frequency electrical stimulation, which is thought to modulate and override the abnormal, oscillatory neuronal activity within the basal ganglia-thalamocortical circuits that underlies motor symptoms (Hemptinne & Swann, 2016; Bergman & Deuschl, 2002).

DBS is highly effective at improving levodopa-responsive motor symptoms, reducing tremor, rigidity, and bradykinesia, and allowing for a reduction in dopaminergic medication, which in turn can decrease dyskinesias (Giladi & Melamed, 2000; Kampić et al., 2021). However, its effects on cognition and neuropsychiatric symptoms are complex and variable. While some studies report improvements in certain non-motor domains, possibly due to medication reduction, DBS can also have adverse effects (Mishra et al., 2024). STN-DBS, in particular, has been associated with a decline in verbal fluency and other executive functions (Castro García et al., 2006; Moreau, 2008). It has also been linked to an increased risk of postoperative apathy, depression, or impulsivity in some patients (Castro García et al., 2006; Stefanini, 2015). These effects are thought to result from the electrical stimulation spreading to non-motor circuits passing through or near the STN, highlighting the intricate integration of motor, cognitive, and limbic functions within the basal ganglia (Stefanini, 2015; Méndez-Herrera, 2011). Therefore, careful patient selection, including a thorough presurgical neuropsychological and psychiatric evaluation, is critical to minimize the risk of adverse cognitive and behavioral outcomes (Kampić et al., 2021).

## Future Directions

Despite significant advances in the symptomatic management of Parkinson’s disease, the field faces two overarching challenges: the lack of treatments that modify the course of the underlying neurodegeneration and the absence of reliable tools for early and definitive diagnosis. Future research is intensely focused on addressing these gaps, with the ultimate goal of moving from symptom management to true neuroprotection and personalized medicine.

### Development of Disease-Modifying Therapies

The most critical unmet need in PD is the development of therapies that can slow, halt, or reverse the relentless progression of the disease (Poewe, 2006; Ahlskog, 2020). Research is pursuing several biological targets identified from our growing understanding of PD pathogenesis.
*   **Targeting α-Synuclein:** As the central protein in Lewy body pathology, α-synuclein is a prime therapeutic target. Strategies under investigation include active and passive immunotherapy (vaccines and monoclonal antibodies) designed to clear pathological α-synuclein aggregates and prevent their cell-to-cell propagation (Domanskyi & Chmielarz, 2021; Schenk et al., 2003). Other approaches aim to reduce α-synuclein production using antisense oligonucleotides or to inhibit its initial aggregation (Domanskyi & Chmielarz, 2021; Chiba‐Falek & Nussbaum, 2003).
*   **Modulating Neuroinflammation:** Given the role of chronic neuroinflammation in driving neuronal death, anti-inflammatory strategies are being explored (Rogers & Kovelowski, 2003; Nath et al., 2020). This includes repurposing existing anti-inflammatory drugs and developing new agents that can modulate microglial activation and reduce the production of neurotoxic inflammatory mediators (Sarkar et al., 2016; Johnson et al., 2018).
*   **Enhancing Mitochondrial Function and Reducing Oxidative Stress:** Therapies aimed at boosting mitochondrial function, improving cellular energy metabolism, and scavenging reactive oxygen species are a major focus (Sarkar et al., 2016; Rezaee et al., 2019). Compounds like coenzyme Q10 have been studied, and new molecules targeting mitochondrial quality control pathways, such as those involving PINK1 and parkin, are in development (Sarkar et al., 2016; Kroemer & Blomgren, 2007).
*   **Targeting Non-Dopaminergic Systems:** For cognitive and neuropsychiatric symptoms, future therapies will need to look beyond the dopamine system. Developing drugs that target cholinergic, noradrenergic, and serotonergic dysfunction in a more specific manner could offer better treatment for dementia, depression, and psychosis with fewer side effects (Barone, 2009; Pérez-Lloret & Barrantes, 2016).

### Advancing Biomarkers for Early Diagnosis and Progression Monitoring

The success of future disease-modifying trials will depend on our ability to diagnose PD in its earliest prodromal stages, before extensive and irreversible neuronal loss has occurred (Poewe, 2006; Gitelman & Simuni, 2012). This requires the development and validation of sensitive and specific biomarkers.
*   **Biochemical Markers:** Research is focused on identifying markers in accessible biofluids like cerebrospinal fluid (CSF) and blood. Potential candidates include levels of total and aggregated α-synuclein, neurofilament light chain (a marker of axonal damage), and markers of inflammation (Mollenhauer & Weintraub, 2017; Sun & Tang, 2017; Akhtar & Mano, 2019; Dutta, 2021). Techniques like protein misfolding cyclic amplification (PMCA) and real-time quaking-induced conversion (RT-QuIC) show promise for detecting minute amounts of pathological α-synuclein seeds (Sun & Tang, 2017; Shahnawaz et al., 2020).
*   **Neuroimaging Markers:** Advanced imaging techniques will continue to play a crucial role. This includes developing novel PET ligands to visualize α-synuclein or tau pathology in the living brain, refining fMRI techniques to detect subtle changes in network connectivity, and using transcranial sonography to identify markers like substantia nigra hyperechogenicity (Gitelman & Simuni, 2012; Arnaldi et al., 2012; Berg & Gaenslen, 2010).
*   **Clinical and Genetic Markers:** Refining the characterization of prodromal clinical markers, such as quantitative olfactory testing and polysomnography for RBD, will be essential for identifying at-risk populations for neuroprotective trials (Hawkes, 2008; Postuma et al., 2010). Combining these clinical markers with genetic risk profiling (e.g., for *GBA* or *LRRK2* mutations) can further stratify risk and enrich trial cohorts (Berg & Bandmann, 2013; Saunders‐Pullman et al., 2019).

### Understanding Disease Heterogeneity and Subtyping

It is increasingly clear that PD is not a monolithic disorder but a heterogeneous syndrome with diverse clinical presentations and rates of progression (Armstrong & Okun, 2020; Moustafa & Poletti, 2013). Future research must focus on delineating distinct biological subtypes of the disease. The "brain-first" versus "gut-first" hypothesis is one such model, suggesting different points of origin for the pathology that may lead to different clinical trajectories (Borghammer & Berge, 2019). Identifying the genetic, molecular, and neurochemical signatures of these subtypes will be paramount for developing personalized medicine approaches, where specific treatments are targeted to the underlying pathophysiology of an individual patient or subgroup. This will likely involve integrating data from genetics, biomarkers, neuroimaging, and clinical phenotyping to build a more nuanced and biologically grounded classification of Parkinson's diseases.

## Conclusion

Major or Mild Neurocognitive Disorder due to Parkinson’s Disease represents a profound and pervasive aspect of the condition, transforming it from a primary motor disorder into a complex neuropsychiatric syndrome. The biological underpinnings of this cognitive decline are multifaceted, stemming from a widespread neurodegenerative process that extends far beyond the dopaminergic nigrostriatal system. The progressive loss of cholinergic, noradrenergic, and serotonergic neurons, coupled with the relentless cortical and limbic spread of α-synuclein pathology, creates a multi-system failure that disrupts the neural networks essential for cognition, mood, and behavior (Poewe, 2008; Emre, 2003; Barone, 2009).

The journey into cognitive impairment begins decades before the cardinal motor signs become apparent, in a prodromal phase marked by non-motor symptoms like hyposmia, constipation, and REM sleep behavior disorder (Savica et al., 2010; Poewe, 2008). This long preclinical window, elucidated by pathological staging models such as Braak's hypothesis, underscores both the insidious nature of the disease and a critical opportunity for future intervention (Braak et al., 2003; Wolters & Braak, 2006). The presence of co-pathologies, particularly Alzheimer's-type and vascular changes, further complicates the neurobiological landscape and contributes to the clinical heterogeneity of dementia in PD (Dickson & Orr, 2011; Korczyn, 2010).

Current treatments remain symptomatic, offering modest relief for cognitive symptoms through cholinergic enhancement and managing psychosis with atypical antipsychotics, while constantly balancing the risk of worsening motor function (Ransmayr, 2015; Schneider et al., 2017). Surgical interventions like deep brain stimulation, while effective for motor complications, have complex and sometimes detrimental effects on cognition and mood, highlighting the integrated nature of the brain circuits affected (Castro García et al., 2006).

The path forward in confronting the cognitive dimensions of Parkinson's disease hinges on a paradigm shift from symptomatic treatment to neuroprotection (Poewe, 2006). This will require the validation of robust biomarkers for early diagnosis in the prodromal phase and for tracking disease progression objectively (Gitelman & Simuni, 2012; McKeown & Peavy, 2015). Ultimately, a deeper understanding of the distinct biological subtypes of PD will be necessary to develop personalized, disease-modifying therapies that target the specific molecular cascades—be it α-synuclein aggregation, mitochondrial dysfunction, or neuroinflammation—driving the disease in individual patients (Armstrong & Okun, 2020; Borghammer & Berge, 2019). Only through this comprehensive, multi-system biological perspective can we hope to effectively address not just the motor symptoms, but the full, devastating spectrum of neurocognitive and psychiatric disorders in Parkinson's disease.


## References

1. Aarsland, D. (2006). DLB than those of other cholinergic agents is not known, although this is theoretically plausible. (3).
2. Aarsland, D., & Svenningsson, P. (2012). Using biomarkers to disentangle different causes of Parkinsonism. Journal of Neurology Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp-2012-303025
3. Aarsland, D., Ehrt, U., & Ballard, C. (2005). Role of Neuropsychiatric Assessment in Diagnosis and Research. Humana Press eBooks. https://doi.org/10.1385/1-59259-834-x:163
4. Aarsland, D., Ehrt, U., & Rektorová, I. (2011). Cognitive and psychiatric disturbances in Parkinson’s disease. Aging Health. https://doi.org/10.2217/ahe.11.3
5. Aarsland, D., Pedersen, K. F., Ehrt, U., Brønnick, K., Gjerstad, M. D., & Larsen, J. (2008). [Neuropsychiatric and cognitive symptoms in Parkinson disease].. PubMed.
6. Ab, S. (2020). Long-term course of negative symptoms in schizophrenia. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198840121.003.0003
7. Adetunji, B., Matthews, M., Basil, B., & Oyemade, A. (2007). "Bipolar Family". The Primary Care Companion to The Journal of Clinical Psychiatry. https://doi.org/10.4088/pcc.v09n0211e
8. Adida, M. (2010). Insight in bipolar disorder. Frontiers in Neuroscience. https://doi.org/10.3389/conf.fnins.2010.12.00009
9. Adler, C. H. (2011). Premotor Symptoms and Early Diagnosis of Parkinson's Disease. International Journal of Neuroscience. https://doi.org/10.3109/00207454.2011.620192
10. Adler, C. H., & Beach, T. G. (2016). Neuropathological basis of nonmotor manifestations of Parkinson's disease. Movement Disorders. https://doi.org/10.1002/mds.26605
11. Agid, Y., & Blin, J. (2007). Nerve Cell Death in Degenerative Diseases of the Central Nervous System: Clinical Aspects. Novartis Foundation symposium. https://doi.org/10.1002/9780470513422.ch2
12. Aguirre, M. E., García, M. M., & Amorena, B. Z. (2010). Bases fisiopatológicas de los síntomas no motores de la enfermedad de Parkinson. Revista de Neurología. https://doi.org/10.33588/rn.50s02.2009734
13. Ahlskog, J. E. (2013). Depression. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780199977567.003.0029
14. Ahlskog, J. E. (2020). Considerations for trials of disease modifying treatments in Parkinson disease. Neurology. https://doi.org/10.1212/wnl.0000000000009127
15. Ahmed, S., Baker, I., & Butler, C. (2016). Diagnosing young onset dementia can be challenging.. PubMed.
16. Ajagun, E. J., Asuku, A. O., Ayinla, M. T., Abdulsalam, T. A., Ajibare, A. J., Olajide, T. S., Hamza, Y. O., & Ganiyu, K. O. (2024). Pharmacotherapy of Parkinson's Disease and Their Limitations. CRC Press eBooks. https://doi.org/10.1201/9781003402893-17
17. Akhmadulina, A. O. (2020). Restless legs syndrome in Parkinson’s disease. S S Korsakov Journal of Neurology and Psychiatry. https://doi.org/10.17116/jnevro202012010280
18. Akhtar, R., & Mano, T. (2019). High serum neurofilament light chain predicts a worse fate in early parkinsonism. Neurology. https://doi.org/10.1212/wnl.0000000000007194
19. Akın, S. (2006). PARKINSON VE HEMŞİRELİK YAKLAŞIMLARI. Florence Nightingale Hemşirelik Dergisi. https://doi.org/10.17672/fnhd.26242
20. Albanese, A. (2006). Can falls be prevented in Parkinson's disease?. Journal of Neurology Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp.2006.108324
21. Albin, R. L., & Dauer, W. T. (2012). Parkinson syndrome. Neurology. https://doi.org/10.1212/wnl.0b013e31825dd3d0
22. Ali, N., Syeda, A., Topgyal, T., Gaur, N. A., & Islam, A. (2021). Parkinson’s Disease: A Current Perspectives on Parkinson’s Disease and Key Bioactive Natural Compounds as Future Potential Drug Candidates. Current Drug Targets. https://doi.org/10.2174/1389450122666210623115505
23. Alia, S., Hidayati, H. B., Hamdan, M., Nugraha, P., Fahmi, A., Turchan, A., & Haryono, Y. (2021). Penyakit Parkinson: Tinjauan Tentang Salah Satu Penyakit Neurodegeneratif yang Paling Umum. AKSONA. https://doi.org/10.20473/aksona.v1i2.145
24. Alizadeh, P., Terroba‐Chambi, C., Achen, B., Flores, K. C., & Bruno, V. (2023). P.024 Pain in monogenic Parkinson’s Disease. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. https://doi.org/10.1017/cjn.2023.128
25. Alonso-Lana, S. (2016). El Trastorno Bipolar: Cambios cerebrales asociados con el estado de ánimo y el deterioro cognitivo. TDX (Tesis Doctorals en Xarxa).
26. Amaral, A. K. B., Nobre, E. A. Q., & Barbosa, F. K. (2015). PARALISIA CEREBRAL: SEUS PARADIGMAS, AVANÇOS E RETROCESSOS. UNILUS Ensino e Pesquisa.
27. Amer, S. A. M., & Akkad, M. (2016). Correlation between Mild Cognitive Impairment and Functional Status among Elderly. Egyptian Journal of Geriatrics and Gerontology. https://doi.org/10.21608/ejgg.2016.30870
28. Amlang, C. J., & Kompoliti, K. (2022). Non‐Parkinsonian movement disorders in the elderly. Pathy's Principles and Practice of Geriatric Medicine. https://doi.org/10.1002/9781119484288.ch54
29. Amores, F. B. C., Pérez, G. P. L., Torres, N. A. C., & Carpio, V. D. P. C. (2023). Sleep pattern impairment in nursing students according to NANDA. Medwave. https://doi.org/10.5867/medwave.2023.s1.uta111
30. Antal, A., Bandini, F., Kéri, S., & Bódis-Wollner, I. (2004). Visuocognitive Dysfunctions in Parkinson’s Disease. CRC Press eBooks. https://doi.org/10.1201/9780203508596-33
31. Antelmi, E., Lanza, G., Mogavero, M. P., Mingolla, G. P., Plazzi, G., Ferini‐Strambi, L., Ferri, R., & Tinazzi, M. (2024). Intersection of Sleep Disorders and Parkinson Disease: Unveiling the Bidirectional Relationship. Movement Disorders Clinical Practice. https://doi.org/10.1002/mdc3.14254
32. Antulić, M. (2019). Komplementarni fizioterapijski pristupi kod osoba s Parkinsonovom bolesti.
33. Apaydın, H., Ahlskog, J. E., Parisi, J. E., Boeve, B. F., & Dickson, D. W. (2002). Parkinson Disease Neuropathology. Archives of Neurology. https://doi.org/10.1001/archneur.59.1.102
34. Arbuck, D. M. (2022). Neurotransmitter-based diagnosis and treatment: A hypothesis (Part 1). Current psychiatry. https://doi.org/10.12788/cp.0242
35. Argaud, S. (2016). Reconnaissance et mimétisme des émotions exprimées sur le visage : vers une compréhension des mécanismes à travers le modèle parkinsonien. https://doi.org/10.13097/archive-ouverte/unige:93815
36. Ariff, K. M., & Hassan, Z. A. (2006). Insomnia: Case Studies In Family Practice.. DOAJ (DOAJ: Directory of Open Access Journals).
37. Armstrong, M. J., & Okun, M. S. (2020). Diagnosis and Treatment of Parkinson Disease. JAMA. https://doi.org/10.1001/jama.2019.22360
38. Armstrong, R. A. (2016). Visual signs and symptoms of corticobasal degeneration. Clinical and Experimental Optometry. https://doi.org/10.1111/cxo.12429
39. Arnaldi, D., Morbelli, S., Morrone, E., Campus, C., & Nobili, F. (2012). Cognitive impairment in degenerative parkinsonisms: role of radionuclide brain imaging.. PubMed.
40. Arora, R., & Khan, Y. S. (2021). Motor Neuron Disease.
41. Arthur, G., & Jeff, M. (2011). Pesticides and Parkinson’s Disease. InTech eBooks. https://doi.org/10.5772/16479
42. Arunraj, E. (2013). Study of Autonomic Nervous System Dysfunction in Parkinson’s Patients..
43. Arya, A., Shilpa, K., & PR, B. (2024). Effect of udwarthana and vamana in rigidity predominant Parkinson’s disease. -Case report. Kerala Journal of Ayurveda. https://doi.org/10.55718/kja.339
44. Asuku, A. O., Ayinla, M. T., Olajide, T. S., Ajagun, E. J., Ganiyu, K. O., Hamza, Y. O., Ajibare, A. J., & Abdulsalam, T. A. (2024). Diagnosis and Biomarkers of Parkinson's Disease. CRC Press eBooks. https://doi.org/10.1201/9781003402893-15
45. Austin, K. W., Ameringer, S., Starkweather, A., Cloud, L., Sturgill, J., & Elswick, R. K. (2016). Biobehavioral Framework of Symptom and Health Outcomes of Uncertainty and Psychological Stress in Parkinson Disease. Journal of Neuroscience Nursing. https://doi.org/10.1097/jnn.0000000000000244
46. Auther, A. M., Gillett, D. A., & Cornblatt, B. A. (2008). Expanding the Boundaries of Early Intervention for Psychosis: Intervening During the Prodrome. Psychiatric Annals. https://doi.org/10.3928/00485713-20080801-02
47. Autissier, M.-R. (2008). Maladie de Parkinson: traitement et conseils officinaux. HAL (Le Centre pour la Communication Scientifique Directe).
48. Awad, R. A. (2011). Neurogenic bowel dysfunction in patients with spinal cord injury, myelomeningocele, multiple sclerosis and Parkinson’s disease. World Journal of Gastroenterology. https://doi.org/10.3748/wjg.v17.i46.5035
49. Axelrod, B. N. (2008). Fabrication of psychiatric symptoms: Somatoform and psychotic disorders. Psychology Press eBooks. https://doi.org/10.4324/9780203890042-23
50. Baba, T. (2023). 嗅覚検査と脳画像でせまるパーキンソン病の認知機能障害. Higher Brain Function Research. https://doi.org/10.2496/hbfr.43.207
51. Badawoud, A. M., Ali, L. S., Abdallah, M. S., Sabaa, R. M. E., Bahaa, M. M., El‐Masry, T. A., Wahsh, E., Yasser, M., Eltantawy, N., Eldesoqui, M., & Hamouda, M. A. (2024). The relation between Parkinson’s disease and non-steroidal anti-inflammatories; a systematic review and meta-analysis. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2024.1434512
52. Baig, F., Lawton, M., Rolinski, M., Ruffmann, C., Nithi, K., Evetts, S., Fernandes, H. J. R., Ben‐Shlomo, Y., & Shulman, J. (2015). Delineating nonmotor symptoms in early Parkinson's disease and first‐degree relatives. Movement Disorders. https://doi.org/10.1002/mds.26281
53. Bailey, G., Hubbard, E., Fasano, A., Tijssen, M. A., Lynch, T., Anderson, K. N., & Peall, K. J. (2021). Sleep disturbance in movement disorders: insights, treatments and challenges. Journal of Neurology Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp-2020-325546
54. Bains, N., Abdijadid, S., & Miller, J. (2021). Major Depressive Disorder (Nursing).
55. Bakay, S., Béchet, S., Moura, A. B. M. D., Delvaux, V., Salmon, É., & Garraux, G. (2011). La demence chez le patient parkinsonien: facteurs de risque, diagnostic et traitement.. RMLG. Revue médicale de Liège.
56. Bansal, R., & Sheldon, S. H. (2008). Parasomnias in Childhood. CRC Press eBooks. https://doi.org/10.3109/9781420048087-26
57. Baquero, M. (2015). Depressive symptoms in neurodegenerative diseases. World Journal of Clinical Cases. https://doi.org/10.12998/wjcc.v3.i8.682
58. Barakat, B., Agosti, R., Ruggeri, E., Tonini, V., Cervellera, M., Guidetti, E., Cevenini, M., Imbrogno, A., Fabbri, D., Pareo, I., Fucili, A., Corinaldesi, R., Stanghellini, V., Pezzilli, R., & Giorgio, R. D. (2012). Atypical presentation of acute idiopathic megacolon in a 14-year-old patient. Emergency Care Journal. https://doi.org/10.4081/ecj.2012.3.5
59. Baranwal, A. K., & Kumar, S. (2021). AN APPLIED PHYSIOLOGY OF PARKINSON’S DISEASE – AN OLD AGE NEUROLOGICAL DISORDER. Journal of Emerging Technologies and Innovative Research.
60. Barbosa, A. F., Chen, J., Freitag, F., Valente, D. F., Souza, C. D. O., Voos, M. C., & Chien, H. F. (2016). Gait, posture and cognition in Parkinson's disease. Dementia & Neuropsychologia. https://doi.org/10.1590/s1980-5764-2016dn1004005
61. Barbosa, A. F., Chen, J., Freitag, F., Valente, D. F., Souza, C. D. O., Voos, M. C., & Chien, H. F. (2018). Gait, posture and cognition in Parkinson's disease. Figshare. https://doi.org/10.6084/m9.figshare.7518644
62. Barbosa, E. R. (2013). Non-motor symptoms in Parkinson's disease. Arquivos de Neuro-Psiquiatria. https://doi.org/10.1590/0004-282x20130001
63. Bareš, M. (2011). Nejčastější chyby a omyly v diagnostice a léčbě Parkinsonovy nemoci. Neurologie pro praxi.
64. Barker, R. A., & Redfern, C. (2019). Parkinson’s Disease, Religious Belief and Spirituality. Cambridge University Press eBooks. https://doi.org/10.1017/9781316014165.011
65. Barone, P. (2009). Neurotransmission in Parkinson’s disease: beyond dopamine. European Journal of Neurology. https://doi.org/10.1111/j.1468-1331.2009.02900.x
66. Barrett, M. J. (2017). Risk Factors for Psychosis in Parkinson’s Disease. touchREVIEWS in Neurology. https://doi.org/10.17925/usn.2017.13.02.78
67. Barrett, M. J. (2017). Risk Factors for Psychosis in Parkinson’s Disease. US Endocrinology. https://doi.org/10.17925/use.2017.13.02.78
68. Barrutia, A. J., Merino, B. T., Gómez‐Esteban, J. C., & Imirizaldu, J. J. Z. (2010). Trastornos del sueño en la enfermedad de Parkinson: trastorno de conducta del sueño REM y síndrome de piernas inquietas. Revista de Neurología. https://doi.org/10.33588/rn.50s02.2010054
69. Barton, B., & Goetz, C. G. (2013). Movement Disorders due to Systemic Disease. https://doi.org/10.1002/9781118414019.ch9
70. Barton, B., Zauber, S. E., & Goetz, C. G. (2009). Movement Disorders Caused by Medical Disease. Seminars in Neurology. https://doi.org/10.1055/s-0029-1213731
71. Bayliss, J., Stark, R., Reichenbach, A., & Zane, B. (2011). Gut Hormones Restrict Neurodegeneration in Parkinson’s Disease. InTech eBooks. https://doi.org/10.5772/28028
72. Beccari, T., Michiara, M., Paciotti, S., Persichetti, E., Chiasserini, D., Castrioto, A., Tambasco, N., Rossi, A., Calabresi, P., Pagliardini, V., Bembi, B., & Parnetti, L. (2011). Role of Lysosomal Enzymes in Parkinson’s Disease: Lesson from Gaucher’s Disease. InTech eBooks. https://doi.org/10.5772/23552
73. Bech, S., Haugbøl, S., & Winge, K. (2017). [Challenges in the differential diagnoses of parkinsonism].. PubMed.
74. Beck, C. H. (1980). Normal Aging of the Human Brain Potentiates the Neuropathologies of Parkinson's Disease, Depression, and Alzheimer's Disease: Behavioural Implications. Canadian Journal of Counselling and Psychotherapy.
75. Begué, N. M., Cobos, E., Quiñones, S. M., & Ginebreda, J. A. (2011). Alteraciones morfologícas del disco óptico. Annals d'oftalmologia: òrgan de les Societats d'Oftalmologia de Catalunya, Valencia i Balears.
76. Bell, B. (2008). Depression and Parkinson’s Disease. touchREVIEWS in Neurology. https://doi.org/10.17925/usn.2008.04.01.67
77. Bellelli, G., Moresco, R., Panina–Bordignon, P., Arosio, B., Gelfi, C., Morandi, A., & Cesari, M. (2017). Is Delirium the Cognitive Harbinger of Frailty in Older Adults? A Review about the Existing Evidence. Frontiers in Medicine. https://doi.org/10.3389/fmed.2017.00188
78. Belli, H., Akbudak, M., Ural, C., & Kulacaoğlu, F. (2012). Solitary lesion in ponto-mesencephalic area related secondary mania: a case report.. PubMed.
79. Bellucci, A., Mercuri, N. B., Venneri, A., Faustini, G., Longhena, F., Pizzi, M., Missale, C., & Spano, P. (2015). Review: Parkinson's disease: from synaptic loss to connectome dysfunction. Neuropathology and Applied Neurobiology. https://doi.org/10.1111/nan.12297
80. Benallel, K., Nzamba, D. N., Kaddaf, A., Gartoum, M., & Kadiri, M. (2022). Psychotic symptoms and Parkinson’s Disease: Clinical and Therapeutic Aspects. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2022.1194
81. Benamer, H. T. S. (2007). Parkinsonism and tremor disorders. A clinical approach. Libyan Journal of Medicine. https://doi.org/10.3402/ljm.v2i2.4698
82. Benaur, M., Burgut, F. T., & Henchcliffe, C. (2006). Late-life depression: a neuropsychiatric approach. Expert Review of Neurotherapeutics. https://doi.org/10.1586/14737175.6.1.65
83. Bencze, J., Simon, V., Bereczki, E., Majer, R., Varkoly, G., Murnyák, B., Kálmán, J., & Hortobágyi, T. (2017). A Lewy-testes demencia klinikai és neuropatológiai jellemzői | Clinical and neuropathological characteristics of dementia with Lewy bodies.
84. Berg, A. T. (2011). Epilepsy, cognition, and behavior: The clinical picture. Epilepsia. https://doi.org/10.1111/j.1528-1167.2010.02905.x
85. Berg, D., & Bandmann, O. (2013). Biomarkers for PD. Neurology. https://doi.org/10.1212/wnl.0b013e3182825184
86. Berg, D., & Gaenslen, A. (2010). Place Value of Transcranial Sonography in Early Diagnosis of Parkinson’s Disease. Neurodegenerative Diseases. https://doi.org/10.1159/000314494
87. Bergman, H., & Deuschl, G. (2002). Pathophysiology of Parkinson's disease: From clinical neurology to basic neuroscience and back. Movement Disorders. https://doi.org/10.1002/mds.10140
88. Berlot, R., Pavlović, A., & Kojović, M. (2024). Secondary parkinsonism associated with focal brain lesions. Frontiers in Neurology. https://doi.org/10.3389/fneur.2024.1438885
89. Bernal-Pacheco, Ó., Limotai, N., Go, C. L., & Fernandez, H. H. (2012). Nonmotor Manifestations in Parkinson Disease. The Neurologist. https://doi.org/10.1097/nrl.0b013e31823d7abb
90. Betarbet, R., & Greenamyre, J. T. (2007). Rotenone Model for Parkinson’s Disease. CRC Press eBooks. https://doi.org/10.3109/9781420019223-25
91. Bhatia, K. P., Cociasu, I., Sorbera, C., Tuttolomondo, A., Morgante, F., & Friedman, J. (2021). Commentary: <scp>Anderson‐Fabry</scp> Disease: A Rare Cause of Levodopa‐Responsive Early Onset Parkinsonism. Movement Disorders Clinical Practice. https://doi.org/10.1002/mdc3.13297
92. Bhatia, K., Cordivari, C., Edwards, M. J., Foltynie, T., Hariz, M., Korlipara, P., Limousin, P., Quinn, N., Tabrizi, S. J., & Warner, T. T. (2016). Movement Disorders. Neurology. https://doi.org/10.1002/9781118486160.ch6
93. Bhattarai, H. B., Basnet, B., Bhattarai, M., Shrestha, A., Gautam, S., Lamichhane, S., Uprety, M., Pokhrel, B., Sah, S., & Yadav, J. K. (2023). Diagnostic pitfalls in young onset parkinsonism and its unique challenges: A case report from rural Nepal. SAGE Open Medical Case Reports. https://doi.org/10.1177/2050313x231197062
94. Bick, R. J., Doursout, M., & Poindexter, B. J. (2016). The Complex Cascade of Parkinson’s Disease: Sniffing out a Therapy?. Journal of nature and science.
95. Bie, R. M. A. D. (2016). Beyond Tremor, Slowness, and Stiffness. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190607555.003.0004
96. Biercewicz, M., & Ćwiękała-Lewis, K. (2024). Sleep Assessment in Parkinson’s Disease – An Assessment Tool. The Journal of Neurological and Neurosurgical Nursing. https://doi.org/10.15225/pnn.2024.13.3.6
97. Bigio, M. R. D. (2021). Neuronal Death. Cambridge University Press eBooks. https://doi.org/10.1017/9781316671863.030
98. Bitnun, A., & Richardson, S. E. (2015). Childhood Encephalitis in Canada in 2015. Canadian Journal of Infectious Diseases and Medical Microbiology. https://doi.org/10.1155/2015/947602
99. Blonder, L. X., & Slevin, J. T. (2011). Emotional Dysfunction in Parkinson’s Disease. Behavioural Neurology. https://doi.org/10.1155/2011/143857
100. Blood, M. R. Y., Ferro, M. M., Munhoz, R. P., Teive, H. A. G., & Camargo, C. H. F. (2016). Classification and Characteristics of Pain Associated with Parkinson’s Disease. Parkinson s Disease. https://doi.org/10.1155/2016/6067132
101. Bocquillon, P. (2012). Approche psycho-physiologique des troubles attentionnels dans la maladie de Parkinson.
102. Boczarska‐Jedynak, M., & Opala, G. (2005). [Sleep disturbances in Parkinson's disease].. PubMed.
103. Boeve, B. (2008). What more can we learn from studying the REM sleep behaviour disorder-Parkinson's disease association?. Journal of Neurology Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp.2008.153551
104. Boeve, B. F. (2009). Early clinical features of the parkinsonian-related dementias. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511581410.015
105. Boeve, B. F. (2015). Parkinsonism-Related Dementiasa. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190244927.003.0036
106. Boeve, B. F., & Saper, C. B. (2006). REM sleep behavior disorder. Neurology. https://doi.org/10.1212/01.wnl.0000209264.61035.bb
107. Bohnen, N. I., & Shulman, J. (2019). Sleep Disturbance as Potential Risk and Progression Factor for Parkinson’s Disease. Journal of Parkinson s Disease. https://doi.org/10.3233/jpd-191627
108. Bohnen, N. I., Marušič, U., Roytman, S., Paalanen, R., Michalakis, F., Brown, T., Scott, P. J. H., Carli, G., Albin, R. L., & Kanel, P. (2024). Dynamic balance and gait impairments in Parkinson’s disease: novel cholinergic patterns. Brain Communications. https://doi.org/10.1093/braincomms/fcae286
109. Bonifati, V. (2003). Autosomal recessive, early-onset Parkinson’s disease.
110. Bonnet, M. (2001). Symptômes de la maladie de Parkinson. Gérontologie et société. https://doi.org/10.3917/gs.097.0129
111. Bonnet, M. H., & Arand, D. L. (2013). Insomnia. https://doi.org/10.3920/9789086867639_003
112. Borek, L. L., Amick, M. M., & Friedman, J. H. (2006). Non-Motor Aspects of Parkinson's Disease. CNS Spectrums. https://doi.org/10.1017/s1092852900013560
113. Borek, L. L., Chou, K. L., & Friedman, J. H. (2007). Management of the behavioral aspects of Parkinson’s disease. Expert Review of Neurotherapeutics. https://doi.org/10.1586/14737175.7.6.711
114. Borghammer, P., & Berge, N. V. D. (2019). Brain-First versus Gut-First Parkinson’s Disease: A Hypothesis. Journal of Parkinson s Disease. https://doi.org/10.3233/jpd-191721
115. Borm, C. D., Bloem, B. R., Hoyng, C. B., Vries, N. M. D., & Theelen, T. (2022). The Many Faces of Blurry Vision in Parkinson’s Disease: An Illustrative Case Series. Case Reports in Neurology. https://doi.org/10.1159/000523987
116. Bornschein, B., Siebert, U., & Dodel, R. (2004). Zusammenhang zwischen Dyskinesien und gesundheitsbezogener Lebensqualitaet bei Patienten mit M. Parkinson. Aktuelle Neurologie. https://doi.org/10.1055/s-2004-833286
117. Borodziuk, B., Borodziuk, F., Ciuba, K., Dąbrowska, P., Żuber, M., Bochyński, K., Molenda, K., Dacka, M., Giżewska, K., & Białogłowski, K. (2024). Preventing Progression: A Comprehensive Approach to Managing Parkinson's Disease. Quality in Sport. https://doi.org/10.12775/qs.2024.15.52254
118. Borrego, L. I. E., Mollineda, K. M., Guerra, V. M. C., & Guerra., E. C. (2018). Diagnóstico temprano de la Parálisis Supra Nuclear Progresiva.. Dilemas contemporáneos Educación Política y Valores.
119. Bor‐Seng‐Shu, E., Almeida, K. J., Andrade, D. C. D., Fonoff, E. T., Teixeira, M. J., & Barbosa, E. R. (2012). Echogenicity of the substantia nigra region in Parkinson's disease. Arquivos de Neuro-Psiquiatria. https://doi.org/10.1590/s0004-282x2012000200016
120. Bosboom, J., & Wolters, E. (2004). Psychotic symptoms in Parkinson?s disease: pathophysiology and management. Expert Opinion on Drug Safety. https://doi.org/10.1517/eods.3.3.209.31071
121. Bountouni, I., Zis, P., Chaudhuri, К. R., & Schrag, A. (2014). Psychosis in Parkinson’s Disease. Neuropsychiatric symptoms of neurological disease. https://doi.org/10.1007/978-3-319-09537-0_6
122. Braak, H., & Tredici, K. D. (2008). Invited Article: Nervous system pathology in sporadic Parkinson disease. Neurology. https://doi.org/10.1212/01.wnl.0000312279.49272.9f
123. Bramon, E., & Murray, R. (2001). A plausible model of schizophrenia must incorporate psychological and social, as well as neuro developmental, risk factors. Dialogues in Clinical Neuroscience. https://doi.org/10.31887/dcns.2001.3.4/ebramon
124. Bransfield, R. C., & Friedman, K. J. (2019). Differentiating Psychosomatic, Somatopsychic, Multisystem Illnesses and Medical Uncertainty. Healthcare. https://doi.org/10.3390/healthcare7040114
125. Braune (2002). Vegetative Störungen beim idiopathischen Parkinsonsyndrom: diagnostische Relevanz und therapeutische Möglichkeiten. Praxis. https://doi.org/10.1024/0369-8394.91.10.402
126. Bravo, M. D. L. (2011). Ansiedad y depresión en la vejez.
127. Brdiczka, P. (2014). Drugs Can Only Affect Symptoms. Deutsches Ärzteblatt international. https://doi.org/10.3238/arztebl.2014.0489a
128. Brefel‐Courbon, C., & Ory‐Magne, F. (2010). La douleur dans la maladie de Parkinson. Neurologie com. https://doi.org/10.1684/nro.2009.0113
129. Britton, T. C., & Chaudhuri, К. R. (2009). REM sleep behavior disorder and the risk of developing Parkinson disease or dementia. Neurology. https://doi.org/10.1212/01.wnl.0000343502.98134.01
130. Bronstein, A. M., & Lempert, T. (2010). Management of the patient with chronic dizziness. Restorative Neurology and Neuroscience. https://doi.org/10.3233/rnn-2010-0530
131. Brooks, D. J. (2022). Neuroimaging Studies in Non-Motor Parkinson’s Disease Symptoms. Cambridge University Press eBooks. https://doi.org/10.1017/9781009039291.006
132. Brown, S. L. (2006). Deterioration. Epilepsia. https://doi.org/10.1111/j.1528-1167.2006.00682.x
133. Bruce, H. J., Tripodis, Y., McClean, M. D., Korell, M., Tanner, C. M., Contreras, B., Gottesman, J., Kirsch, L., Karim, Y., Martin, B., Palmisano, J., Abdolmohammadi, B., Shih, L. C., Stein, T. D., Stern, R. A., Adler, C. H., Mez, J., Nowinski, C., McKee, A. C., & Alosco, M. L. (2023). American Football Play and Parkinson Disease Among Men. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2023.28644
134. Brugger, F., Erro, R., Balint, B., Kägi, G., Barone, P., & Bhatia, K. P. (2015). Why is there motor deterioration in Parkinson’s disease during systemic infections-a hypothetical view. npj Parkinson s Disease. https://doi.org/10.1038/npjparkd.2015.14
135. Bruno, M. K., Dhall, R., Duquette, A., Haq, I., Honig, L. S., Lamotte, G., Mari, Z., McFarland, N. R., Montaser-Kouhsari, L., Rodríguez‐Porcel, F., Shurer, J., Siddiqui, J., Spears, C. C., Wills, A., Diaz, K., & Golbe, L. I. (2024). A General Neurologist's Practical Diagnostic Algorithm for Atypical Parkinsonian Disorders. Neurology Clinical Practice. https://doi.org/10.1212/cpj.0000000000200345
136. Buczek, A., Borończyk, M., Hudzińska, P., Bigajski, H., Białas, A., Balcerzak, W., Marcinkiewicz, K., Milczarek, J., & Siuda, J. (2024). Risk factors for falls in Parkinson's disease and other parkinsonisms. Archives of Gerontology and Geriatrics Plus. https://doi.org/10.1016/j.aggp.2024.100054
137. Budson, A. E., & O’Connor, M. K. (2021). Which other disorders cause dementia?. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780190098124.003.0003
138. Bulut, N. S., Yorguner, N., Bulut, G. Ç., & Tuncer, E. N. (2020). A Case of Chronic Functional Parkinsonism Treated Over 10 Years for the Diagnosis of Juvenile Parkinsonism. Turkish Journal of Psychiatry. https://doi.org/10.5080/u25540
139. Burchill, E., Watson, C., Fanshawe, J. B., Badenoch, J., Rengasamy, E., Ghanem, D. A., Holle, C., Conti, I., Sadeq, M. A., Saini, A., Lahmar, A., Cross, B., McGuigan, G., Nandrha, A., Kane, E. J., Wozniak, J., Ghorab, R. M. F., Song, J., Sommerlad, A., ... Rogers, J. (2024). The impact of psychiatric comorbidity on Parkinson's disease outcomes: a systematic review and meta-analysis. The Lancet Regional Health - Europe. https://doi.org/10.1016/j.lanepe.2024.100870
140. Burn, D. J. (2011). Clinical Features of Dementia Associated with Parkinson's Disease and Dementia with Lewy Bodies. Parkinson s Disease. https://doi.org/10.1002/9781444397970.ch12
141. Busby, C., & Burns, A. (2002). Differential Diagnosis of Dementia. https://doi.org/10.1002/0470846410.ch54
142. Bédard, M., Lemay, S., Gagnon, J., Masson, H., & Paquet, F. (1999). Induction of a Transient Dysexecutive Syndrome in Parkinson’s Disease using a Subclinical Dose of Scopolamine. Behavioural Neurology. https://doi.org/10.1155/1999/316598
143. Bédard, M., Lévesque, M., Lemay, S., & Paquet, F. (2003). Nondopaminergic Influences on Cognition in Parkinson’s Disease. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-326-2_15
144. Bénony, H., Bénony-Viodé, C., & Dumas, J. (2012). Le retard mental. Le point sur... Psychologie.
145. Cabo, I., Rodríguez-Constenla, I., Bellas-Lamas, P., & Cebrián, E. (2010). [Cognitive and neuropsychiatric disorders in Parkinson's disease].. PubMed.
146. Caixeta, L., & Vieira, R. T. (2008). DEMÊNCIA NA DOENÇA DE PARKINSON E PARKINSONISMO NAS DEMÊNCIAS.
147. Caixeta, L., & Vieira, R. T. (2008). Demência na doença de Parkinson. Brazilian Journal of Psychiatry. https://doi.org/10.1590/s1516-44462008000400013
148. Caixeta, L., & Vieira, R. T. (2008). Demência na doença de Parkinson. Brazilian Journal of Psychiatry. https://doi.org/10.1590/s1516-44462008005000016
149. Calne, D. B., & Kebabian, J. K. (1980). Parkinson's disease: unanswered questions.. PubMed.
150. Camicioli, R. (2002). Identification of parkinsonism and Parkinson's disease. Drugs of today. https://doi.org/10.1358/dot.2002.38.10.740195
151. Campoy, A. T., Rotger, M. Y., Gutiérrez, L. R. D. L. H., & Pastorelli, R. V. (2011). ¿Psicosis mental injertada o retraso mental? A propósito de un caso.. Psiquiatria.com.
152. Canales, V. M., & Clavería, C. J. U. (2008). Manifestaciones no motoras en la enfermedad de Parkinson. REVISTA MÉDICAS UIS.
153. Capaldi, D. M., & Kim, H. K. (2014). Comorbidity of Depression and Conduct Disorder. Oxford University Press eBooks. https://doi.org/10.1093/oxfordhb/9780199797004.013.015
154. Capone, G. T., Royal, P., Ares, W. J., & Lannigan, E. (2007). Trastornos neuroconductuales en niños, adolescentes y adultos jóvenes con síndrome de Down: Segunda parte. Revista Síndrome de Down: Revista española de investigación e información sobre el Síndrome de Down.
155. Capone, G. T., Royal, P., Ares, W. J., & Lanningan, E. (2007). Transtornos neuroconductuales en niños, adolescentes y adultos jóvenes con síndrome de Down. Revista Síndrome de Down: Revista española de investigación e información sobre el Síndrome de Down.
156. Cardoso, F. (1995). Tratamento da doença de Parkinson. Arquivos de Neuro-Psiquiatria. https://doi.org/10.1590/s0004-282x1995000100001
157. Caslake, R., Taylor, K., & Counsell, C. (2009). Parkinson's disease misdiagnosed as stroke. BMJ Case Reports. https://doi.org/10.1136/bcr.07.2008.0558
158. Casotti, K. C. D. C., Koga, M. M. P., & Palácio, S. G. (2009). EFEITOS DO ISOSTRETCHING NA DOR E DEPRESSÃO NA DOENÇA DE PARKINSON: ESTUDO DE CASO.
159. Castañeda, C. S. (2009). Structural brain changes, cognitive deficits and visual hallucinations in dementia with lewy bodies and parkinson's disease with dementia. TDX (Tesis Doctorals en Xarxa).
160. Castillo, J. C. R., Ruíz, A. M., López, C. L. M., Soler, M. A. S., & Gutiérrez, C. C. P. (2021). Parkinson genetico: Reporte de un caso clínico y revisión de la literatura. Acta neurológica colombiana. https://doi.org/10.22379/24224022379
161. Ceballos-Baumann, A. (2006). Demenz bei Parkinson-Syndromen. Nervenheilkunde. https://doi.org/10.1055/s-0038-1626803
162. Ceballos-Baumann, A. (2006). Demenz bei Parkinson-Syndromen: Lewy-Körper-Demenz, idiopathisches und andere Parkinson-Syndrome, Normaldruckhydrozephalus. Nervenheilkunde. https://doi.org/10.1055/s-0038-1626818
163. Celaya, L. V., Rodríguez, A. T., Pérez, J. R. G., Márquez, G. M., Toledo‐Cárdenas, M. R., Castilla, P. C., Manzo, J., Coria‐Ávila, G. A., & García, L. I. (2019). Enfermedad de Parkinson más allá de lo motor. eNeurobiología. https://doi.org/10.25009/eb.v10i23.2542
164. Cerame, Á., & Silva, M. L. C. F. D. (2019). DELUSIONAL JEALOUSY IN THE CONTEXT OF PARKINSON’S DISEASE: A CASE REPORT.. https://doi.org/10.26226/morressier.5d1a037257558b317a140326
165. Ceravolo, R., Rossi, C., Kiferle, L., & Bonuccelli, U. (2010). Nonmotor symptoms in Parkinson‘s disease: the dark side of the moon. Future Neurology. https://doi.org/10.2217/fnl.10.69
166. Cervantes‐Arriaga, A., & Rodríguez‐Violante, M. (2011). Disfunción no motora en la enfermedad de Parkinson: una enfermedad neurológica con manifestaciones multisistémicas. Medicina Interna de México.
167. Chakraborty, A., & Diwan, A. (2022). Depression and Parkinson's disease: a Chicken-Egg story. AIMS neuroscience. https://doi.org/10.3934/neuroscience.2022027
168. Chambers, N., Lanza, K., & Bishop, C. (2020). Pedunculopontine Nucleus Degeneration Contributes to Both Motor and Non-Motor Symptoms of Parkinson’s Disease. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2019.01494
169. Chang, F., & Josephs, K. A. (2013). Levodopa Responsiveness in Adult-onset Lower Limb Dystonia is Associated with the Development of Parkinson's Disease.. PubMed. https://doi.org/10.7916/d8vd6x5m
170. Chang, F., & Josephs, K. A. (2013). Levodopa Responsiveness in Adult-onset Lower Limb Dystonia is Associated with the Development of Parkinson’s Disease. Tremor and Other Hyperkinetic Movements. https://doi.org/10.5334/tohm.136
171. Chaudhuri, К. R., & Martínez‐Martín, P. (2004). Clinical assessment of nocturnal disability in Parkinson’s disease. Neurology. https://doi.org/10.1212/wnl.63.8_suppl_3.s17
172. Chaudhuri, К. R., Titova, N., Qamar, M. A., Murășan, I., & Falup‐Pecurariu, C. (2022). The Dashboard Vitals of Parkinson’s: Not to Be Missed Yet an Unmet Need. Journal of Personalized Medicine. https://doi.org/10.3390/jpm12121994
173. Chen, B. (2013). Research Progress of Non-motor Symptoms of Parkinson Disease. Medical Recapitulate.
174. Chen, H., Gallo, V., & Pearce, N. (2020). Idiopathic Parkinson’s disease and classification of parkinsonisms. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198749493.003.0011
175. Chen, S.-Y., & Tsai, S. (2010). The Epidemiology of Parkinson's Disease. Tzu Chi Medical Journal. https://doi.org/10.1016/s1016-3190(10)60044-4
176. Chen, Y., Garcia, G. E., Huang, W., & Constantini, S. (2014). The Involvement of Secondary Neuronal Damage in the Development of Neuropsychiatric Disorders Following Brain Insults. Frontiers in Neurology. https://doi.org/10.3389/fneur.2014.00022
177. Chen, Y.-S. (2012). Association between chronic insomnia and depression in elderly adults. Journal of the Chinese Medical Association. https://doi.org/10.1016/j.jcma.2012.04.001
178. Chiba‐Falek, O., & Nussbaum, R. L. (2003). Regulation of -Synuclein Expression: Implications for Parkinson's Disease. Cold Spring Harbor Symposia on Quantitative Biology. https://doi.org/10.1101/sqb.2003.68.409
179. Chicharro-Ciuffardi, A., González-Silva, M., Marinis-Palombo, A. D., & Gabler-Santalices, G. (2012). Psychiatric disorders secondary to nonconvulsive status epilepticus of frontal origin. Two clinical case reports.. PubMed.
180. Chin, D. H., & Meals, R. A. (2001). Anterior interosseous nerve syndrome. Journal of the American Society for Surgery of the Hand. https://doi.org/10.1053/jssh.2001.28806
181. Chiu, S., & Cutsforth‐Gregory, J. K. (2021). Atypical Parkinsonian Syndromes. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197512166.003.0070
182. Chiu, Y., Lee, S., & Yeh, T. (2016). Diversified psychiatric presentation in a case of progressive supranuclear palsy. Journal of Clinical Gerontology and Geriatrics. https://doi.org/10.1016/j.jcgg.2016.05.001
183. Choukekar, T. D., Mestry, S. L., & Phondke, A. P. (2020). Parkinson’s Disease: An Overview of Various Treatments. International Journal of Research.
184. Chouliaras, L., Topiwala, A., Cristescu, T., & Ebmeier, K. P. (2015). Establishing the cause of memory loss in older people.. PubMed.
185. Chowdhury, T., Roy, P. D., & Chowdhury, H. I. (2021). Delusion in Parkinson’s disease: A Symptom or an Adverse Effect of Dopamine Agonist – A Case Report.
186. Claasen, J.-H. (2010). Neuroinflammatorische Prozesse beim idiopathischen Parkinson-Syndrom : antiinflammatorische Intervention als mögliche Therapieoption?.
187. Claassen, D. O., Josephs, K. A., Ahlskog, J. E., Silber, M. H., Tippmann‐Peikert, M., & Boeve, B. F. (2010). REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century. Neurology. https://doi.org/10.1212/wnl.0b013e3181ec7fac
188. Clarke, C. (2022). Movement Disorders. Neurology. https://doi.org/10.1002/9781119235699.ch7
189. Coakeley, S., Martens, K. A. E., & Almeida, Q. J. (2014). Management of anxiety and motor symptoms in Parkinson’s disease. Expert Review of Neurotherapeutics. https://doi.org/10.1586/14737175.2014.936388
190. Colaci, M., Cassone, G., Manfredi, A., Sebastiani, M., Giuggioli, D., & Ferri, C. (2014). Neurologic Complications Associated with Sjögren’s Disease: Case Reports and Modern Pathogenic Dilemma. Case Reports in Neurological Medicine. https://doi.org/10.1155/2014/590292
191. Connolly, B. S., & Fox, S. H. (2012). Drug treatments for the neuropsychiatric complications of Parkinson’s disease. Expert Review of Neurotherapeutics. https://doi.org/10.1586/ern.12.142
192. Constenla, I. R., Cabo, I., Lamas, P. B., & Pérez, E. M. C. (2010). Trastornos cognitivos y neuropsiquiátricos en la enfermedad de Parkinson. Revista de Neurología. https://doi.org/10.33588/rn.50s02.2009737
193. Cordeiro, Q., Zung, S., & Vallada, H. (2008). Pisa syndrome induced by rapid increase and high dosage of risperidone. Arquivos de Neuro-Psiquiatria. https://doi.org/10.1590/s0004-282x2008000600026
194. Cosgrove, J., & Alty, J. (2018). Cognitive deficits in Parkinson&amp;rsquo;s disease: current perspectives. Journal of Parkinsonism and Restless Legs Syndrome. https://doi.org/10.2147/jprls.s125064
195. Costa, M. P. D., Leite, F., Salgado, H., Campos, O., Carvalho, P. C. L. D., Queirós, P., & Cochat, C. (2016). Clinical aspects of depression in Parkinson's disease. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2016.01.1365
196. Costanza, A., Amerio, A., Aguglia, A., Escelsior, A., Serafini, G., Berardelli, I., Pompili, M., & Amore, M. (2020). When Sick Brain and Hopelessness Meet: Some Aspects of Suicidality in the Neurological Patient. CNS & Neurological Disorders - Drug Targets. https://doi.org/10.2174/1871527319666200611130804
197. Cotterell, P., Weight, D., Joseph, S., & Joseph, P. (2019). Complex Parkinson's disease: review and experiences. British Journal of Healthcare Assistants. https://doi.org/10.12968/bjha.2019.13.8.394
198. Crouse, J. J., Phillips, J. R., Jahanshahi, M., & Moustafa, A. A. (2016). Postural instability and falls in Parkinson’s disease. Reviews in the Neurosciences. https://doi.org/10.1515/revneuro-2016-0002
199. Csóti, I., Fogel, W., Schade, S., Schnitzler, A., Südmeyer, M., Winkler, C., & Winkler, J. (2013). Schmerz bei Parkinson-Patienten. Aktuelle Neurologie. https://doi.org/10.1055/s-0033-1343339
200. Cuenca‐Bermejo, L., Gil-Martínez, A.-L., Cano-Fernandez, L., Sánchez-Rodrigo, C., Estrada, C., Fernández‐Villalba, E., & Herrero, M. T. (2019). Parkinson's disease: a short story of 200 years.. PubMed. https://doi.org/10.14670/hh-18-073
201. Cuevas‐Esteban, J. (2018). Parkinsonismo, depresión, demencia: Un reto clínico y terapeútico. Informaciones psiquiátricas: Publicación científica de los Centros de la Congregación de Hermanas Hospitalarias del Sagrado Corazón de Jesús.
202. Cummings, J. L., Henchcliffe, C., Schaier, S., Simuni, T., Waxman, A., & Kemp, P. M. (2011). The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration. Brain. https://doi.org/10.1093/brain/awr177
203. Czernecki, V., & Bonnet, A. M. (2013). Non-motor symptoms in Parkinson's disease: cognition and behavior. Gériatrie et Psychologie Neuropsychiatrie du Viellissement. https://doi.org/10.1684/pnv.2013.0423
204. Dalamagka, M. I. (2024). Epilepsy in children and anesthesia. Magna Scientia Advanced Research and Reviews. https://doi.org/10.30574/msarr.2024.12.2.0180
205. Dalvi, A., Lyons, K. E., & Pahwa, R. (2006). Secondary Dystonia. CRC Press eBooks. https://doi.org/10.3109/9781420019988-19
206. Dalvi, A., Lyons, K. E., & Pahwa, R. (2012). Secondary dystonia. CRC Press eBooks. https://doi.org/10.3109/9781841848525-20
207. Dan, R., Růžička, F., Bezdíček, O., Růžička, E., Roth, J., Vymazal, J., Goelman, G., & Jech, R. (2017). Separate neural representations of depression, anxiety and apathy in Parkinson’s disease. Scientific Reports. https://doi.org/10.1038/s41598-017-12457-6
208. Daniele, A., & Albanese, A. (2012). Early visual memory deficits. Neurology. https://doi.org/10.1212/wnl.0b013e318253d67b
209. Darnell, R. B., & Posner, J. B. (2010). Cerebral Hemisphere Syndromes. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199772735.003.004
210. Darweesh, S. K., Wolters, F. J., Postuma, R. B., Stricker, B. H., Hofman, A., Koudstaal, P. J., Ikram, M. K., & Ikram, M. A. (2017). Association Between Poor Cognitive Functioning and Risk of Incident Parkinsonism. JAMA Neurology. https://doi.org/10.1001/jamaneurol.2017.2248
211. Das, S., Misra, A. K., Dutt, A., & Das, S. K. (2004). Cognition In Parkinsonian Syndromes : A Review. Annals of Indian Academy of Neurology.
212. Datta, S. (2019). Parkinson's Disease and current medical management strategies.
213. Daude, H., Bousquet-Jacq, N., Kanel, K. V., Boulay, N., Faye, M., Coquery, M., Tronel, S., & Beltran, M. (2015). Repérage et prise en charge multidisciplinaire des troubles du développement cognitif et relationnel de l’enfant né prématurément. Contraste. https://doi.org/10.3917/cont.041.0151
214. Dehanov, S., & Ferreira, T. (2019). AN IMMACULATE CONCEPTION – THE DIFFERENTIAL DIAGNOSIS OF A DELUSION OF PREGNANCY. https://doi.org/10.26226/morressier.5d1a037857558b317a14085a
215. Delattre, J., Moll, J., Antoine, J. C., Brashear, H. R., Drlicek, M., Dropcho, E. J., Giometto, B., Graus, F., Greenlee, J., Honnorat, J., Jaeckle, K. A., Tanaka, K., & Vecht, C. (1995). Guidelines on the detection of paraneoplastic anti-neuronal-specific antibodies. Neurology. https://doi.org/10.1212/wnl.45.10.1937
216. Delgadillo-Iniguez, D., Corvol, J., Gély-Nargeot, M.-C., & Lacomblez, L. (2006). [Parkinson's disease: psychological and behavioral disorders].. HAL (Le Centre pour la Communication Scientifique Directe).
217. Delic, V., Beck, K. D., Pang, K., & Citron, B. A. (2020). Biological links between traumatic brain injury and Parkinson’s disease. Acta Neuropathologica Communications. https://doi.org/10.1186/s40478-020-00924-7
218. DeMarco, E. C., Zhang, Z., Al-Hakeem, H., & Hinyard, L. (2022). Depression After Parkinson’s Disease: Treated Differently or Not At All?. Journal of Geriatric Psychiatry and Neurology. https://doi.org/10.1177/08919887221090217
219. Deonna, T., Roulet, E., Gaillard, F., Peter-Favre, C., & Despland, P. (1991). Acquired Aphasia, Dementia, and Behavior Disorder with Epilepsy and Continuous Spike and Waves During Sleep in a Child. Epilepsia. https://doi.org/10.1111/j.1528-1157.1991.tb04683.x
220. Derry, C. P., & Welch, K. A. (2013). Mild traumatic brain injury and epilepsy: alcohol misuse may underpin the association. Journal of Neurology Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp-2013-306267
221. Deuschl, G. (2006). Neuropsychiatrische Symptome bei Parkinson-Patienten. Aktuelle Neurologie. https://doi.org/10.1055/s-2006-932666
222. Deuschl, G. (2008). Notfälle bei Patienten mit Bewegungsstörungen - Komplikationen auf dem Gebiet extrapyramidaler Erkrankungen. Notfall & Hausarztmedizin. https://doi.org/10.1055/s-2008-1061614
223. Diamond, A., & Jankovic, J. (2006). Treatment of advanced Parkinson’s disease. Expert Review of Neurotherapeutics. https://doi.org/10.1586/14737175.6.8.1181
224. Diarra, E., Jedynak, C. P., & Verny, M. (2008). [Tremor in the elderly].. PubMed. https://doi.org/10.1684/pnv.2008.0139
225. Dickson, D. W., & Orr, C. (2011). Neuropathology of Dementia in Parkinson's Disease. Parkinson s Disease. https://doi.org/10.1002/9781444397970.ch14
226. Diederich, N. J., Stebbins, G. T., Schiltz, C., & Goetz, C. G. (2014). Are patients with Parkinson’s disease blind to blindsight?. Brain. https://doi.org/10.1093/brain/awu094
227. Diesch, T., & Mellor, D. (2013). Birth transitions: Pathophysiology, the onset of consciousness and possible implications for neonatal maladjustment syndrome in the foal. Equine Veterinary Journal. https://doi.org/10.1111/evj.12120
228. Ding, K., Gupta, P. K., & Diaz‐Arrastia, R. (2016). Epilepsy after Traumatic Brain Injury. CRC Press, Taylor and Francis Group eBooks.
229. Diniz, M. L., Morais, A. M. B. D., & Sousa, M. N. A. D. (2024). Influência da síndrome do intestino irritável sobre a depressão e outras comorbidades psiquiátricas. Revista Eletrônica Acervo Científico. https://doi.org/10.25248/reac.e13512.2024
230. Dirkx, M. F., & Helmich, R. C. (2022). Parkinson’s Disease and Parkinsonian Tremor. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197529652.003.0012
231. Disbrow, E. A., Carmichael, O., He, J., Lanni, K. E., Dressler, E. M., Zhang, L., Malhado-Chang, N., & Sigvardt, K. A. (2014). Resting State Functional Connectivity is Associated with Cognitive Dysfunction in Non-Demented People with Parkinson's Disease. Journal of Parkinson s Disease. https://doi.org/10.3233/jpd-130341
232. Dissanayaka, N. (2021). Anxiety in Parkinson’s Disease. Cambridge University Press eBooks. https://doi.org/10.1017/9781139087469.009
233. Djekidel, M., & Harb, W. (2006). A Case of Foot Drop as an Expression of Brain Metastases?. The Neurologist. https://doi.org/10.1097/01.nrl.0000231731.90889.27
234. DM, F. P. G. M., BSc, M. P. C. B., Boyd, D. M., & BSc, M. D. S. S. (2014). Major Medical Problems. https://doi.org/10.1002/9781118690345.ch8
235. Dodds, C., Kumar, C. M., & Servin, F. (2017). Cognitive dysfunction and sleep disorders. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198735571.003.0014
236. Dogaru, G., & Stănescu, I. (2014). TREATMENT AND REHABILITATION IN NON-MOTORS SYMPTOMS OF PARKINSON’S DISEASE. Balneo Research Journal. https://doi.org/10.12680/balneo.2014.1076
237. Doherty, K. A., Silveira‐Moriyama, L., Parkkinen, L., Healy, D. G., Farrell, M., Mencacci, N. E., Ahmed, Z., Brett, F., Hardy, J., Quinn, N., Counihan, T. J., Lynch, T., Fox, Z., Révész, T., Lees, A. J., & Holton, J. L. (2013). PARKIN DISEASE–A CLINICOPATHOLOGICAL ENTITY?. Journal of Neurology Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp-2013-306573.13
238. Domanskyi, A., & Chmielarz, P. (2021). Alpha-synuclein preformed fibrils: a tool to understand Parkinson’s disease and develop disease modifying therapy. Neural Regeneration Research. https://doi.org/10.4103/1673-5374.310686
239. Domoto‐Reilly, K., Sapolsky, D., & Dickerson, B. C. (2014). Mild Cognitive Impairment (MCI) Stage of the Frontotemporal Dementias: Early Diagnosis and Management. Perspectives on Gerontology. https://doi.org/10.1044/gero19.2.57
240. Doręgowska, M., & Rudzińska, M. (2019). SLEEP DISORDERS IN PARKINSON’S DISEASE. Wiadomości Lekarskie. https://doi.org/10.36740/wlek201903120
241. Doty, R. L., & Hawkes, C. H. (2022). Olfactory Dysfunction in Parkinson’s Disease and Related Disorders. Cambridge University Press eBooks. https://doi.org/10.1017/9781009039291.011
242. Doty, R. L., & Tekelı, H. (2012). Chapter 9. Olfactory function in Parkinson’s disease. Advances in consciousness research. https://doi.org/10.1075/aicr.85.16dot
243. Dropcho, E. J. (2008). Paraneoplastic disorders. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511545900.018
244. Du, Y., Zhang, Y., & Zhou, Q. (2019). Research progress on blood pressure regulation disorder in Parkinson′s disease. Chin J Neurol. https://doi.org/10.3760/cma.j.issn.1006-7876.2019.10.010
245. Dubois, B., Pillon, B., & Agid, Y. (1996). Testing cognition may contribute to the diagnosis of movement disorders. Neurology. https://doi.org/10.1212/wnl.46.2.329
246. Duffy, J. R., Strand, E. A., & Josephs, K. A. (2014). Motor speech disorders associated with primary progressive aphasia. Aphasiology. https://doi.org/10.1080/02687038.2013.869307
247. Duntley, S. P. (2004). Insomnia in Primary Sleep Disorders. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-662-1_12
248. Dutta, R. (2021). Role of neuron specific enolase as a biomarker in Parkinson’s disease. Journal of Neuroscience and Neurological Disorders. https://doi.org/10.29328/journal.jnnd.1001052
249. Dwivedi, A., Awasthi, S., Maurya, A., Awasthi, S., Mishra, A., Mishra, A. K., Dubey, B., & Singh, R. (2023). Parkinson’s Disease: A Systematic Review of Neurodegenerative Disease and Its Management. International Journal of Pharmacy and Pharmaceutical Research. https://doi.org/10.25166/ijppr.2023.27.3.15
250. E.M., S., Juliet, M., & Paul, J. (2012). Parkinson’s Disease and Parkin: Insights from Park2 Knockout Mice. InTech eBooks. https://doi.org/10.5772/18148
251. Ebadi, M., Tippin, J., Chou, K. L., Erickson, B. A., Doerschug, K. C., & Fletcher, D. M. J. (2011). Non-motor Symptoms in Parkinson’s Disease. touchREVIEWS in Neurology. https://doi.org/10.17925/usn.2011.07.02.113
252. Ebadi, M., Tippin, J., Chou, K. L., Erickson, B. A., Doerschug, K. C., & Fletcher, D. M. J. (2012). Non-motor Symptoms in Parkinson’s Disease. European Neurological Review. https://doi.org/10.17925/enr.2012.07.01.35
253. Ebersbach, G. (2002). Parkinson-Syndrom und zerebrovaskuläre Morbidität. Steinkopff eBooks. https://doi.org/10.1007/978-3-642-57512-9_6
254. Ebersbach, G. (2008). Halluzinationen und Psychose bei der Parkinson-Erkrankung. Nervenheilkunde. https://doi.org/10.1055/s-0038-1627132
255. Ebersbach, G. (2010). Langzeitverlauf der Parkinson-Erkrankung. Nervenheilkunde. https://doi.org/10.1055/s-0038-1628776
256. Ebner, R. (2014). Incomplete Description. Deutsches Ärzteblatt international. https://doi.org/10.3238/arztebl.2014.0488a
257. Eckert, T., Zgaljardic, D. J., & Eidelberg, D. (2007). Parkinson’s disease. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780198566298.003.0010
258. Eimeren, T. V. (2012). Spielsucht auf Rezept? Impulsivität bei der Parkinsonerkrankung. Klinische Neurophysiologie. https://doi.org/10.1055/s-0032-1301439
259. Elble, R. J. (2016). The essential tremor syndromes. Current Opinion in Neurology. https://doi.org/10.1097/wco.0000000000000347
260. Ellfolk, U., Joutsa, J., Rinne, J. O., Parkkola, R., Jokinen, P., & Karrasch, M. (2013). Brain Volumetric Correlates of Memory in Early Parkinson's Disease. Journal of Parkinson s Disease. https://doi.org/10.3233/jpd-130276
261. Elmer, L., & Hauser, R. A. (2012). Dopaminergic agents. https://doi.org/10.2217/ebo.11.375
262. El‐Mansoury, B., Maloui, A. B., Draoui, A., Hamdan, Y. A., Oukhrib, M., Smimih, K., Elmourid, A., Khiat, A. E., Boulbaroud, S., Meftah, I., Hammoud, M., Chatoui, R., Sabir, E., Gamrani, H., & Jayakumar, A. R. (2023). Non-Motor Symptoms in Parkinson's Disease. Advances in medical diagnosis, treatment, and care (AMDTC) book series. https://doi.org/10.4018/978-1-6684-5156-4.ch003
263. Em, B.-B., Ga, F., & Schiffter, R. (1991). [Difficulties and errors in ambulatory therapy of Parkinson disease].. PubMed.
264. Emre, M. (2003). What causes mental dysfunction in Parkinson's disease?. Movement Disorders. https://doi.org/10.1002/mds.10565
265. Enrique, P. M. L., Gloria, A. S., Efraín, S. C. J., & Luis, G. A. J. (2019). Latencia diagnóstica en la enfermedad de Parkinson y su relación con los síntomas prodrómicos motores y no motores. eNeurobiología.
266. Erro, M. E., Gastón, I., & Navarro, M. C. (2008). [Movement disorders in the emergency department].. PubMed.
267. Erro, R., Bhatia, K. P., & Tinazzi, M. (2015). Parkinsonism following neuroleptic exposure: A double‐hit hypothesis?. Movement Disorders. https://doi.org/10.1002/mds.26209
268. Esparcia, P. G. (2016). Identification of a risk transcriptome and proteome in Parkinson’s disease, Dementia with Lewy bodies and rapidly progressive Dementia with Lewy bodies.
269. Esquiliano, G. R., Ramírez, I. M., Valdés, A. T., & Aguilar, C. A. T. (2004). Daño neurológico secundario a hipoxia isquemia perinatal. Archivos de neurociencias (México, D.F.).
270. EV, A., Swathilakshmi, S., & Vivek, D. (2020). Emerging Novel Drugs For Parkinson’s Disease. American Journal Of Pharmacy And Health Research. https://doi.org/10.46624/ajphr.2020.v8.i10.001
271. Factor, S. A. (2007). Levodopa. CRC Press eBooks. https://doi.org/10.3109/9781420019995-23
272. Factor, S. A., Molho, E., Podskalny, G. D., & Brown, D. (1995). Parkinson's disease: drug-induced psychiatric states.. PubMed.
273. Faggiani, E. (2014). Les systèmes monoaminergiques : implication dans la physiopathologie et la thérapie de la maladie de Parkinson.
274. Fahn, S., Greene, P., Ford, B., & Bressman, S. (2003). Movement Disorders. https://doi.org/10.1007/978-1-4757-4552-8_9
275. Fahn, S., Greene, P., Ford, B., Bressman, S., & Frucht, S. J. (2009). Movement Disorders. https://doi.org/10.1007/978-1-57340-359-7_9
276. Fahn, S., Oakes, D., Shoulson, I., Kieburtz, K., Rudolph, A., Lang, A. E., Olanow, C. W., Tanner, C. M., & Marek, K. (2004). Levodopa and the Progression of Parkinson's Disease. New England Journal of Medicine. https://doi.org/10.1056/nejmoa033447
277. Falk, M. J., & Moreno, M. A. (2019). What Parents Need to Know About Genetic Testing. JAMA Pediatrics. https://doi.org/10.1001/jamapediatrics.2019.0005
278. Farheen, S. A., Shah, P., Gill, M., Ayaz, S., Singh, S., Adikey, A., Sreeram, V., Ahmed, R., Hussain, M., & Ahmed, S. (2017). Translational Science of Psychosis in Parkinsons Disease. Clinical Depression. https://doi.org/10.4172/2572-0791.1000102
279. Farias, L. E., & Silva, E. S. C. E. (2021). O PRECONCEITO SOFRIDO POR PACIENTES COM DOENÇA DE PARKINSON. Anais do II Congresso Brasileiro de Saúde On-line. https://doi.org/10.51161/rems/1452
280. Fasano, A., Lehnerer, S., & Elia, A. E. (2014). Symptoms of dystonia. https://doi.org/10.2217/ebo.13.269
281. Favaro, M., Mauri, S., Bernardo, G., Zordan, M. A., Mazzotta, G., & Ziviani, E. (2024). Usp14 down-regulation corrects sleep and circadian dysfunction of a Drosophila model of Parkinson’s disease. Frontiers in Neuroscience. https://doi.org/10.3389/fnins.2024.1410139
282. Feldman, E. L., Stevens, M. J., & Russell, J. W. (2003). Diabetic Peripheral and Autonomic Neuropathy. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-310-1_24
283. Feng, M., & Zhang, L. (2019). Research progress of freezing of gait in parkinson’s disease. https://doi.org/10.3877/cma.j.issn.2095-123x.2019.04.012
284. Fenichel, G. M. (2005). Psychomotor Retardation and Regression.
285. Ferini‐Strambi, L., Marelli, S., Galbiati, A., Rinaldi, F., & Giora, E. (2015). REM Sleep Behavior Disorder (RBD) as a marker of neurodegenerative disorders. ARCHIVES ITALIENNES DE BIOLOGIE. https://doi.org/10.12871/00039822014238
286. Ferman, T. J., & Boeve, B. F. (2012). Sleep in Parkinson’s Disease and Dementia with Lewy Bodies. Advances in biological psychiatry. https://doi.org/10.1159/000331527
287. Fernández-Egea, E., & Jones, P. B. (2023). Schizophrenia. Cambridge University Press eBooks. https://doi.org/10.1017/9781911623137.065
288. Ferraz, H. B., & Yared, J. H. (2013). Cerebrovascular lesions in parkinsonian patients: when do they really matter?. Arquivos de Neuro-Psiquiatria. https://doi.org/10.1590/0004-282x20130167
289. Fibiger, H. (1984). The Neurobiological Substrates of Depression in Parkinson’s Disease: A Hypothesis. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. https://doi.org/10.1017/s0317167100046230
290. Fierro, Á. D. J. L., Aparicio, S. Y. L., Morgado‐Valle, C., Beltrán‐Parrazal, L., García, L. I., Hernández‐Aguilar, M. E., Manzo, J., & Pérez-Estudillo, C. A. (2022). Trastornos de las neuronas motoras: causas, síntomas, factores de riesgo, diagnósticos y tratamientos. eNeurobiología. https://doi.org/10.25009/eb.v13i31.2599
291. Filho, A. C. O., Gomes, L. M. T., Corrêa, A. C., Leão, E. F. D., Cangussu, D. M., & Torres, S. D. A. S. (2019). BRUXISMO DO SONO. Revista Intercâmbio.
292. Flanagan, M. E., Sonnen, J. A., Keene, C. D., Hevner, R. F., & Montine, T. J. (2017). Molecular Basis of Diseases of the Nervous System. Molecular Pathology. https://doi.org/10.1016/b978-0-12-802761-5.00029-8
293. Folkerth, R. D. (2021). Cerebral Cortical Migration Disorders. Cambridge University Press eBooks. https://doi.org/10.1017/9781316671863.041
294. Ford, B., & Pfeiffer, R. F. (2007). Pain Syndromes and Disorders of Sensation. Humana Press eBooks. https://doi.org/10.1385/1-59259-859-5:255
295. Ford, B., Louis, E. D., Greene, P., & Fahn, S. (1996). Oral and genital pain syndromes in Parkinson's disease. Movement Disorders. https://doi.org/10.1002/mds.870110411
296. Forsyth, D. R., & Roychowdhury, S. (2012). Sleep disturbance in Parkinson disease. Journal of Clinical Gerontology and Geriatrics. https://doi.org/10.1016/j.jcgg.2012.04.002
297. Fox, S. H., & Picillo, M. (2016). “I See Them Sitting on My Bed, Doctor”. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190607555.003.0012
298. Francàs, N. S. (2012). Percepción de fatiga central en la enfermedad de parkinson: factores clínicos, psicopatológicos y neuropsicológicos. TDX (Tesis Doctorals en Xarxa).
299. Frank, C., Pari, G., & Rossiter, J. P. (2006). Approach to diagnosis of Parkinson disease.. PubMed.
300. Franke, S., Dodel, R., Oertel, W. H., & Eggert, K. (2007). Leitlinien für Diagnose und Therapie der Parkinson-Syndrome. Nervenheilkunde. https://doi.org/10.1055/s-0038-1626858
301. Freidenberg, D. L., Huber, S. J., Shuttleworth, E. C., Paulson, G. W., & Christy, J. A. (1989). Neuropsychological impairments associated with severity of Parkinson's disease. Journal of Neuropsychiatry. https://doi.org/10.1176/jnp.1.2.154
302. Freynhagen, R., & Bennett, M. (2009). Diagnosis and management of neuropathic pain. BMJ. https://doi.org/10.1136/bmj.b3002
303. Friedman, A., & Sienkiewicz, J. (1991). Psychotic complications of long-term levodopa treatment of Parkinson's disease. Acta Neurologica Scandinavica. https://doi.org/10.1111/j.1600-0404.1991.tb04918.x
304. Friedman, J. H., & Millman, R. P. (2008). Sleep Disturbances and Parkinson's Disease. CNS Spectrums. https://doi.org/10.1017/s1092852900017272
305. Frommberger, D.-B. U. (2014). In Reply. Deutsches Ärzteblatt international. https://doi.org/10.3238/arztebl.2014.0489c
306. Fuchs, G. (2008). Psychosen beim idiopathischen Parkinson–Syndrom – Risikofaktoren für den Verlauf. psychoneuro. https://doi.org/10.1055/s-0028-1087115
307. Fujioka, H., Uozumi, T., Miyagi, Y., & Urasaki, E. (2019). Off‐period status dystonicus in Parkinson’s disease treated with deep brain stimulation: A case report. Neurology and Clinical Neuroscience. https://doi.org/10.1111/ncn3.12352
308. Fukuda, K., Wakuda, T., Kageyama, M., KITAMURA, K., Tanaka, M., TAWATA, Y., Miyauchi, T., & Ishida, S. (2007). Psychotic symptoms, epilepsy, mental retardation, and brain malformation in a patient with 45,XO/46,XX mosaicism: Detection of mutation of ARX molecule. Psychiatry and Clinical Neurosciences. https://doi.org/10.1111/j.1440-1819.2007.01626.x
309. Fukunishi, I., Hosokawa, K., & Ozaki, S. (1991). Depression Antedating the Onset of Parkinson's Disease. Psychiatry and Clinical Neurosciences. https://doi.org/10.1111/j.1440-1819.1991.tb00499.x
310. Fulda, S. (2011). Idiopathic REM sleep behavior disorder as a long-term predictor of neurodegenerative disorders. The EPMA Journal. https://doi.org/10.1007/s13167-011-0096-8
311. Furtado, S., & Wszołek, Z. K. (2007). Olfactory Dysfunction. Humana Press eBooks. https://doi.org/10.1385/1-59259-859-5:245
312. Fénelon, G. (2006). [Psychotic symptoms in Parkinson's disease].. PubMed.
313. Gaba, B., Kumar, S., Md, S., Baboota, S., Narang, J. K., & Ali, J. (2017). Natural Neuroprotectives for the Management of Parkinson's Disease. https://doi.org/10.1002/9783527803781.ch4
314. Gaig, C., & Tolosa, E. (2009). When does Parkinson's disease begin?. Movement Disorders. https://doi.org/10.1002/mds.22672
315. Gallo, B. V., & Hearron, A. C. (2017). Parkinson’s disease. Routledge eBooks. https://doi.org/10.4324/9781315382760-65
316. Galpern, W. R., & Lang, A. E. (2006). Interface between tauopathies and synucleinopathies: A tale of two proteins. Annals of Neurology. https://doi.org/10.1002/ana.20819
317. Gangopadhaya, P., Mitra, K., & Das, S. (2003). Parkinsonism plus syndrome--a review.. PubMed.
318. Garber, C. E., & Friedman, J. H. (2007). Fatigue. Humana Press eBooks. https://doi.org/10.1385/1-59259-859-5:281
319. García, A. C., Ignacio, Á. S., Pensado, B. A., Quinteiro, J. L. R., Gelabert‐González, M., Rumbo, R. M., & García, M. N. (2006). Complicaciones psiquiátricas y cognitivas de la estimulación subtalámica en la enfermedad de Parkinson. Revista de Neurología. https://doi.org/10.33588/rn.4304.2005581
320. García, M. D. R. G.-R. (2009). Validación al castellano de la escala LARS de apatía en la enfermedad de Parkinson.
321. Gaspar, B. L. (2023). Classification of Immune-Mediated Neuropathies. https://doi.org/10.1007/978-981-19-8421-1_16
322. Gauci, S., Hosking, W., & Bruck, D. (2017). Narcolepsy, cataplexy, hypocretin and co-existing other health complaints: A review. Cogent Medicine. https://doi.org/10.1080/2331205x.2017.1312791
323. Geny, C. (2009). Démence parkinsonienne et démence à corps de Lewy. Neurologie com. https://doi.org/10.1684/nro.2009.0075
324. Geroin, C., Artusi, C. A., Nonnekes, J., Aquino, C., Garg, D., Dale, M. L., Schlosser, D., Lai, Y., Alwardat, M., Salari, M., Wolke, R., Labou, V. T., Imbalzano, G., Camozzi, S., Merello, M., Bloem, B. R., Capato, T., Djaldetti, R., Doherty, K. A., ... Tinazzi, M. (2023). Axial Postural Abnormalities in Parkinsonism: Gaps in Predictors, Pathophysiology, and Management. Movement Disorders. https://doi.org/10.1002/mds.29377
325. Gerschcovich, E. R., & Tseng, K. Y. (2008). Cognitive Deficits in Parkinson’s Disease. Humana Press eBooks. https://doi.org/10.1007/978-1-60327-252-0_19
326. Geuze, R. H. (2016). Motorische ontwikkelingsstoornissen: DCD en dyspraxie.
327. Ghosh, B., Mishra, A., & Sengupta, P. (2005). Is Parkinson's disease a homogeneous disorder--what is the burden of Parkinson's disease in India.. PubMed.
328. Ghosh, R., & Liddle, B. (2010). Emergency presentations of Parkinson's disease: early recognition and treatment are crucial for optimum outcome. Postgraduate Medical Journal. https://doi.org/10.1136/pgmj.2010.104976
329. Giladi, N., & Melamed, E. (2000). The role of functional neurosurgery in Parkinson's disease.. PubMed.
330. Giotakos, O. (2017). Poor insight and psychosis. Psychiatriki. https://doi.org/10.22365/jpsych.2017.284.332
331. Giotakos, O. (2017). Poor insight in psychosis and meta-representation models. DOAJ (DOAJ: Directory of Open Access Journals). https://doi.org/10.26386/obrela.v1i1.5
332. Gitelman, D. R., & Simuni, T. (2012). Imaging studies as biomarkers of Parkinson’s disease. Imaging in Medicine. https://doi.org/10.2217/iim.12.15
333. Giubilei, F., & Orzi, F. (2014). Hetrogeneous pathologies associated with dementia in Parkinsonism share a prion-like spreading mechanism. ARCHIVES ITALIENNES DE BIOLOGIE. https://doi.org/10.12871/00039829201344
334. Giubilei, F., Candela, S. F., & Orzi, F. (2013). Heterogeneous pathologies associated with dementia in Parkinsonism share a prion-like spreading mechanism.. PubMed.
335. Godefroy, O., Barbay, M., Andriuta, D., Tir, M., & Roussel, M. (2016). Global Hypoactivity and Apathy. Neuropsychiatric symptoms of neurological disease. https://doi.org/10.1007/978-3-319-39138-0_5
336. Godwin-Austen, R. B. (2002). Dementia and Parkinson's Disease. https://doi.org/10.1002/0470846410.ch50a
337. Goedert, M., Jakes, R., Crowther, R. A., & Spillantini, M. G. (2003). Parkinson's Disease, Dementia with Lewy Bodies, and Multiple System Atrophy as α-Synucleinopathies. Parkinson s Disease. https://doi.org/10.1385/1-59259-142-6:33
338. Goel, S., Tripathi, A., Choudhury, T., & Kumar, V. (2019). Parkinson's Disease Detection using Soft Computing Technique. https://doi.org/10.1109/smart46866.2019.9117384
339. GOKCAL, E., & YILDIZ, G. B. (2015). Treatment of Motor Symptoms in Idiopathic Parkinson’s Disease. Bezmialem Science. https://doi.org/10.14235/bs.2015.503
340. Golubovsky, J. L., Li, H., Momin, A., Shao, J., Lee, M., Frizon, L. A., Hogue, O., Walter, B. L., Machado, A. G., & Nagel, S. J. (2020). Predictors of second-sided deep brain stimulation for Parkinson’s disease. Journal of neurosurgery. https://doi.org/10.3171/2019.12.jns19638
341. González, A. (2005). Fisiopatología y diagnóstico de la anorexia nerviosa y la bulimia.
342. González, M. J., Bardanca, M. S. G., Vivanco, E. F., Paz, M. T. A., & Allegue, M. D. (2007). Distonía psicógena: un diagnóstico complejo..
343. González-Medina, G., & Cerisola, A. (2002). Primera convulsión en apirexia. Archivos de Pediatría del Uruguay.
344. Gonçalves, G. B., & Pereira, J. S. (2013). Trastorno de la marcha en la enfermedad de Parkinson: freezing y perspectivas actuales. Revista médica de Chile. https://doi.org/10.4067/s0034-98872013000600010
345. Goodin, D. S. (2006). Physical Trauma, Psychological Stress, and Multiple Sclerosis. https://doi.org/10.1093/oso/9780195170320.003.0037
346. Goodwin, G. M. (2006). Depression and associated physical diseases and symptoms. Dialogues in Clinical Neuroscience. https://doi.org/10.31887/dcns.2006.8.2/mgoodwin
347. Grachev, I. D. (2013). Dopamine transporter imaging with [123I]FP-CIT (DaTSCAN) in Parkinson's disease with depressive symptoms: a biological marker for causal relationships?. Journal of Neurology Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp-2013-305380
348. Grasso, M., Piscopo, P., Confaloni, A., & Denti, M. A. (2011). 17 Neurodegenerative Disorders. Georg Thieme Verlag eBooks. https://doi.org/10.1055/b-0034-75424
349. Green, J., & Factor, S. A. (2006). Nonmotor Symptoms in Dystonia. CRC Press eBooks. https://doi.org/10.3109/9781420019988-22
350. Greenland, J. C., & Barker, R. A. (2018). The Differential Diagnosis of Parkinson’s Disease. Codon Publications eBooks. https://doi.org/10.15586/codonpublications.parkinsonsdisease.2018.ch6
351. Greffard, S., & Verny, M. (2012). Quels diagnostics envisager chez un patient âgé présentant l'association d'un syndrome parkinsonien et de troubles cognitifs ? What diagnosis would you consider in case of parkinsonism and cognitive impairment in the elderly?.
352. Grimbergen, Y. A., Langston, J. W., Roos, R. A., & Bloem, B. R. (2009). Postural instability in Parkinson’s disease: the adrenergic hypothesis and the locus coeruleus. Expert Review of Neurotherapeutics. https://doi.org/10.1586/14737175.9.2.279
353. Griswold, K., Regno, P. A. D., & Berger, R. C. (2015). Recognition and Differential Diagnosis of Psychosis in Primary Care.. PubMed.
354. Groisman, A. E., & Seminatore, M. L. (2003). Children and Adolescents Who Have Schizophrenia. Pediatrics in Review. https://doi.org/10.1542/pir.24.10.356
355. Groote, C. D., Dujardin, K., Defebvre, L., Flinois, B., Herlin, V., Carrière, N., & Wawrziczny, É. (2024). Development of a Screening Tool for Assessing Sexual Difficulties Among Patients with Parkinson’s Disease: The PD-SDS. Journal of Parkinson s Disease. https://doi.org/10.3233/jpd-240063
356. Guedes, R. P., & Silva, C. (2010). Inflammation in the Pathogenesis and Progression of Neurological Diseases. Ciência em Movimento. https://doi.org/10.15602/1983-9480/cmbs.v12n24p35-47
357. Gui, Q., Meng, J., Shen, M., Feng, H., Dong, X., Xu, D.-Q., Zhu, W., Cheng, Q., Wang, L., Wu, G.-H., & Lu, Y. (2024). Relationship of Glymphatic Function with Cognitive Impairment, Sleep Disorders, Anxiety and Depression in Patients with Parkinson’s Disease. Neuropsychiatric Disease and Treatment. https://doi.org/10.2147/ndt.s480183
358. Gunn, D. G., Naismith, S. L., & Lewis, S. J. (2010). Sleep Disturbances in Parkinson Disease and Their Potential Role in Heterogeneity. Journal of Geriatric Psychiatry and Neurology. https://doi.org/10.1177/0891988709358591
359. Gupta, M. (2024). Nervous System-I. https://doi.org/10.58532/nbennurebch11
360. Guthrie, E., & Nayak, A. (2012). Medically unexplained symptoms.
361. Gómez-López, S., Jaimes, V., Gutiérrez, C. M. P., Hernández, M. V., & Guerrero, A. (2013). PARÁLISIS CEREBRAL INFANTIL.
362. Gómez‐Esteban, J. C., Jáuregui-Barrutia, A., Tijero-Merino, B., & Zarranz, J. (2010). [Sleep disorders in Parkinson's disease: REM sleep behaviour disorder and restless legs syndrome]..
363. Hai-b, C. (2009). Non-motor Symptoms of Parkinson's Disease(review). Zhongguo kangfu lilun yu shijian.
364. Hainline, B., Gurin, L., & Torres, D. M. (2019). Cognitive Dysfunction Following Concussion. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190937447.003.0034
365. Hainline, B., Gurin, L., & Torres, D. M. (2019). Sleep Disorder Following Concussion. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190937447.003.0013
366. Hainline, B., Gurin, L., & Torres, D. M. (2019). Unmasking Neuropsychiatric Disorders Following Concussion. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190937447.003.0035
367. Hakim, A. M., & Mathieson, G. (1979). Dementia in Parkinson disease. Neurology. https://doi.org/10.1212/wnl.29.9_part_1.1209
368. Hamedani, A. G., Abraham, D. S., Maguire, M. G., & Willis, A. W. (2020). Visual Impairment Is More Common in Parkinson’s Disease and Is a Risk Factor for Poor Health Outcomes. Movement Disorders. https://doi.org/10.1002/mds.28182
369. Han, J. W., Ahn, Y. D., Kim, W., Shin, C. M., Jeong, S. J., Song, Y. S., Bae, Y. J., & Kim, J. (2018). Psychiatric Manifestation in Patients with Parkinson's Disease. Journal of Korean Medical Science. https://doi.org/10.3346/jkms.2018.33.e300
370. Hancock, D. B., Scott, W. K., & Chen, H. (2008). Challenges for Epidemiological Research of Pesticide Exposure and Parkinson’s Disease. touchREVIEWS in Neurology. https://doi.org/10.17925/usn.2008.04.02.48
371. Hantoro, W. D., Setyaningsih, I., & Was’an, M. (2019). Patofisiologi parkinsonism pasca trauma kepala. https://doi.org/10.22146/bns.v18i2.54995
372. Haq, I. Z., Naidu, Y., Reddy, P., & Chaudhuri, К. R. (2010). Narcolepsy in Parkinson’s disease. Expert Review of Neurotherapeutics. https://doi.org/10.1586/ern.10.56
373. Hawkes, C. (1995). Diagnosis and treatment of Parkinson's disease. BMJ. https://doi.org/10.1136/bmj.310.6995.1668
374. Hawkes, C. H. (2008). The prodromal phase of sporadic Parkinson's disease: Does it exist and if so how long is it?. Movement Disorders. https://doi.org/10.1002/mds.22242
375. Hayes, M. W., Fung, V. S., Kimber, T., & O’Sullivan, J. D. (2010). Current concepts in the management of Parkinson disease. The Medical Journal of Australia. https://doi.org/10.5694/j.1326-5377.2010.tb03453.x
376. Hedera, P., & Friedman, J. H. (2014). Can fall of blood pressure prevent falls in Parkinson disease?. Neurology. https://doi.org/10.1212/wnl.0000000000000370
377. Heinrichs, R. W. (1993). Schizophrenia and the brain: Conditions for a neuropsychology of madness.. American Psychologist. https://doi.org/10.1037//0003-066x.48.3.221
378. Heisters, D. (2011). Focus on Parkinson's: causes, treatment and support. British Journal of Community Nursing. https://doi.org/10.12968/bjcn.2011.16.4.182
379. Heisters, D. (2011). Parkinson's: symptoms, treatments and research. British Journal of Nursing. https://doi.org/10.12968/bjon.2011.20.9.548
380. Hemptinne, C. D., & Swann, N. C. (2016). Treating Parkinson’s Disease with Brain-Controlled Electrical Stimulation. Frontiers for Young Minds. https://doi.org/10.3389/frym.2016.00010
381. Hess, C. W., & Ford, B. (2012). Pain in Parkinson’s Disease: Pathophysiology, Classification, and Clinical Approach. Humana Press eBooks. https://doi.org/10.1007/978-1-60761-429-6_24
382. Heuvel, O. A. V. D., & Leentjens, A. F. G. (2015). [Dilemmas in the treatment of psychiatric symptoms in patients with Parkinson's disease].. PubMed.
383. Heuvel, O. A. V. D., Werf, Y. D. V. D., Groenewegen, H., Foncke, E., & Berendse, H. W. (2011). Impulse Control Disorders in Parkinson's Disease. The MIT Press eBooks. https://doi.org/10.7551/mitpress/8595.003.0014
384. Himaja, G., Nagarathna, C. R., Jayasri, A., & Kundan, K. M. (2024). Prediction of Parkinson’s Disease using Handwriting Analysis and Voice Dataset- A Review. Journal of Innovative Image Processing. https://doi.org/10.36548/jiip.2024.2.004
385. Hindle, J. V. (2010). Ageing, neurodegeneration and Parkinson's disease. Age and Ageing. https://doi.org/10.1093/ageing/afp223
386. Hindle, J. V. (2010). Mood Disorders in Parkinson's Disease. https://doi.org/10.1002/9780470669600.ch76
387. Hindle, J. V., Jones, S., & Davies, G. (2017). Parkinsonism, Parkinson’s disease, and related conditions. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198701590.003.0116
388. Hiner, B. C. (2006). Differential Diagnosis of Parkinson's Disease: A New Blood Test?. Clinical Medicine & Research. https://doi.org/10.3121/cmr.4.4.246
389. Hirata, K., Högl, B., Tan, E. K., & Videnović, A. (2015). Sleep Problems in Parkinson’s Disease. Parkinson s Disease. https://doi.org/10.1155/2015/507948
390. Hisahara, S., & Shimoham, S. (2012). Animal Models of Parkinson’s Disease Induced by Toxins and Genetic Manipulation. InTech eBooks. https://doi.org/10.5772/19860
391. Hoehn, M. M., & Yahr, M. D. (1967). Parkinsonism. Neurology. https://doi.org/10.1212/wnl.17.5.427
392. Horstink, M., Dekker, M. C. J., Montagna, P., Bonifati, V., & Warrenburg, B. P. V. D. (2010). Pallidopyramidal disease: A misnomer?. Movement Disorders. https://doi.org/10.1002/mds.23118
393. Huang, L., Lin, R., Zhang, C., & Lin, L. (2022). Effect of magnesium sulfate on retinal dopaminergic neurons in rats with 6-OHDA-induced Parkinson’s disease. Research Square (Research Square). https://doi.org/10.21203/rs.3.rs-1660469/v1
394. Huddleston, D. E., Trotti, L. M., Goldstein, F. C., & Factor, S. A. (2012). Nonmotor symptoms in dystonia. CRC Press eBooks. https://doi.org/10.3109/9781841848525-24
395. Hughes, R. A. (2008). Peripheral nerve diseases: THE BARE ESSENTIALS. Practical Neurology. https://doi.org/10.1136/jnnp.2008.162412
396. Hui-ji, D. (2012). The Characters of Depression and Sleep Disruption between Parkinson and Major Depression. Medicine and Philosophy.
397. Hung, S., & Prasad, E. M. (2020). Behavioral Tests in Neurotoxin-Induced Animal Models of Parkinson’s Disease. Antioxidants. https://doi.org/10.3390/antiox9101007
398. Ibatullin, R., Tunik, V. F., Idrisova, R. F., & Bakhtiyarova, K. Z. (2016). Challenges with the differential diagnosis of progressive supranuclear palsy and Parkinson’s disease. Annals of Clinical and Experimental Neurology. https://doi.org/10.17816/psaic22
399. Ibrahim, I. R., & Amar, K. (2007). Mild cognitive impairment. British Journal of Hospital Medicine. https://doi.org/10.12968/hmed.2007.68.10.27322
400. Ibrahim, N. M., Bhatia, K. P., Østergaard, K., Howard, R., Arabia, G., & Quinn, N. (2007). Primary lateral sclerosis mimicking atypical parkinsonism. Movement Disorders. https://doi.org/10.1002/mds.21645
401. Ille, R., Wabnegger, A., Schwingenschuh, P., Katschnig‐Winter, P., Kögl-Wallner, M., Wenzel, K., & Schienle, A. (2015). Intact emotion recognition and experience but dysfunctional emotion regulation in idiopathic Parkinson's disease. Journal of the Neurological Sciences. https://doi.org/10.1016/j.jns.2015.12.007
402. Ince, P. G. (2011). Dementia with Lewy Bodies and Parkinson's Disease Dementia. https://doi.org/10.1002/9781444341256.ch22
403. Investigación, A. D., & Michalland, B. J. (2008). Estudio del deterioro cognitivo temprano entre enfermos de Mal de Parkinson sin demencia Study of early cognitive deterioration between Parkinson disease patients without dementia.
404. Isaacson, S. (2019). Early Recognition and Diagnosis of Parkinson Disease and Ongoing Assessments. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.ms18003br1c
405. Isáis‐Millán, S., Piña‐Fuentes, D., Guzmán-Astorga, C. A., Cervantes‐Arriaga, A., & Rodríguez‐Violante, M. (2016). [Prevalence of neuropsychiatric disorders in drug-naive subjects with Parkinson's disease (PD)].. PubMed.
406. Jacopini, G. (2000). The Experience of Disease: Psychosocial Aspects of Movement Disorders. Journal of Neuroscience Nursing. https://doi.org/10.1097/01376517-200010000-00005
407. James, S., Rommel, A., Rijsdijk, F., Michelini, G., McLoughlin, G., Brandeis, D., Banaschewski, T., Asherson, P., & Kuntsi, J. (2018). Is Association of Preterm Birth with Cognitive-Neurophysiological Impairments and ADHD Symptoms Consistent with a Causal Inference or Due to Familial Confounds?. SSRN Electronic Journal. https://doi.org/10.2139/ssrn.3228917
408. James, S., Rommel, A., Rijsdijk, F., Michelini, G., McLoughlin, G., Brandeis, D., Banaschewski, T., Asherson, P., & Kuntsi, J. (2018). Is Association of Preterm Birth with Cognitive-Neurophysiological Impairments and ADHD Symptoms Consistent with a Causal Inference or Due to Familial Confounds?. SSRN Electronic Journal. https://doi.org/10.2139/ssrn.3234868
409. Jankovic, J. (2008). Parkinson's disease: clinical features and diagnosis. Journal of Neurology Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp.2007.131045
410. Jasińska‐Myga, B., & Sławek, J. (2006). Depresja w chorobie Parkinsona.
411. Jellinger, K. A. (2011). Postencephalitic Parkinsonism. https://doi.org/10.1002/9781444341256.ch19
412. Jendroska, K. (1997). The relationship of Alzheimer-type pathology to dementia in Parkinson’s disease. https://doi.org/10.1007/978-3-7091-6844-8_3
413. Jian-shen, S. (2012). Role of Neuronal Apoptosis in Parkinson Disease. Medical Recapitulate.
414. Jieyin, F. (2013). The resting state fMRI study of patients with Parkinson's disease associated with cognitive dysfunction. International Journal of Medical Radiology.
415. Jiménez, A., Organista‐Juárez, D., Rocha, L., Estudillo, E., Fernández-Sánchez, V., Cureño-Díaz, M. A., Guzmán‐Ruiz, M. A., & Guevara‐Guzmán, R. (2024). Dysfunction of olfactory structures: A conserved mechanism of neurodegeneration?. Brain Behavior and Immunity Integrative. https://doi.org/10.1016/j.bbii.2024.100053
416. Johnson, D. K., Galvin, J. E., & Storandt, M. (2012). P3‐080: Mild cognitive impairment in Parkinson's disease dementia. Alzheimer s & Dementia. https://doi.org/10.1016/j.jalz.2012.05.1299
417. Johnson, M., Stecher, B., Labrie, V., Brundin, L., & Brundin, P. (2018). Triggers, Facilitators, and Aggravators: Redefining Parkinson’s Disease Pathogenesis. Trends in Neurosciences. https://doi.org/10.1016/j.tins.2018.09.007
418. Jones, J. D., Timblin, H., & Baxter, F. (2022). Cumulative Effect of Head Injuries on Nonmotor Outcomes in Parkinson’s Disease. Journal of Neuropsychiatry. https://doi.org/10.1176/appi.neuropsych.21100257
419. Jones, S., Torsney, K., Scourfield, L., Berryman, K., & Henderson, E. (2020). Mental Health in Parkinson’s Disease. Cambridge University Press eBooks. https://doi.org/10.1017/9781108594714.011
420. Joseph, C. B. (2023). Parkinson Disease. Journal of Consumer Health on the Internet. https://doi.org/10.1080/15398285.2023.2212529
421. Josephs, K. A. (2011). Neuronal intranuclear inclusion disease. Neurology. https://doi.org/10.1212/wnl.0b013e3182166ead
422. Juncos, J. L. (1999). Management of psychotic aspects of Parkinson's disease.. PubMed.
423. K.Pavithra, P., Rhea, A., M.Dhanraj, D., & Pravinya, P. (2018). Prosthodontic Management of a Patient with Parkinson’s disease- A Case Report. Journal of Young Pharmacists. https://doi.org/10.5530/jyp.2018.10.84
424. Kahler, S. G., & Fahey, M. (2003). Metabolic disorders and mental retardation. American Journal of Medical Genetics Part C Seminars in Medical Genetics. https://doi.org/10.1002/ajmg.c.10018
425. Kaiser, S., Heekeren, K., & Simon, J. J. (2011). The Negative Symptoms of Schizophrenia: Category or Continuum?. Psychopathology. https://doi.org/10.1159/000325912
426. Kalirathinam, D., Vaidya, D. S. D., & Nazeer, A. (2014). Analyze The Effect of Dual Task Hand Activities In Parkinsons Patients. IOSR Journal of Nursing and health Science. https://doi.org/10.9790/1959-03515766
427. Kalyani, N., Sullivan, K. A., Moyle, G., Brauer, S., Jeffrey, E. R., & Kerr, G. (2019). Effects of dance on cognitive functions, psychological symptoms and health-related quality of life in Parkinson’s disease.
428. Kampić, K., Vuletić, V., & Chudy, D. (2021). Duboka mozgovna stimulacija – prijeoperacijska priprema i procjena pacijenata s Parkinsonovom bolešću. Medicina Fluminensis. https://doi.org/10.21860/medflum2021_365325
429. Kano, O., Ikeda, K., Cridebring, D., Takazawa, T., Yoshii, Y., & Iwasaki, Y. (2011). Neurobiology of Depression and Anxiety in Parkinson's Disease. Parkinson s Disease. https://doi.org/10.4061/2011/143547
430. Karimi, M., & Perlmutter, J. S. (2011). MRI measures predict progressive supranuclear palsy. Neurology. https://doi.org/10.1212/wnl.0b013e31822e14c7
431. Kasap, M., & Akpınar, G. (2011). Proteomics Approaches to Parkinson’s Disease and Search for Potential Biomarkers: Review. Turkiye Klinikleri Journal of Medical Sciences. https://doi.org/10.5336/medsci.2010-21522
432. Kashihara, K. (2015). IV. Management of Dementia in Parkinson's Disease. Nihon Naika Gakkai Zasshi. https://doi.org/10.2169/naika.104.1565
433. Kaur, B. (2017). CLASSIFICATION ON DEGREE OF HARMING IN PARKINSON DISEASE. International Journal of Advanced Research in Computer Science. https://doi.org/10.26483/ijarcs.v8i8.4668
434. Kavanagh, P. L., & Marder, K. (2007). Dementia. Humana Press eBooks. https://doi.org/10.1385/1-59259-859-5:35
435. Keilman, L. J., Harris, M., & Bronner, S. (2021). 300 - Increasing Complexity Awareness of Parkinson Disease Psychosis: Risk Factors, Symptoms, Diagnosing &amp; Management. International Psychogeriatrics. https://doi.org/10.1017/s1041610221001514
436. Kerchner, G. A., & Rosenbloom, M. (2014). Frontotemporal Neurocognitive Disorder. American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781585625048.gg65
437. Kesler, A., & Korczyn, A. D. (2006). Visual disturbances in Parkinson's disease. Practical Neurology. https://doi.org/10.1136/jnnp.2006.088286
438. Khan, M. A., Quadri, S. A., & Tohid, H. (2017). A comprehensive overview of the neuropsychiatry of Parkinson's disease: A review. Bulletin of the Menninger Clinic. https://doi.org/10.1521/bumc.2017.81.1.53
439. Khan, N. L., Graham, E., Critchley, P., Schrag, A., Wood, N., Lees, A. J., Bhatia, K. P., & Quinn, N. (2003). Parkin disease: a phenotypic study of a large case series. Brain. https://doi.org/10.1093/brain/awg142
440. Khiat, A. E., El‐Mansoury, B., Ali, D. A., Koutbi, M. E., Kaoutar, K., Hamdan, Y. A., Houate, B. E., Tamegart, L., Smimih, K., Hakam, A., Kissani, N., & Gamrani, H. (2023). Symptomatology and Clinical Features of Parkinson's Disease. Advances in medical diagnosis, treatment, and care (AMDTC) book series. https://doi.org/10.4018/978-1-6684-5156-4.ch002
441. Kholin, V., In, K., Kryzhanovskiy, S., Karasevich, N., Khodakovska, M., Shershanova, H., & Movchun, N. O. (2024). Cognitive disorders in Parkinson's disease. Ageing & Longevity. https://doi.org/10.47855/jal9020-2024-5-6
442. Kim, J. S., & Sung, H. Y. (2015). Gastrointestinal Dysfunctions in Parkinson’s Disease. Journal of the Korean Neurological Association. https://doi.org/10.17340/jkna.2015.4.1
443. Kim, J., Bae, H. J., & Cheon, S. M. (2010). P1‐042: Orthostatic hypotension and cognitive impairment in Parkinson's disease. Alzheimer s & Dementia. https://doi.org/10.1016/j.jalz.2010.05.589
444. Kimpara, T., & Takeda, A. (2020). [Parkinson's Disease in the Oldest-Old].. Brain and nerve. https://doi.org/10.11477/mf.1416201691
445. Kish, S. J., & Hornykiewicz, O. (1984). Neurochemical Basis of Dementia in Parkinson’s Disease. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. https://doi.org/10.1017/s0317167100046382
446. Klein, N., Wallner, H., & Fischer, P.-A. (2004). Diagnose und Therapie der Depression bei Morbus Parkinson. Journal für Neurologie, Neurochirurgie und Psychiatrie.
447. Knaap, M. S. V. D., Depienne, C., Sedel, F., & Abbink, T. E. M. (2015). CLCN2-Related Leukoencephalopathy.
448. Knoll, J. (1993). The Pharmacological Basis of the Therapeutic Effect of (—)-Deprenyl in Age-Related Neurological Diseases. Milestones in drug therapy. https://doi.org/10.1007/978-3-0348-6348-3_7
449. Knopman, D. S. (2017). Clinical Aspects of Non-Alzheimer Disease Dementias. DeckerMed Family Medicine. https://doi.org/10.2310/fm.1336
450. Knopman, D. S. (2017). Clinical Aspects of Non-Alzheimer Disease Dementias. https://doi.org/10.2310/neuro.1336
451. Kodžoman, A. (2020). Kineziterapija osoba s intelektualnim poteškoćama.
452. Konrad, K., Firk, C., & Uhlhaas, P. J. (2013). In Reply. Deutsches Ärzteblatt international. https://doi.org/10.3238/arztebl.2013.0733b
453. Končelíková, D. (2022). Sleep disorders in affective disorders. Psychiatrie pro praxi. https://doi.org/10.36290/psy.2022.030
454. Kop, W. J., & Gottdiener, J. S. (2011). The Interaction Between Psychologic Distress and Biobehavioral Processes in Cardiovascular Disease. https://doi.org/10.1002/9780470975138.ch1
455. Korczyn, A. D. (2010). Vascular Contribution to Dementia in Parkinson’s Disease. Neurodegenerative Diseases. https://doi.org/10.1159/000285522
456. Kornhuber, J., & Weiler, M. (1997). Das maligne neuroleptische Syndrom. Aktuelle Neurologie. https://doi.org/10.1055/s-2007-1017796
457. Kos, D., Kerckhofs, E., Nagels, G., D’hooghe, M., & Ilsbroukx, S. (2007). Origin of Fatigue in Multiple Sclerosis: Review of the Literature. Neurorehabilitation and neural repair. https://doi.org/10.1177/1545968306298934
458. Kostić, V., Stefanova, E., Dragašević, N., & Potrebić, S. (2003). Diagnosis and Treatment of Depression in Parkinson’s Disease. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-326-2_27
459. Kovačić, S., Roginić, S., Nemrava, J., Gospocic, K., Šarić, M. S., & Luetić, K. (2017). Acute pancreatitis in two patients with Parkinson’s disease. Cogent Medicine. https://doi.org/10.1080/2331205x.2017.1312802
460. Krause, C., Henschel, S., Höppner, J., & Schläfke, D. (2004). Das maligne neuroleptische Syndrom (Rostock). Steinkopff eBooks. https://doi.org/10.1007/978-3-7985-1957-2_61
461. Krishna, S., Prasad, S., Goel, R., & Prasad, B. K. (2018). PARKINSON’S DISEASE- A REVIEW. Journal of Evolution of Medical and Dental Sciences. https://doi.org/10.14260/jemds/2018/295
462. Kroemer, G., & Blomgren, K. (2007). Mitochondrial Cell Death Control in Familial Parkinson Disease. PLoS Biology. https://doi.org/10.1371/journal.pbio.0050206
463. Krumholz, A., Sung, G., Fisher, R. S., Barry, E. F., Bergey, G. K., & Grattan, L. M. (1995). Complex partial status epilepticus accompanied by serious morbidity and mortality. Neurology. https://doi.org/10.1212/wnl.45.8.1499
464. Kukla, U., Łabuzek, K., Chronowska, J., Krzystanek, M., & Okopień, B. (2015). [Mental disorders in digestive system diseases - internist's and psychiatrist's insight].. PubMed.
465. Kumar, G. D., Deepa, V., Vineela, N., & Emmanuel, G. (2022). Detection of Parkinson’s disease using LightGBM Classifier. 2022 6th International Conference on Computing Methodologies and Communication (ICCMC). https://doi.org/10.1109/iccmc53470.2022.9753909
466. Kurlan, R., Ramani, M., & Muthalagappan, P. L. (2014). Postoperative and Postpartum Onset of Chronic Parkinsonism: Four Case Reports. International Journal of Medical Students. https://doi.org/10.5195/ijms.2014.71
467. Kuzis, G., Sabe, L., Tiberti, C., Leiguarda, R., & Starkstein, S. E. (1997). Cognitive Functions in Major Depression and Parkinson Disease. Archives of Neurology. https://doi.org/10.1001/archneur.1997.00550200046009
468. Kuzuhara, S. (2004). Clinical features of Parkinson's disease in the elderly. Nippon Ronen Igakkai Zasshi Japanese Journal of Geriatrics. https://doi.org/10.3143/geriatrics.41.245
469. Kwon, D.-Y. (2022). Sleep Disturbances in Patients with Parkinson’s Disease. Chronobiology in Medicine. https://doi.org/10.33069/cim.2022.0004
470. Kılıç, S. P. (2010). PARKİNSON HASTALARINDA UYKU BOZUKLUKLARI VE HEMŞİRELİK YÖNETİMİ. Journal of Anatolia Nursing and Health Sciences. https://doi.org/10.17049/ahsbd.81422
471. Lalli, S., & Albanese, A. (2010). The diagnostic challenge of primary dystonia: Evidence from misdiagnosis. Movement Disorders. https://doi.org/10.1002/mds.23137
472. Lamont, P. J. (2004). cognitive decline in a young adult with pre-existent developmental delay - what the adult neurologist needs to know. Practical Neurology. https://doi.org/10.1111/j.1474-7766.2004.02-206.x
473. Landwehr, R., Endres, B., Wittig, C., Wössner, R., Fink, R., & Treib, J. (2009). Der pupillographische Schläfrigkeitstest bei neurologischen Erkrankungen. Aktuelle Neurologie. https://doi.org/10.1055/s-0029-1238642
474. Langeskov‐Christensen, M., Franzén, E., Hvid, L. G., & Dalgas, U. (2024). Exercise as medicine in Parkinson’s disease. Journal of Neurology Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp-2023-332974
475. Larsen, J., Beiske, A. G., Bekkelund, S. I., Dietrichs, E., Tysnes, O., Vilming, S. T., & Aasly, J. (2008). Motor symptoms in Parkinson disease. Tidsskrift for Den Norske Laegeforening.
476. Lasić, D., Mustapić, M., & Uglešić, B. (2015). Dopamine and cytokines in psychiatric disorders.
477. Lassal, R., Laurent, M., & Purper‐Ouakil, D. (2011). [Early signs of mental disorders in children aged 3-12 years].. PubMed.
478. Laumonnier, A. (2006). [Rehabilitation in the elderly subject with Parkinson's disease].. PubMed.
479. Lauretani, F., Caffarra, P., Ruffini, L., Nardelli, A., Ceda, G. P., Maggio, M., & Scaglioni, A. (2011). Brief practical clinical diagnostic criteria for the neurodegenerative diseases in the elderly. Drugs and Therapy Studies. https://doi.org/10.4081/dts.2011.e6
480. Lauretani, F., Saginario, A., Ceda, G. P., Galuppo, L., Ruffini, L., Nardelli, A., & Maggio, M. (2014). Treatment of the Motor and Non-Motor Symptoms in Parkinson's Disease According to Cluster Symptoms Presentation. Current Drug Targets. https://doi.org/10.2174/1389450115666140826104030
481. Lauretani, F., Ticinesi, A., Meschi, T., & Maggio, M. (2017). The key points for treatment of Parkinsonism in older persons. Geriatric Care. https://doi.org/10.4081/gc.2016.6156
482. Lavoie, S., Polari, A., Goldstone, S., Nelson, B., & McGorry, P. D. (2019). Staging model in psychiatry: Review of the evolution of electroencephalography abnormalities in major psychiatric disorders. Early Intervention in Psychiatry. https://doi.org/10.1111/eip.12792
483. Lee, H. M., & Koh, S. (2015). Many Faces of Parkinson's Disease: Non-Motor of Parkinson's Disease.
484. Lee, J., Kim, Y. E., Lee, J. S., Kang, S. Y., Kim, M. S., Kwak, I. H., Park, J., Nam, J. Y., & Ma, H. (2024). Olfactory and Gustatory Function in Early-stage Parkinson’s Disease: Implication for Cognitive Association. Journal of Movement Disorders. https://doi.org/10.14802/jmd.23243
485. Lees, A. J. (2005). Atypical Parkinsonism. Humana Press eBooks. https://doi.org/10.1385/1-59259-834-x:495
486. Leiguarda, R. (2003). Distinctive Features of Apraxia in Corticobasal Degeneration and Other Neurological Illnesses. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-326-2_10
487. Lenka, A., Espay, A. J., & Okun, M. S. (2024). Parkinsonism or catatonia: That’s the question. Annals of Movement Disorders. https://doi.org/10.4103/aomd.aomd_47_24
488. Lennox, B. (2008). Neurocognition of depression. Oxford University Press eBooks. https://doi.org/10.1093/acprof:oso/9780198569275.003.0021
489. Leroi, I., & Burns, A. (2006). Behavioural and psychological symptoms of dementia associated with Parkinson's disease. Journal of Neurology Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp.2006.101162
490. Levenson, J. L. (2008). Psychological Factors Affecting Medical Condition. Psychiatry. https://doi.org/10.1002/9780470515167.ch83
491. Levin, B., & Katzen, H. (2005). Early cognitive changes and nondementing behavioral abnormalities in Parkinson's disease.. PubMed.
492. Levy, G., & Marder, K. (2003). Prevalence, Incidence, and Risk Factors for Dementia in Parkinson’s Disease. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-326-2_20
493. Lewis, K., Natesan, K., Dhanalakshmi, B., & Jaisharma, K. (2021). Role of attribute selection on tuning the learning performance of Parkinson’s data using various intelligent classifiers. International Journal of Advanced Technology and Engineering Exploration. https://doi.org/10.19101/ijatee.2021.874039
494. Lewis, S., & Liddle, J. (2012). Diagnosing non-parkinson's movement disorders.. PubMed.
495. Li, B., Ti, H., & Liu, C. (2024). Massage techniques to treat Parkinson’s spasm symptoms. Advances in Computer and Engineering Technology Research. https://doi.org/10.61935/acetr.3.1.2024.p165
496. Li, L., Liu, S., Zhuang, J.-L., Li, M.-M., Huang, Z., Chen, Y., Chen, X., Chen, C., Lin, S., & Ye, L. (2022). Recent research progress on metabolic syndrome and risk of Parkinson’s disease. Reviews in the Neurosciences. https://doi.org/10.1515/revneuro-2022-0093
497. Li, S., & Chen, H. (2016). Mild cognitive impairment in Parkinson's disease. DOAJ (DOAJ: Directory of Open Access Journals).
498. Lie, C., Dafotakis, M., Behrens, S., & Fink, G. R. (2005). Neural correlates of dysexecutive functions in Parkinson's disease. Aktuelle Neurologie. https://doi.org/10.1055/s-2005-919274
499. Lijo.J, J., James, P. M., & Sherief.S, H. (2020). Case Report on Young Onset Parkinson's Disease. International Journal of Research.
500. Lim, E. C., Quek, A. M., & Seet, R. C. (2024). Deep brain stimulation in Parkinson’s disease: Looking back, looking forward. Annals of the Academy of Medicine Singapore. https://doi.org/10.47102/annals-acadmedsg.2024260
501. Lima, J. C. D. (2018). Evidências de projeções indiretas da substância negra compacta para o núcleo retrotrapezóide por meio da substância cinzenta periaquedutal e as alterações respiratórias observadas nesta via em um modelo da doença de Parkinson.. https://doi.org/10.11606/t.42.2018.tde-20092018-135704
502. Limongelli, G., D‘Alessandro, R., Maddaloni, V., Rea, A., Sárközy, A., & McKenna, W. J. (2013). Skeletal muscle involvement in cardiomyopathies. Journal of Cardiovascular Medicine. https://doi.org/10.2459/jcm.0b013e3283641c69
503. Limosin, F. (2014). Maladie de Parkinson : la psychiatrie en première ligne ?. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2014.09.273
504. Lin, C., Wang, J.-S., Chung, P.-C., Hsu, C., Liou, L.-M., Yang, Y. K., & Yang, Y.-T. (2012). Classification of Parkinson’s Disease Severity Using Heart Rate Variability Analysis. CRC Press eBooks. https://doi.org/10.1201/b12756-27
505. Liu, C., & Dan, L. A. (2010). 尿酸对帕金森病患者不同认知功能域影响分析. Chin J Neurol. https://doi.org/10.3760/cma.j.issn.1006-7876.2010.06.006
506. Lizbeth, V. C., Amiel, T. R., Rafael, G. P. J., Gerardo, M. M., Rebeca, T. C. M., Porfirio, C. C., Jorge, M. D., Genaro, C. A., & Luis, G. H. (2019). Enfermedad de Parkinson más allá de lo motor. eNeurobiología.
507. Llorente, J. M., & Martínez, E. R. (2010). Otros trastornos no motores en la enfermedad de Parkinson. Revista de Neurología. https://doi.org/10.33588/rn.50s02.2009743
508. Lopez, S., Percio, C. D., Pascarelli, M. T., Lizio, R., Noce, G., Ferri, R., Soricelli, A., Nobili, F., Arnaldi, D., Famà, F., Bonanni, L., Franciotti, R., Onofrj, M., Fuhr, P., Gschwandtner, U., Ransmayr, G., Aarsland, D., Parnetti, L., Farotti, L., ... Babiloni, C. (2020). Different abnormalities of electroencephalographic (EEG) markers in quiet wakefulness are related to motor visual hallucinations in patients with Parkinson’s and Lewy body diseases. Alzheimer s & Dementia. https://doi.org/10.1002/alz.045811
509. Louis, E. D. (2013). ‘Essential Tremor' or ‘the Essential Tremors': Is This One Disease or a Family of Diseases?. Neuroepidemiology. https://doi.org/10.1159/000356351
510. Louis, E. D., & Bennett, D. A. (2007). Mild Parkinsonian signs: An overview of an emerging concept. Movement Disorders. https://doi.org/10.1002/mds.21433
511. Lu, S., Shaffery, J. P., Pang, Y., Tien, L., & Fan, L. (2016). Rapid Eye Movement Sleep Homeostatic Response: A Potential Marker for Early Detection of Parkinson’s Disease. Journal of Alzheimer’s Disease & Parkinsonism. https://doi.org/10.4172/2161-0460.1000255
512. Luthert, P. (2013). DEMENTIA IN PARKINSON'S DISEASE.
513. Luthert, P. J., Gibb, W. R., Janota, I., & Lantos, P. L. (1989). Cortical Lewy body dementia: clinical features and classification.. Journal of Neurology Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp.52.2.185
514. Luz, K. P. D. S., & Coronago, V. M. M. O. (2017). A Doença de Parkinson na pessoa Idosa e a Relação com sua Qualidade de Vida. ID on line REVISTA DE PSICOLOGIA. https://doi.org/10.14295/idonline.v11i35.720
515. Lyketsos, C. G. (2012). F1‐01‐02: Tackling overlap of neuropsychiatric symptoms in Alzheimer's and other dementias: Toward a unified approach to evaluation and treatment. Alzheimer s & Dementia. https://doi.org/10.1016/j.jalz.2012.05.191
516. Lyons, K. E., & Pahwa, R. (2011). The impact and management of nonmotor symptoms of Parkinson's disease.. PubMed.
517. Lyros, E., Messinis, L., & Papathanasopoulos, P. (2008). Clinical correlates of mental dysfunction in Parkinson's disease without dementia. Annals of General Psychiatry. https://doi.org/10.1186/1744-859x-7-s1-s262
518. Lévy, R., & Pillon, B. (2006). [Cognitive disorders in Parkinson's disease without dementia].. PubMed.
519. Ma, B., Zhang, J., Cui, Y., & Gao, H. (2023). The Anatomy and Clinical Significance of Sensory Disturbance in Parkinson's Disease. Journal of Integrative Neuroscience. https://doi.org/10.31083/j.jin2203056
520. Macho, L. P., & Andrés, S. B. (2010). Trastornos digestivos en la enfermedad de Parkinson: atonía gástrica, malabsorción y estreñimiento. Revista de Neurología. https://doi.org/10.33588/rn.50s02.2009740
521. Macphee, G. J. (2018). Diagnosis and differential diagnosis of Parkinson’s disease. https://doi.org/10.1201/9781315365428-4
522. Macphee, G. J., & Stewart, D. A. (2006). Parkinson's disease. Reviews in Clinical Gerontology. https://doi.org/10.1017/s0959259806002073
523. Madabushi, J. S., Gupta, M., Pearce, B., & Gupta, N. (2023). Parkinson’s Disease: Diagnostic Challenges Amidst Transdiagnostic and Overlapping Mental Health Symptoms. Cureus. https://doi.org/10.7759/cureus.36661
524. Magrinelli, F., Picelli, A., Tocco, P., Federico, A., Roncari, L., Smania, N., Zanette, G., & Tamburin, S. (2016). Pathophysiology of Motor Dysfunction in Parkinson’s Disease as the Rationale for Drug Treatment and Rehabilitation. Parkinson s Disease. https://doi.org/10.1155/2016/9832839
525. Mahesh, R., Pandey, D. K., Bhatt, S., & Gautam, B. (2010). Depression Associated Disorders: Comorbidity, eurobiological and eurobehavioural Link.
526. Maitland, C. (2012). Vestibular Dysfunction. Humana Press eBooks. https://doi.org/10.1007/978-1-60761-429-6_25
527. Majeske, M., Nistor, V., & Kellner, C. H. (2016). Late‐Life Psychosis. https://doi.org/10.1002/9781118654231.ch35
528. Majhi, V., Paul, S., Saha, G., & Verma, J. K. (2020). Sensor based Detection of Parkinson’s Disease Motor Symptoms. 2021 International Conference on Computational Performance Evaluation (ComPE). https://doi.org/10.1109/compe49325.2020.9200051
529. MALAK, A. L. S. B. (2016). SINTOMAS DE DEPRESSÃO EM PACIENTES COM DECLÍNIO COGNITIVO LEVE NA DOENÇA DE PARKINSON. https://doi.org/10.17771/pucrio.acad.27733
530. Malik, R. A., & Veves, A. (2005). Diabetic Neuropathy. Humana Press eBooks. https://doi.org/10.1385/1-59259-908-7:381
531. Malow, B. A. (1999). Waking up to the importance of sleep in neurologic disorders. Neurology. https://doi.org/10.1212/wnl.52.9.1732
532. Maltseva, L., Lisnycha, V., Kobelatskyy, Y., & Kazimirova, N. (2021). Вплив додаткової нейропротекції Гліатиліном на перебіг септичного процесу і вираженість енцефалопатії в структурі синдрому поліорганної недостатності. EMERGENCY MEDICINE. https://doi.org/10.22141/2224-0586.17.2.2021.230634
533. Maltête, D., Grangeon, L., Goff, F. L., Özel, G., Fetter, D., Ahtoy, P., Temgoua, O., Rouillé, A., & Lefaucheur, R. (2017). Four Cases of Parkinson Disease Diagnosed During the Postpartum Period. Obstetrics and Gynecology. https://doi.org/10.1097/aog.0000000000002066
534. Mann, D. M. A., & Yates, P. O. (1983). PATHOLOGICAL BASIS FOR NEUROTRANSMITTER CHANGES IN PARKINSON'S DISEASE. Neuropathology and Applied Neurobiology. https://doi.org/10.1111/j.1365-2990.1983.tb00320.x
535. Marino, B. L. B., Souza, L. R. D., Sousa, K. P., Ferreira, J. V., Padilha, E. C., Silva, C. H. T. D. P. D., Taft, C. A., & Hage-Melim, L. I. D. S. (2019). Parkinson’s Disease: A Review from Pathophysiology to Treatment. Mini-Reviews in Medicinal Chemistry. https://doi.org/10.2174/1389557519666191104110908
536. Markopoulou, K., & Chase, B. A. (2010). Olfaction in <i>Parkin</i> -associated Parkinson disease. Neurology. https://doi.org/10.1212/wnl.0b013e31820882ee
537. Marković, N., Veljkovic, M., & Zečević-Luković, T. (2013). The treatment of neurogenic bladder dysfunction in patients with spinal cord injury. PONS - medicinski casopis. https://doi.org/10.5937/pons1304157m
538. Marraccini, E. M. (2005). Uma vida que se esvai no Parkinson. Revista Latinoamericana de Psicopatologia Fundamental. https://doi.org/10.1590/1415-47142005001005
539. Marrero, D. H., Pestano, M. M. A., Acosta, B. A., & Miranda, J. L. D. (2020). La ptosis no orgánica: a propósito de un trastorno.
540. Marrero, D. H., Pestano, M. M. A., Acosta, B. A., & Miranda, J. L. D. (2021). La ptosis no orgánica; a propósito de un trastorno conversivo.
541. Marsden, C. D. (1984). Which Motor Disorder in Parkinson's Disease Indicates the True Motor Function of the Basal Ganglia?. Novartis Foundation symposium. https://doi.org/10.1002/9780470720882.ch12
542. Martell, M. A. L. (2019). Marco teórico de la presente investigación. Revista Cubana de Alimentación y Nutrición.
543. Martens, K. A. E., & Lewis, S. J. (2016). Pathology of behavior in PD: What is known and what is not?. Journal of the Neurological Sciences. https://doi.org/10.1016/j.jns.2016.12.062
544. Martin, W. R. W. (2019). Parkinson’s Disease and Aging: Presynaptic Nigrostriatal Function. CRC Press eBooks. https://doi.org/10.4324/9780429284359-6
545. Martín, E. S. S., Juanes, J., Montero, R., & Aguiar, C. S. (2012). Demencia frontotemporal asociada al cromosoma 17 y otros síndromes parkinsonianos asociados a demencia. Revista de Neurología. https://doi.org/10.33588/rn.54s04.2012520
546. Martínez, D. D. N., Ezpeleta, D., & González, G. L. (2022). Enfermedades neurológicas y juego. Kranion. https://doi.org/10.24875/kranion.m22000027
547. Martínez‐Castrillo, J. C., Vela, L., Val, J. D., & Alonso‐Cánovas, A. (2011). Nonmotor Disorders and Their Correlation With Dopamine. The Neurologist. https://doi.org/10.1097/nrl.0b013e318239669f
548. Masgutova, S., Wenberg, S., & Retschler, M. (2008). MASGUTOVA METHOD OF REFLEX INTEGRATION FOR CHILDREN WITH CEREBRAL PALSY.
549. Massey, A., Boag, M. K., Magnier, A., Bispo, D. P. C. F., Khoo, T. K., & Pountney, D. L. (2022). Glymphatic System Dysfunction and Sleep Disturbance May Contribute to the Pathogenesis and Progression of Parkinson’s Disease. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms232112928
550. Mata, M., Dorovini‐Zis, K., Wilson, M. E., & Young, A. B. (1983). New form of familial Parkinson‐dementia syndrome. Neurology. https://doi.org/10.1212/wnl.33.11.1439
551. Matute, M. A., Gómez, R. M. M., Pelegrín, E. M., Portero, N. G., Leciñena, G. C., & Orte, P. L. (2021). Actuación interdisciplinar en el paciente con trastorno neurodegenerativo:: Enfermedad de parkinson.. Revista Sanitaria de Investigación.
552. Maximiano‐Barreto, M. A., & Fermoseli, A. F. D. O. (2017). A importância do acompanhamento Psicológico sobre os indivíduos portadores de Doença de Parkinson e Parkinsonismo usuários de l-dopa. Caderno de Graduação - Ciências Humanas e Sociais - UNIT - ALAGOAS.
553. McCracken, L. M., Hindle, J. V., Bogosian, A., Robertson, N. P., Meco, G., & Hennig, E. M. (2020). Advances in Peripheral Neuropathy in Parkinson’s Disease.
554. McDermott, B. E. (2015). Factitious Disorder. The Encyclopedia of Clinical Psychology. https://doi.org/10.1002/9781118625392.wbecp234
555. McGrane, S., Atria, N. P., & Barwise, J. (2014). Perioperative implications of the patient with autonomic dysfunction. Current Opinion in Anaesthesiology. https://doi.org/10.1097/aco.0000000000000072
556. McKeown, M. J., & Peavy, G. M. (2015). Biomarkers in Parkinson disease. Neurology. https://doi.org/10.1212/wnl.0000000000001692
557. McKinlay, A. (2013). A review of cognitive and other non-motor problems in Parkinson’s disease. Aging Health. https://doi.org/10.2217/ahe.12.84
558. McKinley, J. E., & Perkins, A. (2019). Neurologic Conditions: Parkinson Disease.. PubMed.
559. McKnight, R., Price, J., & Geddes, J. (2019). Introduction to psychiatry. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780198754008.003.0005
560. McKnight, R., Price, J., & Geddes, J. (2019). Sleep disorders. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780198754008.003.0036
561. McNamara, P. (2011). The Cognitive Neuropsychiatry of Parkinson's Disease. The MIT Press eBooks. https://doi.org/10.7551/mitpress/9780262016087.001.0001
562. McNamara, P. J. (2011). Mood Disorders and Apathy in Parkinson’s Disease. The MIT Press eBooks. https://doi.org/10.7551/mitpress/9780262016087.003.0010
563. Medina-Chávez, J. H., Fuentes-Alexandro, S., Gil-Palafox, I. B., Adame-Galván, L., Solís-Lam, F., Sánchez-Herrera, L. Y., & Narváez, F. S. (2014). [Clinical practice guideline. Diagnosis and treatment of insomnia in the elderly].. PubMed.
564. Mehndiratta, M., Garg, R., & Pandey, S. (2011). Nonmotor symptom complex of Parkinson's disease--an under-recognized entity.. Journal of the Association of Physicians of India.
565. Mehta, P., & Rani, G. S. (2020). Identification and Early Intervention of Bipolar Disorder in Adolescence and Adults. International Journal of Engineering and Advanced Technology. https://doi.org/10.35940/ijeat.b3637.029320
566. Mehta, S. H., Morgan, J. C., & Sethi, K. D. (2008). Sleep Disorders Associated with Parkinson's Disease:<i>Role of Dopamine, Epidemiology, and Clinical Scales of Assessment</i>. CNS Spectrums. https://doi.org/10.1017/s1092852900017260
567. Mehta, S., Kharbanda, P., & Sharma, S. (2015). Neuropsychiatric aspects of Parkinson′s disease. Astrocyte. https://doi.org/10.4103/2349-0977.168248
568. Meinck, H., & Ringleb, P. A. (2012). Parkinson-Syndrom und andere Bewegungsstoerungen.
569. Melo, L. M., Barbosa, E. R., & Caramelli, P. (2007). Declínio cognitivo e demência associados à doença de Parkinson: características clínicas e tratamento. Archives of Clinical Psychiatry (São Paulo). https://doi.org/10.1590/s0101-60832007000400003
570. Menakuru, S., Ali, M. I., Ali, M. I., Kalla, S., Kalla, S., Datti, A., & Datti, A. (2020). Multiple system atrophy in a man misdiagnosed with parkinsonism. International Journal of Research in Medical Sciences. https://doi.org/10.18203/2320-6012.ijrms20204915
571. Menculini, G., Chipi, E., Paoletti, F. P., Gaetani, L., Nigro, P., Simoni, S., Mancini, A., Tambasco, N., Filippo, M. D., Tortorella, A., & Parnetti, L. (2021). Insights into the Pathophysiology of Psychiatric Symptoms in Central Nervous System Disorders: Implications for Early and Differential Diagnosis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms22094440
572. Menza, M. (2010). Psychiatric Symptoms Associated With Parkinson Disease.
573. Menza, M., Dobkin, R. D., & Marín, H. (2006). Cognitive and psychiatric aspects of Parkinson’s disease: treatment recommendations. Aging Health. https://doi.org/10.2217/1745509x.2.1.87
574. Merschdorf, U., Berg, D., Csóti, I., Fornádi, F., Merz, B., Naumann, M., Becker, G., & Supprian, T. (2003). Psychopathological Symptoms of Depression in Parkinson’s Disease Compared to Major Depression. Psychopathology. https://doi.org/10.1159/000073446
575. Mesejo, A., Pérez-Sancho, E., & Moreno, E. (2006). [Clinical consequences of neuromuscular impairments in critically ill patients].. Nutrición Hospitalaria.
576. Messinis, L., Lyros, E., Gatzounis, G., & Papathanasopoulos, P. (2011). Neuropsychological Functions and SPECT Neuroimaging in Parkinson’s Disease. InTech eBooks. https://doi.org/10.5772/17948
577. Mestre, T., Strafella, A. P., Thomsen, T., Voon, V., & Miyasaki, J. M. (2013). Diagnosis and treatment of impulse control disorders in patients with movement disorders. Therapeutic Advances in Neurological Disorders. https://doi.org/10.1177/1756285613476127
578. Mg, P. (2011). [Primary and secondary insomnias and sleep related breathing disturbances].. PubMed.
579. Michel, S. F., Oscar, A. C., Correa, T. E. S., Alejandro, P. L., & Micheli, F. (2015). Pisa Syndrome. Clinical Neuropharmacology. https://doi.org/10.1097/wnf.0000000000000092
580. Mihanović, M., Bodor, D., Kezić, S., Restek-Petrović, B., & Silić, A. (2009). Differential diagnosis of psychotropic side effects and symptoms and signs of psychiatric disorders.. PubMed.
581. Miklya, I., Göltl, P., Hafenscher, F., & Pencz, N. (2007). The Role of PARKIN in Parkinson’s Disease. CRC Press eBooks. https://doi.org/10.3109/9781420019223-17
582. Miller, B. L. (2013). Related Disorders: FTD-ALS. Oxford University Press eBooks. https://doi.org/10.1093/med/9780195380491.003.0005
583. Minakawa, E. N. (2019). Sleep abnormality as a potential target of disease-modifying therapy for neurodegenerative diseases. Proceedings for Annual Meeting of The Japanese Pharmacological Society. https://doi.org/10.1254/jpssuppl.92.0_3-s29-3
584. Mindham, R., & Hughes, T. A. (2012). Dementia in Parkinson's disease. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199696758.003.0046
585. Mishra, T., Kamble, N., Bhattacharya, A., Yadav, R., Srinivas, D., & Pal, P. K. (2024). Impact of Deep Brain Stimulation on Non-Motor Symptoms in Parkinson’s Disease. Journal of Movement Disorders. https://doi.org/10.14802/jmd.23247
586. Mizuno, T., Matsumoto, H., Mita, K., Kogauchi, S., Kiyono, Y., Kosaka, H., & Omata, N. (2019). Psychosis is an extension of mood swings from the perspective of neuronal plasticity impairments. Medical Hypotheses. https://doi.org/10.1016/j.mehy.2019.02.001
587. Mizuno, Y. (1997). [Concept and diagnostic criteria of Parkinson's disease and parkinsonism].. PubMed.
588. MM, B., Islam, S., Nh, S., Rahman, M., & Bari, M. (2016). None. MOJ Orthopedics & Rheumatology. https://doi.org/10.15406/mojor.4.1
589. Modugno, N., Lena, F., Biasio, F. D., Cerrone, G. E., Ruggieri, S., & Fornai, F. (2013). A clinical overview of non-motor symptoms in Parkinson's Disease.. PubMed.
590. Molho, E., & Factor, S. A. (2007). Psychosis. Humana Press eBooks. https://doi.org/10.1385/1-59259-859-5:49
591. Molho, E., & Factor, S. A. (2012). Psychosis. Humana Press eBooks. https://doi.org/10.1007/978-1-60761-429-6_5
592. Mollenhauer, B., & Weintraub, D. (2017). The depressed brain in Parkinson's disease: Implications for an inflammatory biomarker. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1700737114
593. Mollenhauer, B., Wenzel, S., & Trenkwalder, C. (2008). Schwerpunktthema: Medikamentöse Behandlung des Morbus Parkinson mit Demenz und anderen neuropsychiatrischen Störungen. Zeitschrift für Psychiatrie Psychologie und Psychotherapie. https://doi.org/10.1024/1661-4747.56.1.13
594. Montaño, M. G., Perdigues, S. R., Villar, C. M. D., Roy, C., Latorre, S., Rico, M. G., Romero, A. B., Torres, S. B., & Rincón, M. (2017). Confusion between symptom and disease. Parkinson vs meningioma. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2017.01.605
595. Morales, D. O. (2019). Muerte encefálica en pediatría..
596. Morales‐Briceño, H., Cervantes‐Arriaga, A., & Rodríguez‐Violante, M. (2011). [Premotor diagnosis of Parkinson's disease].. Gaceta Médica de México.
597. Moreau, C. (2008). Etude des troubles axiaux dans la maladie de Parkinson évoluée, Effet des fréquences de stimulation des noyaux subthalamiques sur les troubles de la marche.
598. Morgan, J. C., Mehta, S. H., & Sethi, K. D. (2013). Differential diagnosis. CRC Press eBooks. https://doi.org/10.1201/b14361-6
599. Morgan, J. M., & Sethi, K. D. (2007). Differential Diagnosis. CRC Press eBooks. https://doi.org/10.3109/9781420019995-7
600. Morin, C. (2009). [Sense of personal identity and focal brain lesions].. PubMed. https://doi.org/10.1684/pnv.2009.0156
601. Moro‐de‐Casillas, M. L., & Riley, D. E. (2012). Insomnia in Parkinson’s Disease. Humana Press eBooks. https://doi.org/10.1007/978-1-60761-429-6_17
602. Morylowska-Topolska, J., Ziemiński, R., Molas, A., Gajewski, J., Flis, M., Stelmach, E., & Karakuła‐Juchnowicz, H. (2016). Schizophrenia and anorexia nervosa – reciprocal relationships. A literature review. Psychiatria Polska. https://doi.org/10.12740/pp/onlinefirst/63514
603. Moshé, S. L., Tuchman, R. F., & Rapin, I. (2005). [Neurodevelopmental disorders and epilepsy].. PubMed.
604. Mosimann, U. P., & McKeith, I. G. (2003). Dementia with Lewy bodies and Parkinson's disease dementia - two synucleinopathies.
605. Mou, L., Ding, W., & Fernández-Fúnez, P. (2019). Open questions on the nature of Parkinson’s disease: from triggers to spreading pathology. Journal of Medical Genetics. https://doi.org/10.1136/jmedgenet-2019-106210
606. Mounika, P., & Rao, S. G. (2021). A Study On Deep Learning And Machine Learning Techniques On Detection Of Parkinson’s Disease. E3S Web of Conferences. https://doi.org/10.1051/e3sconf/202130901008
607. Moustafa, A. A., & Poletti, M. (2013). Neural and behavioral substrates of subtypes of Parkinson’s disease. Frontiers in Systems Neuroscience. https://doi.org/10.3389/fnsys.2013.00117
608. Mulero, P., García, E. C., & Llorente, J. M. (2012). Abordaje terapéutico de los síntomas no motores de la enfermedad de Parkinson. Revista de Neurología. https://doi.org/10.33588/rn.54s05.2012536
609. Mulroy, E., Baschieri, F., Magrinelli, F., Latorre, A., Cortelli, P., & Bhatia, K. P. (2021). Movement Disorders and Liver Disease. Movement Disorders Clinical Practice. https://doi.org/10.1002/mdc3.13238
610. Mur, M. I. B., Usan, M. P. C., Ferrando, A. C., Obón, V. N., Barrachina, E. L., & Pérez, N. B. (2021). El Parkinson y la fisioterapia, artículo monográfico.. Revista Sanitaria de Investigación.
611. Murata, M., & Kanazawa, I. (1997). [Clinical classifications of Parkinson's disease].. PubMed.
612. Murueta‐Goyena, A., Andikoetxea, A., Gómez‐Esteban, J. C., & Gabilondo, I. (2019). Contribution of the GABAergic System to Non-Motor Manifestations in Premotor and Early Stages of Parkinson’s Disease. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2019.01294
613. Muzerengi, S., Lewis, H. M., Edwards, M. J., Kipps, E., Bahl, A., Martínez‐Martín, P., & Chaudhuri, К. R. (2006). Non-motor symptoms in Parkinson's disease: an underdiagnosed problem. Aging Health. https://doi.org/10.2217/1745509x.2.6.967
614. Muñoz, B., Quintana-Peña, V., Alvarez, D. S., Valderrama, J., Takeuchi, Y., & Orozco, J. (2021). Perspectives of Cognitive Impairment and Behavioral Disturbances in Parkinson’s Disease Dementia. IntechOpen eBooks. https://doi.org/10.5772/intechopen.96623
615. Mv, S., An, P., Ra, A., Gv, S., & Ei, G. (2004). [Clinical features of an early stage of Parkinson's disease].. PubMed.
616. Méndez-Herrera, C. R. (2011). El núcleo subtalámico en la fi siopatología de la enfermedad de Parkinson y su rol como diana quirúrgica The subthalamic nucleus in the pathophysiology of Parkinson's disease and its role as a surgical target.
617. Möller, J. C., Schweinfurther, R., & Oechsner, M. (2017). Parkinson-Syndrome in der Neurorehabilitation. Therapeutische Umschau. https://doi.org/10.1024/0040-5930/a000946
618. Nagrik, S. U., Patil, P., Nagrik, D. M., Zagare, V. S., Avchar, P. E., Bahurupi, S., & Ambhore, S. (2020). Herbal drugs Used on Parkinson Disease. Journal of Drug Delivery and Therapeutics. https://doi.org/10.22270/jddt.v10i4-s.4286
619. Najar, L. L., Pouchucq, L. F., Alves, I. L. M., Ferreguett, J. B., Diniz, L. R. D. R., & Gomes, M. D. M. (2021). Parkinson's disease and periodic limb movement in sleep. Revista Brasileira de Neurologia.
620. Nanagas, M. T. (2011). Bipolar Disorders. Pediatrics in Review. https://doi.org/10.1542/pir.32.11.502
621. Narayanan, N. S., Rodnitzky, R. L., & Ebadi, M. (2013). Prefrontal dopamine signaling and cognitive symptoms of Parkinson’s disease. Reviews in the Neurosciences. https://doi.org/10.1515/revneuro-2013-0004
622. Narendra, D. P., Isonaka, R., Nguyen, D., Schindler, A. B., Kokkinis, A., Ehrlich, D., Bardakjian, T., Goldstein, D. S., Liang, T., & Gonzalez‐Alegre, P. (2019). Peripheral synucleinopathy in a <i>DJ1</i> patient with Parkinson disease, cataracts, and hearing loss. Neurology. https://doi.org/10.1212/wnl.0000000000007614
623. Nath, B. D., Debnath, D., Pervin, R., & Hossain, M. A. (2020). Role of Environmental Toxicants and Inflammation in Parkinson’s Disease. CRC Press eBooks. https://doi.org/10.1201/9780429319310-6
624. Navarro-Roa, C., Rodríguez‐Violante, M., & Cervantes‐Arriaga, A. (2019). Terapias de infusión en la enfermedad de Parkinson avanzada. DELETED. https://doi.org/10.24875/rmn.m19000018
625. Negueruela-López, M., Mardomingo, M. J., & Sánchez, P. G.-P. (2012). Prodromal obsessive-compulsive symptoms in a case of schizophrenia.. PubMed.
626. Neiro, J. G. S., Souza, N. B. B. L. D., Leandro, M. E. O., Cândido, F. L. R., & Mainardes, S. C. C. (2007). A DOENÇA DE PARKINSON E O EFEITO TERAPÊUTICO DA LEVODOPA.
627. Nelson, A. J., & Klassen, B. T. (2015). Hypokinetic Movement Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190244927.003.0025
628. Nestor, P. J. (2010). 007 Mild cognitive impairment. Journal of Neurology Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp.2010.217554.7
629. Nestor, P. J. (2010). Dementia in Lewy body syndromes. Neurology. https://doi.org/10.1212/wnl.0b013e3181d55f79
630. Nevado‐Holgado, A., Terry, J. R., & Bogacz, R. (2011). Bifurcation analysis points towards the source of beta neuronal oscillations in Parkinson's disease. https://doi.org/10.1109/cdc.2011.6160899
631. Ng, J. S. C. (2018). Palliative care for Parkinson’s disease. Annals of Palliative Medicine. https://doi.org/10.21037/apm.2017.12.02
632. Nicastro, N. (2021). Molecular imaging in degenerative parkinsonisms: windows into the brain. https://doi.org/10.13097/archive-ouverte/unige:148477
633. Nijhof, G. (2009). Interactioneel ongemak als gevolg van gezichtsverstijving bij mensen met de ziekte van Parkinson. Mens & Maatschappij. https://doi.org/10.5117/mem2009.1.nijh
634. Nikpour, S. (2012). Neurological manifestations, diagnosis, and treatment of celiac disease: A comprehensive review.. PubMed.
635. Nițescu, D., Nicolau, A., Caraiola, S., Predețeanu, D., Ionescu, R., & Tănăsescu, C. (2011). Neuromyelitis optica--complication or comorbidity in primary Sjögren's syndrome?. PubMed.
636. Noachtar, S., & Rémi, J. (2010). Vegetative seizures. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511781780.015
637. Nodel, M. R., Yakhno, N. N., & Yakhno, N. N. (2009). NERVOUS AND MENTAL DISORDERS OF PARKINSON'S DISEASE. Neurology neuropsychiatry Psychosomatics. https://doi.org/10.14412/2074-2711-2009-30
638. Noé, E., Irimia, P., Arias, E. M. P., Martínez‐Vila, E., & Piudo, M. R. L. (2001). Trastornos neuropsiquiátricos en la enfermedad de Parkinson. Revista de Neurología. https://doi.org/10.33588/rn.3207.2000179
639. Nurmansyah, W., & Hartati, S. (2014). Prototipe Sistem Pakar Penentu Jenis Gangguan Psikologi Klinis Menggunakan Forward Chaining dan Formula Bayes.
640. Nzamba, D. N., Benallel, K., Salim, J., Gartoum, M., & Kadiri, M. (2022). PSYCHOTIC SYMPTOMS AND PARKINSONS DISEASE: CLINICAL AND THERAPEUTIC ASPECTS. International Journal of Advanced Research. https://doi.org/10.21474/ijar01/15221
641. Oakley, D. A., Ward, N., Halligan, P. W., & Frackowiak, R. S. J. (2003). Differential brain activations for malingered and subjectively ‘real’ paralysis. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780198515548.003.0021
642. Oare, C. (2017). Imaging Parkinson's Disease: Gray Matter Atrophy Associated With Motor Dysfunction. Journal of Purdue Undergraduate Research. https://doi.org/10.5703/1288284316395
643. Oers, H. M. V. (2019). Correlates of psychiatric and psychological distress in patients with Parkinson’s disease. https://doi.org/10.36811/jphsm.2019.110010
644. Oertel, W. H., Vadász, D., Ries, V., Mayer, G., Eggert, K., Krenzer, M., Unger, M. M., Höglinger, G. U., Mollenhauer, B., Sixel-Döring, F., Trenkwalder, C., & Depboylu, C. (2013). Prodromale Marker der Parkinson-Krankheit. Aktuelle Neurologie. https://doi.org/10.1055/s-0033-1355379
645. Ogata, T., Sakakibara, R., Tateno, F., Tsuyusaki, Y., Tateno, H., Aiba, Y., Kishi, M., Inaoka, T., Terada, H., Doi, H., & Suzuki, Y. (2016). Mild Cognitive Impairment as the Initial Manifestation of Progressive Supranuclear Palsy. Journal of the American Geriatrics Society. https://doi.org/10.1111/jgs.14001
646. Ogawa, N., & Mori, A. (1995). Parkinson’s disease, dopamine and free radicals. Birkhäuser Basel eBooks. https://doi.org/10.1007/978-3-0348-7337-6_28
647. Okai, D., Samuel, M., Askey‐Jones, S., David, A. S., & Brown, R. G. (2011). Impulse control disorders and dopamine dysregulation in Parkinson’s disease: a broader conceptual framework. European Journal of Neurology. https://doi.org/10.1111/j.1468-1331.2011.03432.x
648. Oken, B. (2003). Non-prescription and non-pharmacological therapies for dementia. CRC Press eBooks. https://doi.org/10.3109/9780203494578-29
649. Oliveira, F. D. A. M. D., Filho, R. F. G. N., Rabelo, L. C. D. S., Freire, E. V. R. D. L., Santos, K. M. G. S. D., Brito, A. K. A., Mendes, N. D. O., Bernardes, D. D. S. V., & Sá, D. R. D. (2024). CORRELAÇÃO ENTRE O DECLÍNIO COGNITIVO E ANSIEDADE EM PACIENTES COM DOENÇA DE PARKINSON. Revista CPAQV - Centro de Pesquisas Avançadas em Qualidade de Vida. https://doi.org/10.36692/v16n2-109r
650. Oliveira, R. K. D., Praetzel, R. P., Bayer, L. R., Ruschel, P. H., Heinen, A., & Delgado, P. J. (2017). Lesión del nervio cubital tras fractura cerrada de antebrazo – dos casos clínicos. Revista Iberoamericana de Cirugía de la Mano. https://doi.org/10.1055/s-0037-1606284
651. Olszewski, J., Zielińska‐Bliźniewska, H., & Pietkiewicz, P. (2011). Zaburzenia połykania jako interdyscyplinarny problem diagnostyczny i leczniczy. Polski Przegląd Otorynolaryngologiczny. https://doi.org/10.1016/s2084-5308(11)70060-0
652. Ong, L. T. C., Galambos, G., & Brown, D. A. (2017). Primary Sjogren’s Syndrome Associated With Treatment-Resistant Obsessive–Compulsive Disorder. Frontiers in Psychiatry. https://doi.org/10.3389/fpsyt.2017.00124
653. Ongini, E. (2003). Introduction: Adenosine A <sub>2A</sub> receptors in nonlocomotor features of Parkinson’s disease. Neurology. https://doi.org/10.1212/01.wnl.0000095217.17071.b6
654. Onofrj, M., Paci, C., & Thomas, A. G. (1998). Sudden appearence of invalidating dyskinesia-dystonia and off fluctuations after the introduction of levodopa in two dopaminomimetic drug naive patients with stage IV Parkinson's disease. Journal of Neurology Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp.65.4.605
655. Onofrj, M., Thomas, A., Bonanni, L., Giannantonio, M. D., Gambi, F., & Sepede, G. (2012). Somatoform Disorders in Parkinson’s Disease and Dementia with Lewy Bodies Evidence Underlying Psychotic Traits. Advances in biological psychiatry. https://doi.org/10.1159/000331658
656. Orta, D. S.-J., & Castillo-Calcáneo, J. D. (2010). Sueño y enfermedad de Parkinson. Archivos de neurociencias (México, D.F.).
657. Ortiz, G. (2006). Trastornos neurogenéticos y neurometabólicos paroxísticos. Revista de Neurología. https://doi.org/10.33588/rn.42s03.2006027
658. Ortiz, Y. D. L. C. R., García, M. D. L. C. C., Castillo, M. C., Rodríguez, S. T., & García, A. O. G. (2012). Síndrome de Guillain Barré en edad pediátrica. Presentación atípica.. Gaceta Médica Espirituana.
659. Osona-Núñez, L., Guisado, J. A., & Pons, M. (2011). Cognition and Lewy body disease.. PubMed.
660. Ospina, B., & Vélez, J. L. O. (2019). Espectro clínico y tratamiento del trastorno cognoscitivo y demencia asociada a la enfermedad de Parkinson. Acta neurológica colombiana. https://doi.org/10.22379/24224022248
661. Ospina-García, N. (2019). Trastornos del sueño y dolor en la enfermedad de Parkinson. Acta neurológica colombiana. https://doi.org/10.22379/24224022251
662. Oukhrib, M., Tamegart, L., Ghachi, H. E., Maloui, A. B., El‐Mansoury, B., Chraa, M., & Gamrani, H. (2023). Epidemiology of Parkinson's Disease. Advances in medical diagnosis, treatment, and care (AMDTC) book series. https://doi.org/10.4018/978-1-6684-5156-4.ch001
663. Ozdemir, D., & Sahni, S. (2019). Conversion Disorder (Functional Neurological Symptom Disorder) Masquerading as Multiple Sclerosis: A Case Report. Cureus. https://doi.org/10.7759/cureus.4893
664. Ozturk, B. (2024). Cardiac effects and comorbidities of neurological diseases. TURKISH JOURNAL OF MEDICAL SCIENCES. https://doi.org/10.55730/1300-0144.5928
665. O’Donnell, B. F. (2007). Cognitive Impairment in Schizophrenia: A Life Span Perspective. American Journal of Alzheimer s Disease & Other Dementias®. https://doi.org/10.1177/1533317507304745
666. Pacchetti, C., Cristina, S., Mancini, F., Fundarò, C., Corengia, E., Martignoni, E., & Nappi, G. (2000). Sintomi non motori nella malattia di Parkinson: Procedure per la diagnosi, la terapia e la riabilitazione.
667. Paelecke–Habermann, Y., Ebersbach, G., & Leplow, B. (2007). Depressivität und Depression bei der Parkinson-Erkrankung. Zeitschrift für Neuropsychologie. https://doi.org/10.1024/1016-264x.18.3.207
668. Pahwa, R., & Koller, W. C. (1993). Is There a Relationship Between Parkinsonʼs Disease and Essential Tremor?. Clinical Neuropharmacology. https://doi.org/10.1097/00002826-199302000-00003
669. Pahwa, R., & Lyons, K. E. (2010). Early diagnosis of Parkinson's disease: recommendations from diagnostic clinical guidelines.. PubMed.
670. Palma, N. Z., Cruz, M. D., Santos, L. R., Cruz, M., Cunha, F., Fagundes, V., Pires, L., & Mesquita, M. (2020). Autoimmune polyendocrine syndrome type II: After adrenal crisis. Case Reports in Internal Medicine. https://doi.org/10.5430/crim.v7n2p3
671. Pandya, M., Kubu, C. S., & Giroux, M. (2008). Parkinson disease: Not just a movement disorder. Cleveland Clinic Journal of Medicine. https://doi.org/10.3949/ccjm.75a.07005
672. Panigrahi, B., Pillai, K. S., Radhakrishnan, D. M., Rajan, R., & Srivastava, A. (2024). Fatigue in Parkinson’s disease—A narrative review. Annals of Movement Disorders. https://doi.org/10.4103/aomd.aomd_99_24
673. Pantoularis, I., Garyfallos, G., Lobtzianidou, M., Livanos, A., Dasoukis, I., & Adamopoulou, A. (2008). Axis I-Axis II comorbidity of borderline personality disorder: gender-related differences. Annals of General Psychiatry. https://doi.org/10.1186/1744-859x-7-s1-s226
674. Panza, F., Frisardi, V., Capurso, C., D’Introno, A., Colacicco, A. M., Seripa, D., Pilotto, A., Vendemiale, G., Capurso, A., & Solfrizzi, V. (2009). POSSIBLE PREDICTORS OF VASCULAR COGNITIVE IMPAIRMENT–NO DEMENTIA. Journal of the American Geriatrics Society. https://doi.org/10.1111/j.1532-5415.2009.02236.x
675. Pareés, I., Saifee, T. A., Kojović, M., Kassavetis, P., Rubio‐Agusti, I., Sadnicka, A., Bhatia, K. P., & Edwards, M. J. (2013). Functional (psychogenic) symptoms in Parkinson's disease. Movement Disorders. https://doi.org/10.1002/mds.25544
676. Park, B.-J. (2009). A Research on 7 Cases of the Treatment Process for Patients with Idiopathic Parkinson's Disease or Parkinsonism. Journal of Oriental Neuropsychiatry.
677. Park, S. J., Song, I., Chung, S., & Yang, Y. (2015). Clinical Implication of High Sensitivity C-Reactive Protein for the Development of Dementia in Parkinson's Disease. Dementia and Neurocognitive Disorders. https://doi.org/10.12779/dnd.2015.14.3.123
678. Parnham, J. (2008). Diagnosis and management of Parkinson's disease: what the NICE guidelines say, and why.
679. Pascal, A. (2020). Early identification and intervention for infants at high risk of neurodevelopmental disorders.
680. Patel, D., Sharma, K., Chauhan, C., & Jadon, G. (2014). A CHRONIC, PROGRESSIVE NEUROLOGICAL DISORDER PARKINSON’S DISEASE- MECHANISMS AND TREATMENT. Journal of Drug Delivery and Therapeutics. https://doi.org/10.22270/jddt.v4i1.674
681. Patel, H. B., Patel, A., Mushtaq, S., Haq, F., & Raza, S. (2011). Aripiprazole-Induced Parkinsonism in a Child. The Primary Care Companion For CNS Disorders. https://doi.org/10.4088/pcc.10l01081
682. Patel, R. S., Kamil, S., Shah, M., Bhimanadham, N. N., & Imran, S. (2019). Pros and Cons of Marijuana in Treatment of Parkinson's Disease. PMC.
683. Patel, R. S., Kamil, S., Shah, M., Bhimanadham, N. N., & Imran, S. (2019). Pros and Cons of Marijuana in Treatment of Parkinson’s Disease. Cureus. https://doi.org/10.7759/cureus.4813
684. Paulig, M. (2006). Kognitive Störungen bei idiopathischem Parkinson-Syndrom. psychoneuro. https://doi.org/10.1055/s-2006-955079
685. Paz, T. D. S. R., Silva, A. E. L., Martins, N. I. M., Brito, V. L. S. D., Leite, M. A. A., & Corrêa, C. L. (2019). Congelamento da marcha e de membros superiores na doença de Parkinson. Revista Brasileira de Neurologia.
686. Pedroso, J. L., Godeiro‐Júnior, C., Felício, A. C., Maia, A. C. M., Aquino, C., Souza, L. T. D., & Barsottini, O. G. P. (2008). Multi-lacunar strokes mimicking atypical parkinsonism with an unusual neuroimaging presentation: état criblé. Arquivos de Neuro-Psiquiatria. https://doi.org/10.1590/s0004-282x2008000600030
687. Pedrão, L. F. A. T., Medeiros, P., Leandro, E. C., & Falquetto, B. (2024). Parkinson’s disease models and death signaling: what do we know until now?. Frontiers in Neuroanatomy. https://doi.org/10.3389/fnana.2024.1419108
688. Pehl, C. (2012). Sekundäre Form der Obstipation aufgrund von medikamentösen Nebenwirkungen und endokrinen, neurologischen und psychiatrischen Erkrankungen  medikamentös-konservative Therapieoptionen. Viszeralmedizin. https://doi.org/10.1159/000341720
689. Peixinho, A. T., Azevedo, A., & Simões, R. M. (2006). Alterações neuropsiquiátricas da doença de Parkinson. https://doi.org/10.25752/psi.6037
690. Peköz, M. T., Gök, D. K., Bozdemir, H., & Aslan, K. (2017). Diagnostic Criteria of Parasomnias and Other Paroxysmal Events in Sleep. Turkish Journal of Family Medicine & Primary Care. https://doi.org/10.21763/tjfmpc.318059
691. Peralta, C. (2013). [Neuropsychiatric non motor symptoms of Parkinson's disease].. PubMed.
692. Peña, M. L., Cuenca-López, M. D., & Guijo, J. M. H. (2010). Que nos dice la historia de la enfermedad de Parkinson. Actualidad en farmacología y terapéutica.
693. Peñuelas‐Calvo, I., Llewellyn-Jones, J. S., Cervesi, C., Sareen, A., & Moreno, A. G. (2016). The importance of establishing a good differential diagnosis in bipolar disorder. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2016.01.1182
694. Pfeiffer, R. F. (2012). Intestinal Dysfunction in Parkinson’s Disease. Humana Press eBooks. https://doi.org/10.1007/978-1-60761-429-6_10
695. Plané, J. B. (2018). Beyond the motor impairment in dyskinetic cerebral palsy: neuropsychological and connectome-based approach. TDX (Tesis Doctorals en Xarxa).
696. Plotkin, K. E. (2004). Insomnia Caused by Medical and Neurological Disorders. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-662-1_10
697. Plotkin, K. E. (2007). Insomnia Caused by Medical Disorders. Humana Press eBooks. https://doi.org/10.1007/978-1-60327-042-7_15
698. Poewe, W. (2006). The need for neuroprotective therapies in Parkinson’s disease. Neurology. https://doi.org/10.1212/wnl.66.10_suppl_4.s2
699. Poewe, W. (2008). Non‐motor symptoms in Parkinson’s disease. European Journal of Neurology. https://doi.org/10.1111/j.1468-1331.2008.02056.x
700. Poisson, A. (2014). Les hallucinations dans la maladie de Parkinson. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2014.09.276
701. Pokorski, M. (2013). Breathing and its rehabilitation in Parkinson's disease. BIOPHILIA. https://doi.org/10.14813/ibra.3.25
702. Polat, B. S. A. (2011). Parkinson hastalığında antiparkinson tedaviye bağlı cinsel işlev bozukluğu ve hiperseksüalite sıklığı parkinson hastalığında antiparkinson tedaviye bağlı cinsel işlev bozukluğu ve hiperseksüalite sıklığı.
703. Poletti, M. (2008). Deficit cognitivi e disturbi neuropsichiatrici nella Malattia di Parkinson: ambiti operativi dello psicologo. PSICOLOGIA DELLA SALUTE.
704. Poletti, M., Frosini, D., Pagni, C., Baldacci, F., Giuntini, M., Mazzucchi, S., Tognoni, G., Lucetti, C., Dotto, P. D., Ceravolo, R., & Bonuccelli, U. (2012). The relationship between motor symptom lateralization and cognitive performance in newly diagnosed drug-naïve patients with Parkinson's disease. Journal of Clinical and Experimental Neuropsychology. https://doi.org/10.1080/13803395.2012.751966
705. Poliakoff, E. (2013). Representation of action in Parkinson's disease: Imagining, observing, and naming actions. Journal of Neuropsychology. https://doi.org/10.1111/jnp.12005
706. Politis, M., Wu, K., Molloy, S., Bain, P. G., Chaudhuri, К. R., & Piccini, P. (2010). Parkinson's disease symptoms: The patient's perspective. Movement Disorders. https://doi.org/10.1002/mds.23135
707. Possin, K. L., & Kaufer, D. (2010). Parkinsonian Dementias. CONTINUUM Lifelong Learning in Neurology. https://doi.org/10.1212/01.con.0000368212.86835.a8
708. Post, B., Eijk, M. V. D., Munneke, M., & Bloem, B. R. (2011). Multidisciplinary care for Parkinson's disease: not if, but how!. Practical Neurology. https://doi.org/10.1136/jnnp.2011.241604
709. Post, B., Eijk, M. V. D., Munneke, M., & Bloem, B. R. (2011). Multidisciplinary care for Parkinson’s disease: not if, but how!. Postgraduate Medical Journal. https://doi.org/10.1136/pgmj.2011.241604rep
710. Postma, M. J., & Boersma, C. (2011). Flexibility of Markov modeling for clinical pharmacoeconomics: illustration for cost–effectiveness in early Parkinson’s disease. Expert Review of Clinical Pharmacology. https://doi.org/10.1586/ecp.11.69
711. Postuma, R. B., Gagnon, J., Rompré, S., & Montplaisir, J. (2010). Severity of REM atonia loss in idiopathic REM sleep behavior disorder predicts Parkinson disease. Neurology. https://doi.org/10.1212/wnl.0b013e3181ca0166
712. Poujois, A., & Woimant, F. (2019). Challenges in the diagnosis of Wilson disease. Annals of Translational Medicine. https://doi.org/10.21037/atm.2019.02.10
713. Prajjwal, P., Kolanu, N. D., Reddy, Y. B., Ahmed, A., Marsool, M. D. M., Santoshi, K., Pattani, H. H., John, J., Chandrasekar, K. K., & Hussin, O. A. (2024). Association of Parkinson's disease to Parkinson's plus syndromes, Lewy body dementia, and Alzheimer's dementia. Health Science Reports. https://doi.org/10.1002/hsr2.2019
714. Pratibha, S. (2010). Etiology of Late Onset Seizures.
715. Prenger, M. T. M., Madray, R., Hedger, K. V., Anello, M., & MacDonald, P. A. (2020). Social Symptoms of Parkinson’s Disease. https://doi.org/10.20944/preprints202007.0604.v1
716. Prenger, M., Madray, R., Hedger, K. V., Anello, M., & MacDonald, P. A. (2020). Social Symptoms of Parkinson’s Disease. Parkinson s Disease. https://doi.org/10.1155/2020/8846544
717. Presečki, P., Filipčić, I., Arbanas, G., & Mimica, N. (2014). Neurocognitive disorders in DSM-5.
718. Press, D. Z. (2004). Parkinson's Disease Dementia — A First Step?. New England Journal of Medicine. https://doi.org/10.1056/nejme048305
719. Putri, P. R. N. E. (2020). Asuhan keperawatan diabetes mellitus tipe 2 dengan ulkus diabetik pada ny. J di upt puskesmas rawat inap sungai pakning.
720. Pérez, E. S., Lahera, I. N., & Pacheco, O. R. A. (2016). Caracterización de los síntomas no motores en la enfermedad de Parkinson. Revista cubana de neurología y neurocirugía.
721. Pérez, J. M. V., & Alonso, C. M. (2009). Trastornos del movimiento inducidos por fármacos. Revista de Neurología. https://doi.org/10.33588/rn.48s01.2009039
722. Pérez-Lloret, S., & Barrantes, F. J. (2016). Deficits in cholinergic neurotransmission and their clinical correlates in Parkinson’s disease. npj Parkinson s Disease. https://doi.org/10.1038/npjparkd.2016.1
723. Pękala, K., Ponichtera-Kasprzykowska, M., & Sobów, T. (2015). Depression diagnosis in patients with Parkinson’s disease using various diagnostic tools. Aktualności Neurologiczne. https://doi.org/10.15557/an.2015.0028
724. Qayyum, A., Varanese, S., Perfetti, B., Di, A., Suzuki, K., Miyamoto, T., Miyamoto, M., Iwanami, M., Hirata, K., Fernandez, R. R., António, J., Casado, M., Lieu, C. A., Shivkumar, V., Gilmour, T. P., Venkiteswaran, K., Nolt, M. J., Deogaonkar, M., Subramanian, T., ... Ribarič, S. (2011). Symptoms of Parkinson's Disease. InTech eBooks. https://doi.org/10.5772/953
725. Quadri, M. (2013). Finding Genes for Parkinsonism.
726. Rabbani, S. A., Khaled, B., Khaled, H., Sharma, S., Pottoo, F. H., & Mahtab, A. (2023). Neurochemical Alterations in Parkinson's Disease. CRC Press eBooks. https://doi.org/10.1201/9780429265198-9
727. Radad, K., Moldzio, R., Krewenka, C., Kranner, B., & Rausch, W. (2023). Pathophysiology of non-motor signs in Parkinson’s disease: some recent updating with brief presentation. Exploration of Neuroprotective Therapy. https://doi.org/10.37349/ent.2023.00036
728. Rafferty, M., Foster, E. R., Roberts, A., Smaller, K., Johnson, L., & Lawson, R. (2024). Stemming the Tide: The Proactive Role of Allied Health Therapy in Parkinson’s Disease. Journal of Parkinson s Disease. https://doi.org/10.3233/jpd-230267
729. Rahim, F., Sayad, R., Kedwany, A. M., Sayed, H., Caprara, A. L. F., & Rissardo, J. P. (2024). Cardiovascular dysautonomia and cognitive impairment in Parkinson's disease (Review). Medicine International. https://doi.org/10.3892/mi.2024.194
730. Rana, A. Q., Ahmed, U. S., Chaudry, Z. M., & Vasan, S. (2015). Parkinson’s disease: a review of non-motor symptoms. Expert Review of Neurotherapeutics. https://doi.org/10.1586/14737175.2015.1038244
731. Ranchet, M., Hoang, I., Cheminon, M., Derollepot, R., Devos, H., Perrey, S., Luauté, J., Danaila, T., & Paire‐Ficout, L. (2019). Mesure de l'activité cérébrale pendant la marche dans la maladie de Parkinson.
732. Ransmayr, G. (2015). Cognitive impairment in Parkinson's disease.. PubMed.
733. Rascol, O., & Schelosky, L. (2009). <sup>123</sup>I‐metaiodobenzylguanidine scintigraphy in Parkinson's disease and related disorders. Movement Disorders. https://doi.org/10.1002/mds.22499
734. Rascol, O., Payoux, P., Ory, F., Ferreira, J. J., Brefel‐Courbon, C., & Montastruc, J. (2003). Limitations of current Parkinson's disease therapy. Annals of Neurology. https://doi.org/10.1002/ana.10513
735. Ratti, P. (2014). Troubles du sommeil dans la maladie de Parkinson et les autres synucléinopathies.
736. Ravina, B., Marder, K., Fernandez, H. H., Friedman, J. H., McDonald, W. M., Murphy, D., Aarsland, D., Babcock, D., Cummings, J., Endicott, J., Factor, S. A., Galpern, W. R., Lees, A. J., Marsh, L., Stacy, M., Gwinn, K., Voon, V., & Goetz, C. G. (2007). Diagnostic criteria for psychosis in Parkinson's disease: Report of an NINDS, NIMH work group. Movement Disorders. https://doi.org/10.1002/mds.21382
737. Regal, P. (2013). Neurologic manifestations of <i>E coli</i> infection–induced hemolytic-uremic syndrome in adults. Neurology. https://doi.org/10.1212/01.wnl.0000430450.15615.c3
738. Reichenberg, L. W., & Seligman, L. (2016). Neurocognitive Disorders. https://doi.org/10.1002/9781394259465.ch18
739. Reichmann, H. (2010). Clinical Criteria for the Diagnosis of Parkinson’s Disease. Neurodegenerative Diseases. https://doi.org/10.1159/000314478
740. Reichmann, H., & Schüpbach, W. M. M. (2008). Pramipexole in the management of Parkinson’s disease. Aging Health. https://doi.org/10.2217/1745509x.4.3.225
741. Reichmann, H., & Sommer, Ü. (2001). Demenz beim idiopathischen Parkinson-Syndrom. Aktuelle Neurologie. https://doi.org/10.1055/s-2001-18909
742. Reijnders, M. R., Leventer, R. J., Lee, B. H., Baralle, D., Selber, P., Paciorkowski, A. R., & Hunt, D. (2017). PURA-Related Neurodevelopmental Disorders. University of Washington, Seattle eBooks.
743. Reis, R. D., Batista, M. A., & Silva, J. V. D. (2019). Doença de Parkinson: representação material da vulnerabilidade humana no contexto do cuidador familiar. Revista Brasileira de Bioética. https://doi.org/10.26512/rbb.v14iedsup.26453
744. Reisberg, ‌., Ferris, S. H., Kluger, A., Franssen, E., Węgiel, J., & Leon, M. J. D. (2007). Mild cognitive impairment (MCI): a historical perspective. International Psychogeriatrics. https://doi.org/10.1017/s1041610207006394
745. Rektorová, I., Aarsland, D., Chaudhuri, К. R., & Strafella, A. P. (2011). Nonmotor Symptoms of Parkinson's Disease. Parkinson s Disease. https://doi.org/10.4061/2011/351461
746. Reuter, I., Mehnert, S., Oechsner, M., & Engelhardt, M. (2011). Cognitive Rehabilitation in Parkinson's Disease Using Neuropsychological Training, Transfer Training and Sports Therapy. InTech eBooks. https://doi.org/10.5772/17685
747. Revuelta, G. J., Kumaraswamy, G. K., & Lippa, C. F. (2015). Pathological correlates of dementia in Parkinson’s disease. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199681648.003.0015
748. Rezaee, Z., Marandi, M., Alaei, H., & Esfarjani, F. (2019). Molecular Mechanisms of Parkinson's Disease. The Neuroscience Journal of Shefaye Khatam. https://doi.org/10.29252/shefa.8.1.120
749. Rezola, E. M., Echarren, I. A., Martínez, J. R., & Martí-Massó, J. (2010). Trastornos del sueño en la enfermedad de Parkinson: insomnio y fragmentación del sueño, hipersomnia diurna, alteraciones del ritmo circadiano y síndrome de apnea del sueño. Revista de Neurología. https://doi.org/10.33588/rn.50s02.2009735
750. Richter, E. O., & Lozano, A. M. (2004). Deep Brain Stimulation for Parkinson’s Disease and Movement Disorders. CRC Press eBooks. https://doi.org/10.3109/9780203021651-24
751. Riederer, P., & Gerlach, M. (1993). The Pathophysiological Basis of Parkinson’s Disease. Milestones in drug therapy. https://doi.org/10.1007/978-3-0348-6348-3_2
752. Riggio, S., Filipovic‐Jewell, Z., & Thakur, D. S. (2016). Neuropsychiatric Illnesses. https://doi.org/10.1002/9781118654231.ch19
753. Rilianto, B. (2015). Mild Cognitive Impairment (MCI): Transisi dari Penuaan Normal Menjadi Alzheimer. Cermin Dunia Kedokteran.
754. Rinalduzzi, S., Trompetto, C., Marinelli, L., Alibardi, A., Missori, P., Fattapposta, F., Pierelli, F., & Currà, A. (2015). Balance Dysfunction in Parkinson’s Disease. BioMed Research International. https://doi.org/10.1155/2015/434683
755. Riquer, A. I. D., Bergareche, A., & Campos, V. Z. (2011). Sleep Disorders in Parkinson Disease. The Neurologist. https://doi.org/10.1097/nrl.0b013e31823966f8
756. Rischbieth, R. H. C. (1979). The support of the long term neurological cripple.. PubMed.
757. Ritz, L., Pitel, A., Vabret, F., Eustache, F., & Beaunieux, H. (2012). Alcoolodépendance : atteintes neuropsychologiques et diagnostics différentiels. Revue de neuropsychologie. https://doi.org/10.1684/nrp.2012.0227
758. Rocha, E. A., Mehta, N., Távora‐Mehta, M. Z. P., Roncari, C. F., Cidrão, A. A. D. L., & Elías, J. (2021). Disautonomia: Uma Condição Esquecida – Parte 1. Arquivos Brasileiros de Cardiologia. https://doi.org/10.36660/abc.20200420
759. Rocha, N. P., Reis, H. J., Berghe, P. V., & Cirillo, C. (2014). Depression and Cognitive Impairment in Parkinson's Disease: A Role for Inflammation and Immunomodulation?. NeuroImmunoModulation. https://doi.org/10.1159/000356531
760. Rodner, C. M., Tinsley, B. A., & O’Malley, M. (2013). Pronator Syndrome and Anterior Interosseous Nerve Syndrome. Journal of the American Academy of Orthopaedic Surgeons. https://doi.org/10.5435/00124635-201305000-00003
761. Rodner, C. M., Tinsley, B. A., & O’Malley, M. (2013). Pronator Syndrome and Anterior Interosseous Nerve Syndrome. Journal of the American Academy of Orthopaedic Surgeons. https://doi.org/10.5435/jaaos-21-05-268
762. Rodríguez-Martínez, E., Vázquez-Sáánchez, F., & Arés-Luque, A. (2010). [Urinary disorders, sexual dysfunction and hypersexuality in Parkinson's disease].. PubMed.
763. Rogers, J., & Kovelowski, C. J. (2003). Inflammatory Mechanisms in Parkinson’s Disease. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-297-5_21
764. Rolinski, M., & Ebmeier, K. P. (2011). Tackling dementia in patients with Parkinson's disease..
765. Ronco, C., McCullough, P. A., Anker, S. D., Anand, I. S., Aspromonte, N., Bagshaw, S. M., Bellomo, R., Berl, T., Bobek, I., Cruz, D. N., Daliento, L., Davenport, A., Haapio, M., Hillege, H. L., House, A. A., Katz, N., Maisel, A. S., Mankad, S., Zanco, P., ... Ponikowski, P. (2010). Cardiorenal Syndromes: An Executive Summary from the Consensus Conference of the Acute Dialysis Quality Initiative (ADQI). Contributions to nephrology. https://doi.org/10.1159/000313745
766. Rose, O. (2016). Parkinson’s Disease: Basic knowledge.. PubMed.
767. Rossi, M., Wainsztein, N., & Merello, M. (2021). Cardiac Involvement in Movement Disorders. Movement Disorders Clinical Practice. https://doi.org/10.1002/mdc3.13188
768. Roversi, K., Callai-Silva, N., Roversi, K., Griffith, M., Boutopoulos, C., Prediger, R. D., & Talbot, S. (2021). Neuro-Immunity and Gut Dysbiosis Drive Parkinson’s Disease-Induced Pain. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2021.759679
769. Ruberg, M., France‐Lanord, V., Brugg, B., Hunot, S., Anglade, P., Damier, P., Faucheux, B., & Agid, Y. (1997). Parkinson's Disease, Apoptosis, and Oxidative Stress. CRC Press eBooks. https://doi.org/10.1201/9781482292213-42
770. Rucci, J. M., & Feinstein, R. E. (2014). Neurocognitive Disorders and Mental Disorders Due to Another Medical Condition. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199326075.003.0005
771. Ruthirago, D., Julayanont, P., & Rassameehiran, S. (2016). Acute porphyrias and porphyric neuropathy. DOAJ (DOAJ: Directory of Open Access Journals).
772. Ruthirago, D., Julayanont, P., Rassameehiran, S., & Abstract, M. (2016). Acute porphyrias and porphyric neuropathy. The Southwest Respiratory and Critical Care Chronicles. https://doi.org/10.12746/swrccc2016.0415.197
773. Saaresranta, T., Polo‐Kantola, P., & Polo, O. (2007). Menopausal Insomnia. Humana Press eBooks. https://doi.org/10.1007/978-1-60327-042-7_9
774. Sabol, M. (2017). Procjena aktivnosti svakodnevnog života osoba s cerebralnom paralizom.
775. Saint‐Hilaire, M., & Ellis, T. (2013). A prescription for physical therapy and exercise in Parkinson’s disease. Advances in Parkinson s Disease. https://doi.org/10.4236/apd.2013.24023
776. Saito, Y., & Murayama, S. (2012). [Braak's hypothesis and non-motor symptoms of Parkinson disease].. PubMed.
777. Saka, M. J., Abdulraheem, I. S., & Saka, A. (2011). Postpolio syndrome: Epidemiology, pathogenesis and management. Journal of Infectious Diseases and Immunity. https://doi.org/10.5897/jidi.9000031
778. Salari, S., & Bagheri, M. (2019). In vivo, in vitro and pharmacologic models of Parkinson's disease. Physiological Research. https://doi.org/10.33549/physiolres.933895
779. Salawu, F. K., & Olokoba, A. B. (2015). Excessive Daytime Sleepiness and Unintended Sleep Episodes Associated with Parkinson’s Disease. Oman Medical Journal. https://doi.org/10.5001/omj.2015.02
780. Saleem, H., Bilal, M., & Awan, A. R. (2024). Generalized Fatigue: Why Post-Polio Syndrome Should Be Included as A Differential Diagnosis. Journal of the Pakistan Medical Association. https://doi.org/10.47391/jpma.11113
781. Sander, R. (2015). Search for early indicators of Parkinson’s disease. Nursing Older People. https://doi.org/10.7748/nop.27.4.13.s16
782. Santana, C. L., & Saúco, M. Á. (2006). Levodopa y alteraciones cognitivas en la enfermedad de Parkinson. Revista de Neurología. https://doi.org/10.33588/rn.4302.2005571
783. Santiago, A., & Factor, S. A. (2003). Levodopa. CRC Press eBooks. https://doi.org/10.1201/9780203912164-21
784. Santos, J. B. D., Farias, W. M. D., Aguiar, I. M., Maximiano‐Barreto, M. A., Fermoseli, A. F. O., & Siqueira, T. C. A. (2019). PREJUÍZO DA MEMÓRIA EPISÓDICA EM IDOSOS DEPRESSIVOS COM DOENÇA DE PARKINSON. Semana de Pesquisa do Centro Universitário Tiradentes - SEMPESq - Alagoas.
785. Santos, R. S., Camargo, C. H. F., Abdulmassih, E. M. D. S., & Teive, H. A. G. (2015). Dysphagia in Parkinson’s Disease. InTech eBooks. https://doi.org/10.5772/60983
786. Santos‐García, D., Aneiros-Díaz, A., Macías-Arribi, M., Llaneza-Gonzalez, M. A., Abella-Corral, J., & Santos-Canelles, H. (2010). [Sensory symptoms in Parkinson's disease]..
787. Santos‐García, D., Deus, T. D., Pérez, C. T., Expósito-Ruiz, I., Suárez-Castro, E., Carpintero, P., & Macías-Arribi, M. (2015). Gastroparesia y otros síntomas gastrointestinales en la enfermedad de Parkinson. Revista de Neurología. https://doi.org/10.33588/rn.6106.2015203
788. Santos‐García, D., Díaz, Á. A., Arribi, M. M., González, M. A. L., Corral, J. A., & Canelles, H. S. (2010). Síntomas sensoriales en la enfermedad de Parkinson. Revista de Neurología. https://doi.org/10.33588/rn.50s02.2009742
789. Sarkar, S., Raymick, J., & Imam, S. (2016). Neuroprotective and Therapeutic Strategies against Parkinson’s Disease: Recent Perspectives. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms17060904
790. Sarmento, F., Lamp, G., Lavu, V. S., Madamangalam, A. S., Dwarampudi, J. M. R., Yuan, Q., Martinez-Nunez, A. E., Choi, J. T., Johnson, K. A., Hemptinne, C. D., & Wong, J. K. (2024). Exploring the layers of fatigue in Parkinson’s Disease: A comprehensive analysis of its prevalence and contributing factors. Clinical Parkinsonism & Related Disorders. https://doi.org/10.1016/j.prdoa.2024.100288
791. Sauerbier, A., Qamar, M. A., Politis, M., Carr, H. J., Loehrer, P. A., & Chaudhuri, К. R. (2017). Presynaptic dopaminergic terminal imaging and non-motor symptoms assessment of Parkinson’s disease: evidence for dopaminergic basis?. npj Parkinson s Disease. https://doi.org/10.1038/s41531-016-0006-9
792. Saunders‐Pullman, R., Raymond, D., & Elango, S. (2019). LRRK2 Parkinson Disease.
793. Savica, R., Rocca, W. A., & Ahlskog, J. E. (2010). When Does Parkinson Disease Start?. Archives of Neurology. https://doi.org/10.1001/archneurol.2010.135
794. Saviluoto, A., Stępień, K. M., Das‐Munshi, J., Cook, A. M., Ocak, U., & Barnacle, J. (2020). Advances in Respiratory Emergencies in Neurological Diseases.
795. Sawada, H., Oeda, T., Umemura, A., Tomita, S., Kohsaka, M., Park, K., & Yamamoto, K. (2018). Risks and Triggers of Psychosis in Parkinson Disease. Journal of Alzheimer’s Disease & Parkinsonism. https://doi.org/10.4172/2161-0460.1000413
796. Saïd, G. (2012). Diabetic Neuropathies. Encyclopedia of Life Sciences. https://doi.org/10.1002/9780470015902.a0024020
797. Scherder, E., Oosterman, J. M., Ooms, M., Ribbe, M. W., & Swaab, D. F. (2005). [Chronic pain in dementia and in disorders with a high risk for congnitive impairment].. PubMed.
798. Schneider, J. S., Sendek, S., & Yang, C. (2015). Relationship between Motor Symptoms, Cognition, and Demographic Characteristics in Treated Mild/Moderate Parkinson’s Disease. PLoS ONE. https://doi.org/10.1371/journal.pone.0123231
799. Schneider, L. S., & Abou‐Saleh, U. B. M. T. (2002). Neurochemistry. https://doi.org/10.1002/0470846410.ch72
800. Schneider, R. B., Iourinets, J., & Richard, I. H. (2017). Parkinson’s Disease Psychosis: Presentation, Diagnosis and Management. Neurodegenerative Disease Management. https://doi.org/10.2217/nmt-2017-0028
801. Schneider, S. A., & Klein, C. (2014). PINK1 Type of Young-Onset Parkinson Disease.
802. Schrag, A. (2005). Driving in Parkinson's disease. Journal of Neurology Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp.2004.053694
803. Schroeteler, F. (2013). Evidenzbasierte Physiotherapie bei idiopathischem Parkinson-Syndrom. neuroreha. https://doi.org/10.1055/s-0033-1355431
804. Schulz, J. B., Benecke, R., Dodel, R., Eggert, K., Fogel, W., Gerlach, M., Reichmann, H., Riederer, P., Schwartz, A., & Winkler, J. (2005). Strukturierte Diagnostik bei Parkinson-Syndromen. Aktuelle Neurologie. Sup./Aktuelle Neurologie. Supplement. https://doi.org/10.1055/s-2005-866880
805. Schumacher, S. (2012). Veränderungen somatosensorischer Funktionen bei asymptomatischen PINK1-Mutationsträgern und asymptomatischen PARKIN-Mutationsträgern im Vergleich zu gesunden Kontrollen.
806. Schuster, J. (2014). Dépression et maladie de Parkinson. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2014.09.274
807. Schuster, P. (2010). Restriktive Valvulopathie im Rahmen einer Behandlung mit Dopaminagonisten.
808. Scott, B. M., & Benge, J. F. (2024). Lewy Body Disease and Atypical Parkinsonian Conditions. Dementia. https://doi.org/10.1093/med/9780197690024.003.0012
809. Segal, G. S., Xie, S. J., Paracha, S.-U.-R., & Grossberg, G. T. (2021). Psychosis in Parkinson’s Disease: Current Treatment Options and Impact on Patients and Caregivers. Journal of Geriatric Psychiatry and Neurology. https://doi.org/10.1177/08919887211018280
810. Selikhova, M., Kempster, P., Révész, T., Holton, J. L., & Lees, A. J. (2012). Neuropathological findings in benign tremulous Parkinsonism. Movement Disorders. https://doi.org/10.1002/mds.25220
811. Selvarajah, D., Sloan, G., & Tesfaye, S. (2020). Diabetic Neuropathy. https://doi.org/10.1002/9781119445821.ch5
812. Seppi, K., & Rascol, O. (2007). Dementia with Lewy bodies and Parkinson disease with dementia. Neurology. https://doi.org/10.1212/01.wnl.0000269667.17041.66
813. Sethi, K. D. (2003). Clinical aspects of Parkinson disease. Current Opinion in Internal Medicine. https://doi.org/10.1097/00132980-200302010-00004
814. Sethi, K. D., & Mehta, S. H. (2012). A clinical primer on restless legs syndrome: what we know, and what we don't know.. PubMed.
815. Shafiya, S., Teja, B. S., Tejaswini, T., Dhanush, P., & Nadendla, R. (2014). NONMOTOR COMPLICATIONS OF PARKINSON DISEASE. Indo American Journal of Pharmaceutical Research.
816. Shah, V. V., Singh, G., Goyal, S., & Palanthandalam‐Madapusi, H. J. (2014). A Control-System Perspective on Parkinsonian Tremor with Implications on Diagnosis and Disease Monitoring. arXiv (Cornell University).
817. Shapoval'iants, O. S. (2012). [Diagnostics and treatment of polyglandular syndrome of adults].. PubMed.
818. Sharma, U., Anjali, S., Surendra, V., Taj, N., & Manjunatha, P. M. (2019). Parkinson’s Disease: A Brief Outlook.
819. Sherer, T., Betarbet, R., & Greenamyre, J. T. (2001). Pesticides and Parkinson’s Disease. The Scientific World JOURNAL. https://doi.org/10.1100/tsw.2001.35
820. Shibasaki, H., & Hallett, M. (2016). Psychogenic Neurologic Diseases. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190240974.003.0026
821. Shibasaki, H., Hallett, M., Bhatia, K. P., Reich, S. G., & Balint, B. (2020). Disorders of Increased Muscle Stiffness or Overactivity. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190865047.003.0009
822. Shiraishi, T., Murakami, H., & Iguchi, Y. (2019). [Diagnosis and Treatment of Cognitive Impairment in Parkinson's Disease].. PubMed. https://doi.org/10.11477/mf.1416201367
823. Shrivastava, D. (2022). Does the Patient Have Abnormal Movements at Night?. CRC Press eBooks. https://doi.org/10.1201/9781003093381-11
824. Shrivastava, D. (2022). Is There a Complaint of Depression, Anxiety, Stress, etc.?. CRC Press eBooks. https://doi.org/10.1201/9781003093381-13
825. Shrivastava, D. (2022). Pharmacological Agents Used in Various Sleep Disorders. CRC Press eBooks. https://doi.org/10.1201/9781003093381-28
826. Shults, C. W. (2003). Treatments of Parkinson Disease. Archives of Neurology. https://doi.org/10.1001/archneur.60.12.1680
827. Siciliano, M., Micco, R. D., Sant’Elia, V., Goldman, J. G., Chiorri, C., Silvestro, M., Russo, A. G., Caiazzo, G., Esposito, F., & Tessitore, A. (2024). Cognitive and Morphometric Features of Mild Cognitive Impairment Reversion in Early Patients with Parkinson’s Disease. Parkinsonism & Related Disorders. https://doi.org/10.1016/j.parkreldis.2024.107077
828. Sieb, J. P., & Günnewig, T. (2004). M. Parkinson im hohen Lebensalter. psychoneuro. https://doi.org/10.1055/s-2004-833662
829. Silber, M. H. (2013). Sleep Dysfunction in Parkinson’s Plus Syndrome. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199795161.003.0052
830. Silva, J. V. M. B. D., & Duarte, I. H. F. (2022). RELEVÂNCIA DO TRATAMENTO FISIOTERAPÊUTICO EM PACIENTES PORTADORES DE PARKINSON. Anais do I Congresso Brasileiro de Saúde Pública On-line: Uma abordagem Multiprofissional. https://doi.org/10.51161/rems/3307
831. Silva, P. A. B., Silva, E. G. P. L. D., Godoy, M. E. C., Silva, M. V. D., Ferreira, L. L. F., MARCOLINA, L. C., Silva, L. A. D., Silva, I. D. R. E., VARGE, H. M. D. S., Matos, G. B. D. C., Silva, F. A. P., Pereira, A. G. D. N., Brahm, A. T., & Orikassa, V. K. (2024). O IMPACTO DA ATIVIDADE FÍSICA PARA PREVENÇÃO E TRATAMENTO DA DOENÇA DE PARKINSON. Revista CPAQV - Centro de Pesquisas Avançadas em Qualidade de Vida. https://doi.org/10.36692/v16n2-60r
832. Silverdale, M., Kobylecki, C., Kass‐Iliyya, L., Martínez‐Martín, P., Lawton, M., Cotterill, S., Chaudhuri, К. R., Morris, H. R., Baig, F., Williams, N., Hubbard, L., Shulman, J., & Grosset, D. G. (2018). A detailed clinical study of pain in 1957 participants with early/moderate Parkinson's disease. Parkinsonism & Related Disorders. https://doi.org/10.1016/j.parkreldis.2018.06.001
833. Simonet, C., Tolosa, E., Cámara, A., & Valldeoriola, F. (2019). Emergencies and critical issues in Parkinson’s disease. Practical Neurology. https://doi.org/10.1136/practneurol-2018-002075
834. Singh, N. R., & Sandhu, I. M. S. (2019). Absence of Nocturnal Penile Tumescence: An Earlier Sign of Erectile Dysfunction and Its Linked Comorbid Conditions. AMEI s Current Trends in Diagnosis & Treatment. https://doi.org/10.5005/jp-journals-10055-0074
835. Singh, S. (2015). Mental health in infancy. International Journal of Clinical & Medical Imaging. https://doi.org/10.4172/2376-0249.1000393
836. Skjærbæk, C., Knudsen, K., Horsager, J., & Borghammer, P. (2021). Gastrointestinal Dysfunction in Parkinson’s Disease. Journal of Clinical Medicine. https://doi.org/10.3390/jcm10030493
837. Slow, E., & Lang, A. E. (2019). Parkinsonism and Related Disorders. DeckerMed Family Medicine. https://doi.org/10.2310/fm.1178
838. Slow, E., & Lang, A. E. (2019). Parkinsonism and Related Disorders. DeckerMed Medicine. https://doi.org/10.2310/im.1178
839. Slow, E., & Lang, A. E. (2019). Parkinsonism and Related Disorders. DeckerMed Transitional Year Weekly Curriculum™. https://doi.org/10.2310/tywc.1178
840. Snow, B. J. (2003). Objective measures for the progression of Parkinson's disease. Journal of Neurology Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp.74.3.287
841. Snowdon, J. (1997). Epidemiologic questions on mood disorders in old age.. PubMed.
842. Sobrido, M. J., Silva, J. J. D., & Castro, B. Q. (2009). Trastornos del comportamiento en la enfermedad de Parkinson. Aspectos genéticos, farmacológicos y médico-legales. Revista de Neurología. https://doi.org/10.33588/rn.48s01.2008730
843. Sobrido, M., Dias-Silva, J. J., & Quintáns, B. (2009). [Behavioral disorders in Parkinson's disease. Genetic, pharmacological and medico-legal aspects]..
844. Sohail, S., Yu, L., Schneider, J. A., Bennett, D. A., Buchman, A. S., & Lim, A. (2017). Sleep fragmentation and Parkinson's disease pathology in older adults without Parkinson's disease. Movement Disorders. https://doi.org/10.1002/mds.27200
845. Solas, G., Bustamante, P., & Grandez, K. (2011). Neurodegenerative Disease Monitoring Using a Portable Wireless Sensor Device. InTech eBooks. https://doi.org/10.5772/29814
846. Solida, A. (2002). Acute dopaminergic challenge tests to assess postural/kinetic tremor of different origin: a case report. Journal of Neurology Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp.73.2.206
847. Sommer, I. E., & Laar, T. V. (2019). [Parkinson's disease as a neuropsychiatric disorder].. PubMed.
848. Sommer, I. E., Koops, S., & Blom, J. D. (2012). Comparison of auditory hallucinations across different disorders and syndromes. Neuropsychiatry. https://doi.org/10.2217/npy.12.2
849. Son, A. Y., Cucca, A., Agarwal, S., Liu, A., Rocco, A. D., & Biagioni, M. (2017). Are we missing non-motor seizures in Parkinson’s disease? Two case reports. Journal of Clinical Movement Disorders. https://doi.org/10.1186/s40734-017-0061-3
850. Spina, E., Barone, P., Mosca, L. L., Davanzati, R. F., Lombardi, A., Longo, K., Iavarone, A., & Amboni, M. (2016). Music Therapy for Motor and Nonmotor Symptoms of Parkinson's Disease: A Prospective, Randomized, Controlled, Single‐Blinded Study. Journal of the American Geriatrics Society. https://doi.org/10.1111/jgs.14295
851. Spollett, G., & Childs, B. P. (2017). Peripheral and Autonomic Neuropathy. American Diabetes Association eBooks. https://doi.org/10.2337/9781580405690.ch16
852. Sritharan, B., Shakthi, C., Muthuveeran, M., Manivannan, M., Justin, C., & GanesaPandian, D. (2019). Prevalence of non-motor symptoms in Parkinson’s disease. International Journal of Research in Medical Sciences. https://doi.org/10.18203/2320-6012.ijrms20191488
853. Stacy, M. (2013). Management of non-motor symptoms of Parkinson‘s disease. https://doi.org/10.2217/ebo.13.122
854. Stacy, M., & Jakel, R. J. (2014). Parkinson&amp;rsquo;s disease psychosis. Journal of Parkinsonism and Restless Legs Syndrome. https://doi.org/10.2147/jprls.s40946
855. Stacy, M., & Jankovic, J. (2011). Overview of the Medical Treatment of the Non‐Motor and Non‐Dopaminergic Features of Parkinson's Disease. Parkinson s Disease. https://doi.org/10.1002/9781444397970.ch35
856. Stamelou, M., Sheerin, U., Wood, N., & Bhatia, K. P. (2014). The entity of parkinsonism and associated lipomatosis. Neurology. https://doi.org/10.1212/wnl.0000000000000937
857. Stamenović, J., Đurić, S., Jolić, M., Živadinović, B., & Đurić, V. (2005). Examination of cognitive functions in patients with Parkinsons disease.
858. Stamenović, J., Živadinović, B., & Đurić, V. (2024). Clinical characteristics and treatment of psychosis in Parkinson's disease: A narrative review. Journal of the Chinese Medical Association. https://doi.org/10.1097/jcma.0000000000001146
859. Stanković, I., & Wenning, G. K. (2014). Neuropsychiatric Manifestations in Atypical Parkinsonian Syndromes. Neuropsychiatric symptoms of neurological disease. https://doi.org/10.1007/978-3-319-09537-0_7
860. Starkstein, S. E. (2009). Neuropsychiatric disorders in early untreated Parkinson's disease. Journal of Neurology Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp.2008.171231
861. Starovasnik, B., & Sever, A. (2004). Motnje kognitivnih sposobnosti pri bolnikih s Parkinsonovo boleznijo. Psihološka obzorja. https://doi.org/10.20419/2004.13.149
862. Steen, J. T. V. D., Lennaerts, H., Hommel, D., Augustijn, B., Groot, M., Hasselaar, J., Bloem, B. R., & Koopmans, R. T. (2019). Dementia and Parkinson's Disease: Similar and Divergent Challenges in Providing Palliative Care. Frontiers in Neurology. https://doi.org/10.3389/fneur.2019.00054
863. Stefanini, L. (2015). Évolution de l'impulsivité et des troubles du contrôle des impulsions après stimulation cérébrale profonde des noyaux sous thalamiques dans la maladie de Parkinson idiopathique.
864. Steffens, D. C., Blazer, D. G., & Beyer, J. L. (2013). Mood Disorders. American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781615370016.mt05
865. Stella, F., Radanovic, M., Balthazar, M. L. F., Canineu, P. R., Souza, L. C. D., & Forlenza, O. V. (2014). Neuropsychiatric symptoms in the prodromal stages of dementia. Current Opinion in Psychiatry. https://doi.org/10.1097/yco.0000000000000050
866. Stern, M. B., & Siderowf, A. (2010). Chapter 3 Clinical features: motor and nonmotor. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199550630.003.0003
867. Stocchi, F., Manfredi, M., & Vacca, L. (1995). Differential diagnosis of parkinsonism.. PubMed.
868. Stoessl, A. J., & Rivest, J. (1999). Differential Diagnosis of Parkinsonism. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. https://doi.org/10.1017/s0317167100000020
869. Stone, J., Pal, S., Blackburn, D., Reuber, M., Thekkumpurath, P., & Carson, A. (2015). Functional (Psychogenic) Cognitive Disorders: A Perspective from the Neurology Clinic. Journal of Alzheimer s Disease. https://doi.org/10.3233/jad-150430
870. Stępień, A., Góral, M., & Kantorska-Janiec, M. (2008). Mental disorders in paraneoplastic syndromes.
871. Su, J., Chen, T., Zhang, S., Cai, B., & Liu, Y. (2019). Research progress on non motor symptoms of Parkinson′s disease. Zhongguo yishi zazhi. https://doi.org/10.3760/cma.j.issn.1008-1372.2019.04.042
872. Suchowersky, O., & Salat-Foix, D. (2012). The management of gastrointestinal symptoms in Parkinson’s disease. Expert Review of Neurotherapeutics. https://doi.org/10.1586/ern.11.192
873. Suchowersky, O., Reich, S. G., Perlmutter, J. S., Zesiewicz, T., Gronseth, G., & Weiner, W. J. (2006). Practice Parameter: Diagnosis and prognosis of new onset Parkinson disease (an evidence-based review) [RETIRED]. Neurology. https://doi.org/10.1212/01.wnl.0000215437.80053.d0
874. Suharti, S. (2020). Patofisiologi Penurunan Kognitif pada Penyakit Parkinson. UMI Medical Journal. https://doi.org/10.33096/umj.v5i1.76
875. Sun, Q., & Tang, B. (2017). α-Syn-PMCA in cerebrospinal fluid has diagnostic potential in Parkinson’s disease. Journal of Xiangya Medicine. https://doi.org/10.21037/jxym.2017.12.03
876. Sutia, D. (2014). HUBUNGAN KADAR ALPHA SYNUCLEIN PLASMA DENGAN PENYAKIT PARKINSON.
877. Suzuki, K., Fujita, H., Watanabe, Y., Matsubara, T., Kadowaki, T., Sakuramoto, H., Hamaguchi, M., Nozawa, N., & Hirata, K. (2019). Leg restlessness preceding the onset of motor symptoms of Parkinson disease. Medicine. https://doi.org/10.1097/md.0000000000016892
878. Suzuki, K., Mivamoto, M., & Matsubara, T. (2017). Detection and management of sleep disturbances in Parkinson's disease.. PubMed.
879. Suzuki, K., Miyamoto, M., & Hirata, K. (2017). Sleep Disturbances in Neurodegenerative Diseases. Nihon Naika Gakkai Zasshi. https://doi.org/10.2169/naika.106.309
880. Suzuki, K., Miyamoto, M., Miyamoto, T., Iwanami, M., & Hirata, K. (2011). Sleep Disturbances Associated with Parkinson's Disease. Parkinson s Disease. https://doi.org/10.4061/2011/219056
881. Suzuki, K., Miyamoto, M., Miyamoto, T., Iwanami, M., Sakuta, H., & Hirata, K. (2012). [Sleep disturbances in patients with Parkinson disease].. PubMed.
882. Sveinbjörnsdóttir, S. (2016). The clinical symptoms of Parkinson's disease. Journal of Neurochemistry. https://doi.org/10.1111/jnc.13691
883. Swan, A. (2020). Clinical Improvement in a Patient with Parkinsonism and Vascular Dementia Receiving PCSK9 Inhibitor for Ischemic Heart Disease: A Case Report.
884. Szatmári, S., Illigens, B. M.-W., Siepmann, T., Pintér, A., Takáts, A., & Bereczki, D. (2017). Neuropsychiatric symptoms in untreated Parkinson&amp;rsquo;s disease. Neuropsychiatric Disease and Treatment. https://doi.org/10.2147/ndt.s130997
885. Szluz, B. (2019). Doświadczanie choroby Parkinsona (ujęcie socjologiczne). Seminare Poszukiwania naukowe. https://doi.org/10.21852/sem.2019.2.04
886. Szot, P., Franklin, A., & Murray, A. (2011). The Noradrenergic System is a Major Component in Parkinson’s Disease. InTech eBooks. https://doi.org/10.5772/17094
887. Sławek, J., Jasińska‐Myga, B., & Wieczorek, D. (2006). Zaburzenia poznawcze w chorobie Parkinsona. Polski Przegląd Neurologiczny.
888. Tabaquim, M. D. L. M., & Joaquim, R. M. (2013). FUNÇÕES NEUROPSICOLÓGICAS NA PARALISIA CEREBRAL. ARCHIVES OF HEALTH INVESTIGATION.
889. Tabernacle, B., Honey, M., & Jinks, A. (2009). Chapter 10 Idiopathic Parkinson's disease. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199213283.003.0010
890. TAKANASHI, M. (2010). パーキンソン病の非運動症状. Juntendō Igaku/Juntendo igaku. https://doi.org/10.14789/pjmj.56.444
891. Tani, M., & Iwanami, A. (2013). [Disorder of train of thought in the elderly].. PubMed.
892. Taniguchi, S., & Takeda, A. (2015). I. New Insights into Symptoms in Parkinson's Disease Including Non Motor Featrures. Nihon Naika Gakkai Zasshi. https://doi.org/10.2169/naika.104.1546
893. Tanrıverdi, M., Düzenli, S., Gündüz, M., Arslantürk, A., & Erekdağ, A. (2024). Investigation of Neurogenic Dysphagia in Different Neurological Diseases. Anadolu Kliniği Tıp Bilimleri Dergisi. https://doi.org/10.21673/anadoluklin.1432672
894. Taylor, C. A. (2003). Neuropsychiatry. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511547256.023
895. Tedrus, G. M. A. S., Fonseca, L. C., Letro, G. H., Bossoni, A. S., & Bastos, S. A. (2009). Dementia and mild cognitive impairment in Parkinson's disease. Arquivos de Neuro-Psiquiatria. https://doi.org/10.1590/s0004-282x2009000600038
896. tefanec, D. Š., Puharić, Z., Mrkonjić, R., Bis, S., & tefoković, J. M.-Š. (2016). „Javnozdravstveni značaj Parkinsonove bolesti-prikaz slučaja“. Hrvatski časopis za javno zdravstvo.
897. Teive, H. A. G., Filho, D. C. B., & Munhoz, R. P. (2016). Unusual motor and non-motor symptoms and signs in the early stage of Parkinson’s disease. Arquivos de Neuro-Psiquiatria. https://doi.org/10.1590/0004-282x20160126
898. Teixeira, A. L., Dias, F. M. V., Kümmer, A., Doyle, Harsanyi, Cardoso, & Fontenelle, L. F. (2011). Psychiatric disorders in primary focal dystonia and in Parkinson&amp;rsquo;s disease. Neuropsychiatric Disease and Treatment. https://doi.org/10.2147/ndt.s17507
899. Teixeira, A. L., Fontenelle, L. F., Lauterbach, E. C., & Starkstein, S. (2012). Neuropsychiatry of Parkinson's Disease. Parkinson s Disease. https://doi.org/10.1155/2012/908943
900. Tennenbaum, J., Mékinian, A., Lahuna, C., Dellal, A., Belfeki, N., Capron, J., Januel, É., Stankoff, B., Alamowitch, S., & Fain, O. (2020). Primary Sjögren's syndrome: central and peripheral nervous system involvements.. PubMed.
901. Thaisetthawatkul, P., & Dyck, P. J. B. (2023). Asymmetric Diabetic Neuropathy: Radiculoplexus Neuropathies, Mononeuropathies, and Cranial Neuropathies. Contemporary diabetes. https://doi.org/10.1007/978-3-031-15613-7_10
902. Thanvi, B., Lo, N., & Robinson, T. (2005). Vascular parkinsonism--an important cause of parkinsonism in older people. Age and Ageing. https://doi.org/10.1093/ageing/afi025
903. Theis, C., Schelle, G., Neto, I. F. C., Viana, K. F., Nishikawa, L., Sperandio, G. F. C., & Robles, L. (2022). USO DA LUBIPROSTONA EM PACIENTES PORTADORES DE DOENÇA DE PARKINSON. Journal of Coloproctology. https://doi.org/10.1055/s-0043-1764845
904. Thomas, M., & Jankovic, J. (2005). Clinical Diagnosis of Vascular Parkinsonism and Nondegenerative Atypical Parkinsonian Disorders. Humana Press eBooks. https://doi.org/10.1385/1-59259-834-x:393
905. Thomas-Antérion, C., & Krolak‐Salmon, P. (2010). L'évaluation des fonctions exécutives en pratique courante dans la maladie de Parkinson et les syndromes apparentés. Revue de neuropsychologie. https://doi.org/10.1684/nrp.2010.0073
906. Thomas-Antérion, C., & Krolak‐Salmon, P. (2010). L'évaluation des fonctions exécutives en pratique courante dans la maladie de Parkinson et les syndromes apparentés. Revue de neuropsychologie. https://doi.org/10.3917/rne.025.0007
907. Thomsen, T., & Miyasaki, J. M. (2012). Psychogenic Movement Disorders. Humana Press eBooks. https://doi.org/10.1007/978-1-60327-120-2_7
908. Tian, Y., Guo, J., & Tang, B. (2018). Attach importance to the comorbidities of Parkinson's disease. https://doi.org/10.3760/cma.j.issn.1008-1372.2018.01.001
909. Timmer, M. H., Beek, M. V., Bloem, B. R., & Esselink, R. A. (2017). What a neurologist should know about depression in Parkinson’s disease. Practical Neurology. https://doi.org/10.1136/practneurol-2017-001650
910. Tisel, S. M., & Klassen, B. T. (2021). Hypokinetic Movement Disorders: Parkinson Disease. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197512166.003.0069
911. Tn, S. (2010). [Characteristics of motor, cognitive, and emotional manifestations depending on the clinical variant of Parkinson's disease]..
912. Toda, K., & Harada, T. (2010). Prevalence, Classification, and Etiology of Pain in Parkinson's Disease: Association between Parkinson's Disease and Fibromyalgia or Chronic Widespread Pain. The Tohoku Journal of Experimental Medicine. https://doi.org/10.1620/tjem.222.1
913. Tolani, S. (2021). Impact of Major Depressive Disorder on Psychiatric Comorbidity of Females in Low Income Countries. Clinical and Experimental Psychology. https://doi.org/10.35248/2471-2701.21.7.244
914. Tolosa, E., Barone, P., & Rye, D. B. (2004). Parkinson’s disease and sleep. Neurology. https://doi.org/10.1212/wnl.63.8_suppl_3.s1
915. Tolosa, E., Coelho, M., & Gallardo, M. (2003). DAT imaging in drug-induced and psychogenic parkinsonism. Movement Disorders. https://doi.org/10.1002/mds.10575
916. Tolosa, E., Martı́, M. J., & Compta, Y. (2012). Dystonic symptoms associated with parkinsonian disorders. CRC Press eBooks. https://doi.org/10.3109/9781841848525-21
917. Toyoshima, Y., Takahashi, H., Katada, S., Kojima, N., Tada, M., Tani, T., Koike, R., Nozawa, T., Aida, I., Nakajima, T., Onodera, O., & Kakita, A. (2021). Parkinson's disease and parkinsonism: Clinicopathological discrepancies on diagnosis in three patients. Neuropathology. https://doi.org/10.1111/neup.12777
918. Tredici, K. D., & Braak, H. (2012). Dysfunction of the locus coeruleus–norepinephrine system and related circuitry in Parkinson's disease-related dementia. Journal of Neurology Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp-2011-301817
919. Trimmer, P. A., Tuttle, J. B., Sheehan, J. P., & Bennett, J. P. (1996). Mechanisms of Selective Neuronal Vulnerability to 1-Methyl-4-Phenylpyridinium (MPP+) Toxicity. Neurodegenerative Diseases. https://doi.org/10.1007/978-1-4899-0209-2_53
920. Trisnawati, S. Y., Gde, P. S. D. P., Kurniawan, L. S., Goller, A. A. C., & Dewi, V. T. (2022). GEJALA PSIKOTIK PADA PENYAKIT PARKINSON: SEBUAH LAPORAN KASUS DAN TINJAUAN PUSTAKA. Callosum Neurology. https://doi.org/10.29342/cnj.v4i2.152
921. Trošt, M., Perovnik, M., & Pirtošek, Z. (2019). Correlations of Neuropsychological and Metabolic Brain Changes in Parkinson's Disease and Other α-Synucleinopathies. Frontiers in Neurology. https://doi.org/10.3389/fneur.2019.01204
922. Truglia, S., Shehab, A. H. I. A., Ciureanu, I.-A., Voinescu, D. C., Burlea, L. Ş., & Ciubară, A. B. (2024). The Influence of Depression in the Evolution of Parkinson’s Disease: A Psychiatric Perspective. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2024.629
923. Trèves, R. (2015). Aux confins de la neurologie et de la rhumatologie. Bulletin de l Académie Nationale de Médecine. https://doi.org/10.1016/s0001-4079(19)30927-6
924. Tsarkov, A., & Petlovanyi, P. (2020). Use of pramipexole in neuropsychiatry. World Journal of Advanced Research and Reviews. https://doi.org/10.30574/wjarr.2020.7.2.0283
925. Tsarkov, A., & Petlovanyi, P. (2020). Use of pramipexole in neuropsychiatry. Zenodo (CERN European Organization for Nuclear Research). https://doi.org/10.5281/zenodo.4317103
926. Tso, I. F., Chun, J., & Deldin, P. J. (2010). Schizoaffective Disorder. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0818
927. Tuchman, R., Moshé, S. L., & Rapin, I. (2005). Trastornos del neurodesarrollo y epilepsia. Revista de Neurología. https://doi.org/10.33588/rn.40s01.2004649
928. Turnbull, C. D., & Fitzsimmons, P. (2009). Neuropsychiatric features of Parkinson’s disease. The Journal of the Royal College of Physicians of Edinburgh. https://doi.org/10.4997/jrcpe.2009.407
929. Tyutina, R. R., Pilipovich, A. A., & Danilov, A. B. (2020). Microbiota and Parkinson's disease (overview). Medical alphabet. https://doi.org/10.33667/2078-5631-2020-1-10-14
930. Ugrumov, M. V. (2017). Ophthalmic disorders as a manifestation of Parkinson's disease. S S Korsakov Journal of Neurology and Psychiatry. https://doi.org/10.17116/jnevro201711791124-131
931. Varghese, A., Anju, P., Roy, A., Suresh, S., Joy, E., & Sunder, R. (2020). Recent Survey on Parkinson Disease Diagnose using Deep Learning Mechanism. https://doi.org/10.1109/icimia48430.2020.9074896
932. Vasquez-Builes, S., Jaramillo, D., Ortiz, M. J., Pérez, S., & Rojas, I. C. (2022). Disfunción urinaria en la enfermedad de Parkinson: una revisión práctica.. Revista chilena de neuro-psiquiatría. https://doi.org/10.4067/s0717-92272022000100062
933. Vasylieva, N., & Krychun, I. I. (2021). PREGABALINS IN THE MANAGEMENT OF DIABETIC AND ALCOHOLIC POLYNEUROPATHY. Актуальні проблеми сучасної медицини Вісник Української медичної стоматологічної академії. https://doi.org/10.31718/2077-1096.21.2.24
934. Vaughan, C., & Goldman, J. G. (2012). Psychosis and Parkinson’s Disease. Humana Press eBooks. https://doi.org/10.1007/978-1-60761-835-5_6
935. Vela, L., Urso, D., Lopez, M. O., & Hoenicka, J. (2022). Non-Motor Symptoms in PLA2G6-Associated Dystonia-Parkinsonism: A Case Report and Literature Review. Journal of Clinical Medicine. https://doi.org/10.3390/jcm11061590
936. Verdoux, H., & Sutter, A. (2002). Perinatal risk factors for schizophrenia: Diagnostic specificity and relationships with maternal psychopathology. American Journal of Medical Genetics. https://doi.org/10.1002/ajmg.10906
937. Viana, M. L. S. (2024). EPILEPSIA COMO FATOR DE RISCO PARA O DESENVOLVIMENTO DA DOENÇA DE PARKINSON: UMA REVISÃO BIBLIOGRÁFICA. Revista CPAQV - Centro de Pesquisas Avançadas em Qualidade de Vida. https://doi.org/10.36692/v16n2-49r
938. Videnović, A., & Messinis, L. (2019). Enlightened PD. Neurology. https://doi.org/10.1212/wnl.0000000000007078
939. Vieira, R. T., Caixeta, L., Machado, S., & Caixeta, M. (2011). Dementia in Parkinson's Disease: A Clinical Review. Neuroscience International. https://doi.org/10.3844/amjnsp.2011.35.47
940. Vigevano, F., & Bartuli, A. (2002). Infantile epileptic syndromes and metabolic etiologies.. PubMed.
941. Vilariño‐Güell, C., Soto, Á., Young, J. E., Lin, S.-H., Uitti, R. J., Wszołek, Z. K., & Farrer, M. J. (2008). Susceptibility genes for restless legs syndrome are not associated with Parkinson disease. Neurology. https://doi.org/10.1212/01.wnl.0000317101.67684.e3
942. Villagran, A. M., & Scullin, M. K. (2019). Sleep Disorders and Neurocognition. https://doi.org/10.1093/oxfordhb/9780190664121.013.16
943. Vingerhoets, G. (2003). Predictors of cognitive impairment in advanced Parkinson's disease. Journal of Neurology Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp.74.6.793
944. Vink, R., & Thornton, E. W. (2015). Substance P and its tachykinin NK1 receptor: a novel neuroprotective target for Parkinson′s disease. Neural Regeneration Research. https://doi.org/10.4103/1673-5374.165505
945. Visanji, N. P., & Marras, C. (2015). The relevance of pre-motor symptoms in Parkinson’s disease. Expert Review of Neurotherapeutics. https://doi.org/10.1586/14737175.2015.1083423
946. Vizcarra, J. A., Lang, A. E., Sethi, K. D., & Espay, A. J. (2015). Vascular <scp>P</scp>arkinsonism: <scp>D</scp>econstructing a <scp>S</scp>yndrome. Movement Disorders. https://doi.org/10.1002/mds.26263
947. Vollmann, H., Hübner-Kosney, N., Schroeter, M. L., Fritz, T. H., Claßen, J., & Saur, D. (2013). EEG-Neurofeedback bei Patienten mit M. Parkinson. Klinische Neurophysiologie. https://doi.org/10.1055/s-0033-1337241
948. Vos, R. A. I. D., Jansen, E., Yilmazer‐Hanke, D., Braak, H., & Braak, E. (1996). Pathological and clinical features of Parkinson's disease with and without dementia. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511601187.026
949. Vásquez-Márquez, I., & Castellanos-Olivares, A. (2011). Delirio postoperatorio en el paciente geriátrico. Deleted Journal.
950. Vázquez-Sánchez, F., Martínez, E. R., & Luque, A. A. (2010). Trastornos urinarios, disfunción sexual e hipersexualidad en la enfermedad de Parkinson. Revista de Neurología. https://doi.org/10.33588/rn.50s02.2009736
951. Wada, N. (2019). Autonomic Disorders Associated with Parkinson's Disease. The Japanese Journal of Rehabilitation Medicine. https://doi.org/10.2490/jjrmc.56.204
952. Waechter, S. (2012). Fahren mit Parkinson - Erfahrungen mit aerztlich begleiteten Kontrollfahrten in Zuerich, Schweiz. SCHRIFTENREIHE FAHREIGNUNG.
953. Walder, D. J., Statucka, M., Daly, M., & Yaffe, B. (2014). Psychotic Disorders. Psychology. https://doi.org/10.1093/obo/9780199828340-0151
954. Wallner, R., Senczyszyn, A., Budrewićz, S., & Rymaszewska, J. (2019). Zaburzenia poznawcze i neuropsychiatryczne w chorobie Parkinsona. Polski Przegląd Neurologiczny. https://doi.org/10.5603/ppn.2019.0018
955. Walsh, K., & Bennett, G. (2000). Parkinson's disease: a guide for care staff. Nursing and Residential Care. https://doi.org/10.12968/nrec.2000.2.2.74
956. Walsh, R. A. (2016). Parkinson’s Disease with an Unusual Tremor. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190607555.003.0009
957. Walsh, R. A., Bie, R. M. A. D., & Fox, S. H. (2013). Nonmotor Symptoms in Parkinson’s Disease. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199927524.003.0006
958. Wang, Y., Peng, Q., & He, S. (2019). Sensory disorders and electrophysiological study in Parkinson′s disease. Chin J Neurol. https://doi.org/10.3760/cma.j.issn.1006-7876.2019.05.010
959. Watson, E., Laurell, A., Hatfield, C., & Dudas, R. B. (2023). Violence and delusional jealousy in Parkinson’s disease. BMJ Case Reports. https://doi.org/10.1136/bcr-2023-256682
960. Weerkamp, N. J., Ommen-Nijhof, A. V., & Tissingh, G. (2009). Non-Motor Symptoms of Parkinson's Disease. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199237234.001.0001
961. Wei, C. C. (2012). 帕金森病非运动症状的识别与处理：从忽视到重视. Chin J Neurol. https://doi.org/10.3760/cma.j.issn.1006-7876.2012.06.001
962. Weigel, G. (2014). Critical Additions Required. Deutsches Ärzteblatt international. https://doi.org/10.3238/arztebl.2014.0488b
963. Weinberg, M. A., Segelnick, S. L., Insler, J. S., & Kramer, S. (2015). Diseases of the neurological system. https://doi.org/10.1002/9781118991473.ch8
964. Weiner, W. J. (2008). Early diagnosis of Parkinson's disease and initiation of treatment.. Reviews in neurological diseases.
965. Weiner, W. J., & Robottom, B. (2009). Parkinsons Disease Dementia. Current Psychiatry Reviews. https://doi.org/10.2174/157340009788971128
966. Weiner, W. J., Robottom, B., & Factor, S. A. (2011). Movement Disorders Emergencies Part 1. Archives of Neurology. https://doi.org/10.1001/archneurol.2011.84
967. Weller, R. O., Swash, M., McLellan, D. L., & Scholtz, C. L. (1983). The Interpretation of Neurological Symptoms and Signs. Clinical Neuropathology. https://doi.org/10.1007/978-1-4471-1335-5_3
968. Wenderlein, J. M. (2008). Treatment of idiopathic Parkinson's syndrome: Is the Risk of Parkinson's Syndrome Reducible?. Deutsches Ärzteblatt international. https://doi.org/10.3238/arztebl.2008.0054a
969. Werneck, A. L. S. (2010). Doença de Parkinson: Etiopatogenia, Clínica e Terapêutica. Revista Hospital Universitário Pedro Ernesto (TÍTULO NÃO-CORRENTE).
970. Widyastuti, K., & Laksmidewi, A. A. A. P. (2018). LAPORAN KASUS PARKINSON DISEASE DEMENTIA: ASPEK NEUROKOGNITIF DAN HALUSINASI VISUAL. Callosum Neurology. https://doi.org/10.29342/cnj.v1i1.8
971. Wieczorek, D., Sitek, E. J., Wójcik, J., & Sławek, J. (2013). Łagodne zaburzenia funkcji poznawczych i otępienie w chorobie Parkinsona — obraz kliniczny i aktualne kryteria diagnostyczne. Polski Przegląd Neurologiczny.
972. Wierenga, C. E., & Bondi, M. W. (2011). Dementia and Alzheimer's Disease: What We Know Now. Generations.
973. Wijaya, V. O. (2019). Impact of Pain on Stroke and Hypertension as Comorbidities In Parkinson’s Disease. American Journal of Biomedical Science & Research. https://doi.org/10.34297/ajbsr.2019.01.000519
974. Williams, D. R. (2013). Progressive Supranuclear Palsy and Corticobasal Degeneration. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199609536.003.0014
975. Wills, A. J. (2006). The neurology of enteric disease. Journal of Neurology Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp.2005.085365
976. Wolters, E. C., & Braak, H. (2006). Parkinson’s disease: premotor clinico-pathological correlations. https://doi.org/10.1007/978-3-211-45295-0_47
977. Won, M. S., Mikos, A., Hurd, M., Fernandez, H., Eskin, T. A., Romrell, J., & Okun, M. S. (2009). Tardive parkinsonism in a bipolar patient: Post-mortem examination supports a physiological rather than pathological dysfunction. Neurocase. https://doi.org/10.1080/13554790802613033
978. Wong, V., & Chung, B. H. (2006). Evaluating a Child with Partial Developmental Delay (ParDD), Global Developmental Delay (GDD)/Mental Retardation (MR): Clinical Expertise Based or Evidence-Based?. Current Pediatric Reviews. https://doi.org/10.2174/157339606776894621
979. Woods, B., Clare, L., Tuokko, H., & Hultsch, D. F. (2006). Cognition-based therapies and Mild Cognitive Impairment.. https://doi.org/10.4324/9780203782996-22
980. Xavier, V. R. (2019). DOENÇA DE PARKINSON E PRINCIPAIS CAUSAS DE QUEDAS: UMA REVISÃO DE LITERATURA. Anais do EVINCI - UniBrasil.
981. Xie, W. (2011). Alpha-synuclein impairs normal dynamics of mitochondria in cell and animal models of Parkinson's disease. https://doi.org/10.14711/thesis-b1155461
982. Yakubovich, S., Israeli‐Korn, S., Halperin, O., Yahalom, G., Hassin‐Baer, S., & Zaidel, A. (2020). Visual self-motion cues are impaired yet overweighted during visual–vestibular integration in Parkinson’s disease. Brain Communications. https://doi.org/10.1093/braincomms/fcaa035
983. Yamamoto, T., & Tamura, N. (2012). [Autonomic features in Parkinson disease].. PubMed.
984. Yan, R. M., Cardonne, M. M., Reyes, E. J. M., & Leyva, A. G. (2022). Herramienta para la obtención de Patrones de Conectividad Cerebral en Pacientes con Deterioro Cognitivo. Orange Journal. https://doi.org/10.46502/issn.2710-995x/2021.6.04
985. Yang, Y., Shi, Y., Schweighauser, M., Zhang, X., Kotecha, A., Murzin, A. G., Garringer, H. J., Cullinane, P. W., Saito, Y., Foroud, T., Warner, T. T., Hasegawa, K., Vidal, R., Murayama, S., Révész, T., Ghetti, B., Hasegawa, M., Lashley, T., Scheres, S. H. W., & Goedert, M. (2022). Cryo-EM structures of α-synuclein filaments from Parkinson’s disease and dementia with Lewy bodies. bioRxiv (Cold Spring Harbor Laboratory). https://doi.org/10.1101/2022.07.12.499706
986. Yao, L., Wu, J., Koç, S., & Lu, G. (2021). Genetic Imaging of Neuroinflammation in Parkinson’s Disease: Recent Advancements. Frontiers in Cell and Developmental Biology. https://doi.org/10.3389/fcell.2021.655819
987. Yen, M. Y., Tirtayasa, K., & Sutjana, D. P. (2013). RATIONAL MANAGEMENT OF PARKINSON’S DISEASE.
988. Yenişehir, S., Batur, V., Karakaya, İ. Ç., & Karakaya, M. G. (2020). Patient-Reported and Performance-Based Outcome Measures for Functional Mobility and Activity Limitation in Individuals with Parkinson's Disease. Anadolu Kliniği Tıp Bilimleri Dergisi. https://doi.org/10.21673/anadoluklin.622194
989. Yi, X., Qiao, D., & Zhang, X. (2017). Subthalamic nuclei-deep brain stimulation on motor symptoms in Parkinson′s disease. https://doi.org/10.3877/cma.j.issn.2095-123x.2017.02.013
990. Yokochi, M. (2007). [Mesolimbic and mesocortical pathways in Parkinson disease].. Brain and nerve.
991. Yoo, D., Park, S., Kim, M. J., & Ahn, T. (2022). Burning chest pain as a prodromal sign in autopsy- proven Parkinson’s disease dementia. Deleted Journal. https://doi.org/10.54029/2022tew
992. Young, A. H. (2008). Management commentary. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511544187.025
993. Youssef, P. E., Mack, K. J., & Flemming, K. D. (2015). Classification and Approach to Movement Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190244927.003.0024
994. Yung, A. R. (2011). Risk, Disorder and Diagnosis. Australian & New Zealand Journal of Psychiatry. https://doi.org/10.3109/00048674.2011.614926
995. Zesiewicz, T., Sullivan, K. L., & Hauser, R. A. (2006). Nonmotor symptoms of Parkinson’s disease. Expert Review of Neurotherapeutics. https://doi.org/10.1586/14737175.6.12.1811
996. Zhang, F., Luo, A., Liao, S., Liu, M., Zhang, J., & Xu, Z. (2024). Progress of non‐motor symptoms in early‐onset Parkinson's disease. Ibrain. https://doi.org/10.1002/ibra.12180
997. Zhang, J. (2019). LRRK2 Signalling Pathways in Parkinson’s Disease. Archives in Neurology & Neuroscience. https://doi.org/10.33552/ann.2019.02.000540
998. Zhang, T., Yu, S., Guo, P., Du, Y., Hu, Y., Piao, Y., Zuo, L., Lian, T., Wang, R., Yu, Q.-J., Jin, Z., & Zhang, W. (2016). Nonmotor symptoms in patients with Parkinson disease. Medicine. https://doi.org/10.1097/md.0000000000005400
999. Zhang, W. (2012). 帕金森病认知障碍的异质性. Chin J Neurol. https://doi.org/10.3760/cma.j.issn.1006-7876.2012.06.018
1000. Zheng, Z., Zou, K., Guo, W., Tang, G., & Zheng, B. (2013). A case of early onset Parkinson&amp;#39;s disease after major stress. Neuropsychiatric Disease and Treatment. https://doi.org/10.2147/ndt.s48455
1001. Zinkstok, J., Velders, F. P., Rieken, R., Houben, M., Fiksinski, A., Amelsvoort, T. V., & Boot, E. (2020). Psychosis and movement disorders in an adolescent with 22q11.2 deletion syndrome. Tijdschrift voor psychiatrie.
1002. Ziégler, M. (2006). [Advanced Parkinson's disease].. PubMed.
1003. Zorkina, Y., Zubkov, E., Morozova, А., Abramova, O., & Karimova, O. S. (2020). EFFECTS OF ELECTROCONVULSIVE STIMULATION IN RATS WITH 6-OHDA INDUCED HEMIPARKINSONISM. BIOTECHNOLOGY STATE OF THE ART AND PERSPECTIVES. https://doi.org/10.37747/2312-640x-2020-18-184-186
1004. Álvarez, M. M., Cano-Herrera, G., Martínez, M. F. O., Gonzales-Portillo, J. V., Monroy, G. R., Pérez, R. M., Torres-Ríos, J. A., Tienhoven, X. A. V., Bernot, E. M. G., Salazar, F. E., & Ibarra, A. (2024). A Comprehensive Approach to Parkinson’s Disease: Addressing Its Molecular, Clinical, and Therapeutic Aspects. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25137183
1005. Çetinel, G., SARICA, E., & ALKHATIB, A. (2020). The Role of Dysphonia and Voice Recordings in Diagnosis of Parkinson’s Disease. International Journal of Applied Mathematics Electronics and Computers. https://doi.org/10.18100/ijamec.679038
1006. Şenel, G. B., & Karadeniz, D. (2022). Neuroanatomical and Etiological Approaches to Secondary Narcolepsy. Neurological Sciences and Neurophysiology. https://doi.org/10.4103/nsn.nsn_5_22
1007. Оstroumova, Т. М., & Koberskaya, N. N. (2020). Near-moderate cognitive decline. Neurology neuropsychiatry Psychosomatics. https://doi.org/10.14412/2074-2711-2020-2-92-97
1008. Оstroumova, Т. М., & Soloveva, A. S. (2021). Drug-induced parkinsonism. Neurology neuropsychiatry Psychosomatics. https://doi.org/10.14412/2074-2711-2021-6-91-97